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ABSTRACT 
 
Health Technology Assessment Evidence Criteria:  
What Types of Evidence Should be Presented for Products Used to Screen for Disease in 
the United States? 
(Under the direction of John Paul, PhD) 
 
New technologies can be tools of innovative change in healthcare.  They can be 
associated with improved treatment options, quality of care for patients, and cost savings.  
Distinguishing valuable technologies from those that offer added costs with no 
improvements in outcomes is the art of technology assessment.  A key function of that art  
involves selecting those patients, conditions, providers and settings in which a technology 
may offer improvements over current care.    With recent scientific discoveries such as 
the mapping of the human genome, development of genetic marker tests, and the growing 
interest in stem cell technologies, innovation is far ahead of any type of assessment that is 
currently used to establish which technologies should be made accessible to patients.  
 Screening technologies are on the forefront of innovation and may have a 
dramatic impact on the care of patients in terms of identifying disease and appropriate 
treatment options at an early stage.  As a result, screening technologies are of key interest 
to health technology assessment (HTA) agencies in the United States and abroad.  
Similarly, because screening technologies are developing quickly and are believed to 
have the potential to make a significant change in patient care, it is important to develop a 
robust level of HTA criteria to evaluate these new technologies and determine which 
 iv 
technologies should be integrated into the practice of medicine and made accessible to 
patients. 
Findings from this study indicate that while technology assessment organizations 
do have standard sets of criteria to evaluate products that are therapeutic, the assessment 
and level of evidence used to evaluate screening technologies are less clear.  The 
objective of this research study is to evaluate existing technology assessment standards 
for screening technologies in order to establish a best practice that may be implemented 
by US technology assessment organizations to broaden the criteria used in assessments 
for screening products.  The results of this study indicate that the best practices should 
include criteria to: support screening reliability, sensitivity and specificity; evaluate data 
to identify appropriate patient populations; reference to the natural course of the disease; 
consider ethical implications; and the impact of cost. 
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Chapter 1: Introduction 
 
New technologies can be tools of innovative change in healthcare.  They can be 
associated with improved treatment options, improved quality of care for patients, and 
cost savings.  Distinguishing valuable technologies from those that offer added costs with 
insufficient improvements in outcomes to offset added marginal costs is the art of 
technology assessment.  A key function of that art also involves selecting those patients, 
conditions, providers and settings in which a technology may offer improvements over 
current care.    With recent scientific discoveries such as the mapping of the human 
genome, development of genetic marker tests, and the growing interest in stem cell 
technologies, innovation is far ahead of any type of assessment that is currently used to 
establish which technologies should be made accessible to patients.  
 Screening technologies offer a useful case study in where and how technology 
assessment as currently practiced stumbles when applied to what might be called “non-
traditional” innovations in medicine.  Screening devices are on the forefront of 
innovation and may have a dramatic impact on the care of patients in terms of identifying 
disease and appropriate treatment options at an early stage.  As a result, screening 
technologies are of key interest to health technology assessment (HTA) agencies in the 
United States and abroad.  Similarly, because screening technologies are developing 
quickly and are believed to have the potential to make a significant change in patient 
care, it will be important to develop a robust level of HTA criteria to evaluate these new 
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technologies and determine which technologies should be integrated into the practice of 
medicine and made accessible to patients during their course of care.  
Health Technology Assessment 
Health technology assessment (HTA) is the applied arm of evidence-based 
medicine that is often used by payers and providers to determine patient access to new 
technology.  Traditionally, technology assessments have been applied to new healthcare 
technologies that provide a therapeutic outcome in patients.  Evaluating screening 
technologies is an area of HTA that is evolving.  One complicating factor is that 
outcomes evidence is particularly difficult and expensive to obtain in evaluating 
interventions for screening tests and procedures.  As this is a new area in healthcare and 
may provide a pathway to discovering disease and evaluating treatment options earlier in 
the clinical pathway, it is particularly important to understand the level of evidence 
required for screening products to successfully meet the standards of the HTA.  
The purpose of HTA is to review new technologies, by examining existing 
evidence, in order to understand if the technology is effective as compared to existing 
methods.  In addition, the purpose of HTA is to help healthcare stakeholders, such as 
payers, ensure that their choices about whether or not to cover a technology is consistent 
with their stated goals and obligations to their beneficiaries.   
Technology assessment is a concept that first arose in the mid-1960s from a 
burgeoning appreciation of the critical role of technology in society.  In addition to the 
positive aspects of new technology, there was also a growing realization for the potential 
of unintended, possibly harmful, consequences of adopting technology before 
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understanding whether or not it was safe.1 In this sense, technology assessment “was 
conceived as a way to identify the desirable first-order, intended effects of technologies 
as well as the higher-order, unintended social, economic and environmental effects.”2   
There is no single standard for conducting HTA in the US.  Currently, 
assessments are conducted by diverse groups of stakeholders that apply analytic 
frameworks that draw on a variety of methods for a variety of objectives.  Examples of 
types of organizations that conduct and employ HTA include: regulatory agencies, 
government and private payers, managed care organizations, health professions 
organizations, group purchasing organizations, and investors.3  Depending on the 
frameworks and methods that are employed by the reviewing agency, the findings of a 
HTA conducted by separate organizations may be different and conflicting for the same 
technology.  This result may occur because stakeholder preferences drive the types and 
levels of evidence used in the technology assessments.  For example, in Europe, HTA 
conducted by government payers employ cost as an evidence measure;4 while in the US, 
cost has typically not been included in assessments conducted by public payers.  
Screening Technologies 
Screening technologies may be able to help identify whether or not a patient has a 
specific disease in order to inform treatment decisions before symptoms occur.  In 
                                                
1 Goodman, C.  HTA 101 Introduction to Health Technology Assessment. 2004.  
http://www.nlm.nih.gov/nichsr/hta101/ta10103.html#Heading4  Accessed January 25, 2009. 
 
2 Ibid. 
 
3 Ibid. http://www.nlm.nih.gov/nichsr/hta101/ta10104.html#Heading7  Accessed January 25, 2009. 
 
4 NICE: Our Guidance Sets the Standard for Good Healthcare; NHS National Institute for Health and 
Clinical Evidence.  Page 9.  30 December 2008. 
http://www.nice.org.uk/aboutnice/?domedia=1&mid=EE5AA72F-19B9-E0B5-D4215C860E77FD2E  
Accessed February 22, 2009. 
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addition, screening might also identify risk factors beyond phenotype risks.  For some 
diseases earlier diagnosis is associated with greater probability of cure or successful 
management – for others not.  This varies depending upon the treatments that are 
currently available.  For example, when treatments are available for a particular diagnosis 
a patient’s life might be improved by reducing the burden of a treatment by finding the 
disease before it progresses.  Similarly, when treatments are available and can be 
pursued, the patient’s emotional burden of having an illness might be reduced.  However, 
conversely, if a treatment does not exist, screening for disease and finding disease might 
increase the emotional burden on the patient.   
There are confounders related to screening technologies.  There is not consensus 
as to whether the discovery of a disease in an early phase may ultimately cost the insurer 
more or less to treat the patient.  In addition, the ultimate need for screening might be 
called into question in cases in which defining when a risk factor indicates that treatment 
is needed versus identifying a pre-condition that may not progress into disease.  Another 
controversy concerns the length of the observation period.  Is a screening useful in 
defining a meaningful proportion of patients found to be at high risk for developing 
symptoms or negative health outcomes after 1 year, 10 or 20 or only after 30?   
Regardless of the confounders, a significant amount of private sector innovation is 
occurring to develop new technologies that can identify a disease early.  As such, it is 
unclear how far down the clinical pathway one must go in order to validate that a 
screening product actually helped the patient.  Because these interventions typically do 
not cure the condition and may not be directly linked to higher rates of cures or improved 
management, their outcomes measurements address metrics such as earlier diagnosis and 
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identification symptoms in order to improve patient reported outcomes and/or delayed 
onset of disease.   
Objective of Research Study 
While technology assessment organizations do have standard sets of criteria to 
evaluate products that are therapeutic, the assessment and level of evidence used to 
evaluate screening technologies have not caught up with the development of innovative 
new products to screen for disease.  Thus, the objective of this research study is to 
evaluate existing technology assessment standards for screening technologies in order to 
create a best practice to expand the types of criteria that might be evaluated during an 
HTA of a screening technology.  These best practices will guide the process of evaluating 
new criteria and may be implemented by U.S. technology assessment organizations in the 
future. 
Research Study Deliverables 
In order to accomplish this objective, the following research steps will be 
conducted and deliverables created: 
1. Survey identified selected HTA agencies to at least one publicly available 
assessments, and related materials, if available, for the same screening 
technology/product. 
Deliverable: Summary of searched HTA websites to identify relevant screening 
technology/product. 
2. Create an evidence table that compares and displays the similarities and 
differences between the HTAs. 
Deliverable: Evidence table with written analysis. 
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3. Develop an interview guide based on the analysis.  
Deliverable: Draft interview guide for Dissertation Committee review, IRB 
clearance, and comment.  
4. Schedule and conduct telephone interviews with 8-10 HTA decision-makers.  
Decision-makers will be identified from the research of the specific screening 
technology/product, from suggestions from Dissertation Committee members, and 
individuals identified during the research process.  
Deliverable: Summary and analysis of the interview results. 
5. Synthesis of data and information from the evidence table and interviews. 
Deliverable: Suggested criteria for screening technologies and recommendation 
for implementation. 
Plan for Change 
The plan for change resulting from this research will be the creation of best 
practice that health technology assessment organizations may consider in assessing 
screening products in the future.  The objective of the best practice will be to refine 
traditional HTA criteria to include different types of evidence that are more relevant to 
screening products.  The ability to take non-traditional types of evidence into 
consideration during a screening product HTA will focus assessments as to whether or 
not a particular screening technology might help a specific patient population.  As a 
result, more screening products that are appropriate for specific patient populations will 
be available.   
Refined criteria for screening products will help organizations that use HTA 
better understand which technologies meet their stated organizational goals and 
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objectives so that they may make intentional choices about which screening products 
bring the most value to their patient populations.  The best practices will help to direct 
better private sector investment in technologies that deliver improved health outcomes.  
Patients, manufacturers, and physicians will charge payers and HTA organizations to 
consider the refinement of criteria for screening products via this best practice so that 
specific patient populations are not uniformly denied access to screening products which 
may be highly effective. 
 
 
  
Chapter 2: Literature Review 
This section describes the methods and results of the literature review conducted 
for this study.  As a preliminary step, definitions were researched to provide overall 
guidance to the topics to be researched.  Three steps were then performed for the 
literature examined: (1) search; (2) selection – inclusion and exclusion criteria; and (3) 
review. 
Definitions 
Technology Assessment5 – Technology assessment (TA) is a category of studies, 
intended to provide decision makers with information about the possible impacts and 
consequences of a new technology or a significant change in an old technology.  TA is 
concerned with both direct and indirect or secondary consequences, both benefits and 
disadvantages, and with mapping the uncertainties involved in any government or private 
use or transfer of a technology.  TA provides decision makers with an ordered set of 
analyzed policy options, and an understanding of their implications for the economy, the 
environment, and the social, political, and legal processes and institutions of society.6 
Technology assessment is a form of policy research that examines short- and 
long-term social consequences (for example, societal, economic, ethical, and legal) of the 
                                                
5 Goodman, C.  HTA 101 Introduction to Health Technology Assessment. 2004.  “Some Definitions of TA 
and HTA”.  http://www.nlm.nih.gov/nichsr/hta101/ta10103.html#Heading4  Accessed August 2, 2009. 
 
6 Coates & Jarratt, Inc. Course Workbook: Technology Assessment. Anticipating the Consequences of 
Technological Choices. 1992. Washington, DC. 
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application of technology. The goal of technology assessment is to provide policy-makers 
with information on policy alternatives.7 
Health Technology Assessment8 (United States) – Health technology assessment is a 
structured analysis of a health technology, a set of related technologies, or a technology-
related issue that is performed for the purpose of providing input to a policy decision.9 
Health Technology Assessment10 (United Kingdom) – Health technology assessment 
considers the effectiveness, appropriateness and cost of technologies. It does this by 
asking four fundamental questions: Does the technology work, for whom, at what cost, 
and how does it compare with alternatives?11 
Screening – performance of a test in an asymptomatic population with the purpose of 
reducing morbidity and/or mortality from disease.12 
Screening Test – A screening test is any testing procedure designed to separate people or 
objects according to a fixed characteristic or property, with the intention of detecting 
                                                
7 Banta HD, Luce BR. (1993). Health Care Technology and Its Assessment: An International Perspective. 
New York, NY: Oxford University Press. 
 
8 Goodman, C.  HTA 101 Introduction to Health Technology Assessment. 2004.  “Some Definitions of TA 
and HTA”.  http://www.nlm.nih.gov/nichsr/hta101/ta10103.html#Heading4  Accessed August 2, 2009. 
 
9 US Congress, Office of Technology Assessment. Protecting Privacy in Computerized Medical 
Information. Washington, DC: US Government Printing Office; 1994. 
 
10 Goodman, C.  HTA 101 Introduction to Health Technology Assessment. 2004.  “Some Definitions of 
TA and HTA”.  http://www.nlm.nih.gov/nichsr/hta101/ta10103.html#Heading4  Accessed August 2, 2009. 
 
11 UK National Health Service R&D Health Technology Assessment Programme, 2003. 
http://www.ncchta.org/about/whatishta.shtml. Accessed August 2, 2009. 
 
12 Sunshine, JH, et al. Technology assessment for radiologists. Radiology, 2004; 230:309-314. 
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early evidence of disease.13  For purposes of this research study, a screening technology 
is a type of screening test or procedure used to detect early evidence of disease or to 
identify patient population segments who should receive diagnostic tests. 
Diagnosis – “the process of determining by examination the nature and circumstances of 
a diseased condition.”14  
Diagnostic – is a tool, such as a test, used to determine a medical diagnosis. 
QALY – A Quality Adjusted Life Year (QALY) is a calculation that provides an idea of 
how many extra months or years of life of a reasonable quality a person might gain as a 
result of treatment.15  It is used to determine the monetary value of a particular medical 
treatment. 
Comparative Effectiveness Research – Comparative effectiveness research (CER) “is 
the generation and synthesis of evidence that compares the benefits and harms of 
alternative methods to prevent, diagnose, treat, and monitor a clinical condition or to 
improve the delivery of care.  The purpose of CER is to assist consumers, clinicians, 
purchasers, and policy makers to make informed decisions that will improve healthcare at 
both the individual and population levels.”16 
                                                
13 Stedman’s Online Medical Dictionary. http://www.stedmans.com/section.cfm/45.  Accessed: August 2, 
2009. 
 
14 Definition “diagnosis”.  http://dictionary.reference.com/browse/diagnosis.  Accessed July 1, 2011. 
 
15 Measuring  Effectiveness and Cost Effectiveness: the QALY. National Institute for Health and Clinical 
Excellence. 
http://www.nice.org.uk/newsroom/features/measuringeffectivenessandcosteffectivenesstheqaly.jsp.  
Accessed July 1, 2011. 
 
16 Initial National Priorities for Comparative Effectiveness Research, Committee on Comparative 
Effectiveness Research, Prioritization Board on Health Care Services, page S-9. Institute of Medicine of the 
National Academies. http://www.nap.edu/catalog.12648.html.  Accessed December 6, 2009. 
 11 
Literature Search 
Healthcare technology assessments intersect areas related to both healthcare 
delivery and policy.  For purposes of this literature review, databases and websites were 
used to learn how researchers and policy makers assess technologies related to screening 
products. 
PubMed was the database resource used to identify peer-reviewed literature for 
this review.  Key word searches were utilized to narrow in on thematic issues around 
healthcare technology assessment, diagnostics, screening, and criteria.  Diagnostics are 
included in the search criteria in order to capture references that might include both 
diagnostic and screening products.  The initial key words that were used for the literature 
search are shown, below, in Table 1. 
Table 1. Initial Key Words 
Healthcare AND Technology A/E AND C/D/S AND Test 
Healthcare 
OR 
Healthcare 
OR 
Healthcare 
OR 
Healthcare 
OR 
Healthcare 
OR 
Healthcare 
OR 
Healthcare 
OR 
Healthcare 
OR 
Healthcare 
OR 
Healthcare 
 Technology Assessment 
OR 
Technology Evaluation 
OR 
Technology Assessment 
OR 
Technology Assessment 
OR 
Technology Evaluation 
OR 
Technology Evaluation 
OR 
Technology Assessment 
OR 
Technology Assessment 
OR 
Technology Evaluation 
OR 
Technology Evaluation 
 Criteria 
OR 
Criteria 
OR 
Diagnostic 
OR 
Screening 
OR 
Diagnostic 
OR 
Screening 
OR 
Diagnostic 
OR 
Screening 
OR 
Diagnostic 
OR 
Screening 
  
 
 
 
 
 
 
 
 
 
 
 
Test 
OR 
Test 
OR 
Test 
OR 
Test 
 
An initial search on PubMed was conducted using the search terms yielded the 
preliminary search results set forth, below, in Table 2. 
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Table 2. PubMed Initial Key Word Search Results 
Key Words Search Results 
Healthcare Technology Assessment Criteria 1,287 
Healthcare Technology Evaluation Criteria 1,571 
Healthcare Technology Assessment Diagnostic 1,437 
Healthcare Technology Assessment Screening 776 
Healthcare Technology Evaluation Diagnostic 1,789 
Healthcare Technology Evaluation Screening 996 
Healthcare Technology Assessment Diagnostic Test 47 
Healthcare Technology Assessment Screening Test 217 
Healthcare Technology Evaluation Diagnostic Test 61 
Healthcare Technology Evaluation Screening Test 327 
 
 
The websites researched include institutions and agencies that have provided 
guidance and influence regarding HTA and the development of HTA criteria and 
standards of evidence.  These websites are set forth in Table 3.   
Table 3. HTA Websites 
Institution/Agency Website 
Centers for Medicare and Medicaid Services http://www.cms.hhs.gov/default.asp? 
Agency for Healthcare Research and Quality http://www.ahrq.gov/ 
Blue Cross Blue Shield Association 
Technology Evaluation Center 
http://www.bcbs.com/blueresources/tec/ 
U.S. Preventative Services Task Force http://www.ahrq.gov/CLINIC/uspstfix.htm 
National Library of Medicine – National 
Institutes of Health 
http://www.nlm.nih.gov/ 
State of Washington’s Health Technology 
Assessment 
http://www.hta.hca.wa.gov/ 
Evaluation of Genomic Applications in 
Practice and Prevention 
http://www.egappreviews.org/ 
Cochrane Collaboration http://www.cochrane.org/ 
National Institute of Health and Clinical 
Excellence 
http://www.nice.org.uk/ 
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Details regarding the significance of each agency and institution are set forth in 
greater detail, below.  As peer-reviewed articles that specify the methodology for the 
evaluation of technologies used to screen diseases are difficult to find, these websites set 
forth the current criteria and standards for evaluating relevant healthcare technologies 
that are targeted toward screening for particular diseases. 
• Centers for Medicare and Medicaid Services (CMS) – CMS is the largest 
public payer in the United States.  As such, it has a great deal of influence over 
which new healthcare technologies will be covered and paid for by the Medicare 
Program.  As many chronic diseases affect individuals that are 65 years or older, 
HTA decisions made by CMS are important in determining which technologies 
will be deemed acceptable for integration into clinical management of the 
Medicare patient population.  Screening technologies may help to identify disease 
earlier in this segment of the patient population.  As such, innovation in this area 
may alter the course of treatment for many diseases that affect Medicare patients.  
Medicare covers and pays for the care and treatment of medical conditions.  One 
key issue is that Medicare does not cover and pay for the determination of risk 
factors or care for pre-conditions.  
• Agency for Healthcare Research and Quality (AHRQ) – Health technology 
assessments are conducted for CMS by AHRQ.  These HTA are used by CMS to 
help inform national coverage decisions for the Medicare program, as well as 
provide information to Medicare carriers.  AHRQs HTA program uses current 
methodologies for evaluating the clinical utility of new technologies.  HTAs are 
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based on a systematic review of literature, as well as qualitative and quantitative 
methods of synthesizing data from multiple studies.  HTAs are conducted by 
AHRQ staff and can also be conducted in conjunction with one of the Evidence-
based Practice Centers (EPCs).17  In addition to its work for CMS, AHRQ has 
developed a program that contracts with institutions to participate in their EPC 
Program.  The EPC’s “review all relevant scientific literature on clinical, 
behavioral, and organization and financing topics to produce evidence reports and 
technology assessments. These reports are used for informing and developing 
coverage decisions, quality measures, educational materials and tools, guidelines, 
and research agendas.”18  When available, HTA topics are linked to 
corresponding information on the CMS website. 
• Blue Cross Blue Shield Association Technology Evaluation Center 
(BCBSATEC) – Blue Cross Blue Shield is one of the largest private payers in the 
United States.  BCBSATEC is one of the fourteen EPCs that are currently funded 
by AHRQ.19   
• U.S. Preventative Services Task Force (USPSTF) – Since 1998, AHRQ has 
sponsored the USPSTF.  USPSTF was first convened by the U.S. Public Health 
Service in 1984, and is the leading independent panel of private-sector experts in 
prevention and primary care. The USPSTF conducts rigorous, impartial 
assessments of the scientific evidence for the effectiveness of a broad range of 
                                                
17 Agency for Healthcare Research and Quality, Evidence-based Practice Program: Synthesizing scientific 
evidence to improve quality and effectiveness in healthcare. http://www.ahrq.gov/clinic/epc/.  Accessed 
August 16, 2009. 
 
18 Ibid. http://www.ahrq.gov/clinic/epc/.  Accessed March 15, 2009. 
 
19 Ibid. http://www.ahrq.gov/clinic/epc/epcenters.htm  Accessed March 15, 2009. 
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clinical preventive services, including screening, counseling, and preventive 
medications. Its recommendations are considered the "gold standard" for clinical 
preventive services.20  The mission of the USPSTF is to evaluate the benefits of 
individual services based on age, gender, and risk factors for disease; make 
recommendations about which preventive services should be incorporated 
routinely into primary medical care and for which populations; and identify a 
research agenda for clinical preventive care.21 
• National Library of Medicine (NLM) and National Institutes of Health (NIH) 
– These agencies have information that discusses the foundation of HTA and 
other ancillary policy topics that are relevant to the field of HTA, such as 
comparative effectiveness research (CER), in the United States.   
• State of Washington’s Health Technology Assessment (WAHTA) – This 
agency is included because it provides an example of a state’s process for 
introducing healthcare technology assessment to its population.   
• California Technology Assessment Forum (CTAF) – “A community forum 
dedicated to objectivity and transparency regarding medical technologies; a 
community forum for dialog and decisions regarding the safety and effectiveness 
of new and emerging technologies.”22  
• Evaluation of Genomic Applications in Practice and Prevention (EGAPP) – 
EGAPP is “an initiative launched in 2004 to support a coordinated, systematic 
process for evaluating genetic tests and other genomic applications that are in 
                                                
20 “About USPSTF”. http://www.ahrq.gov/clinic/uspstfab.htm. Accessed: August 2, 2009. 
 
21 Ibid.  Accessed: August 2, 2009. 
 
22 CTAF website: http://www.ctaf.org/.  Accessed: February 27, 2010. 
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transition from research to clinical and public health practice in the United States.  
The EGAPP Working Group was established in 2005 to support the development 
of a systematic process for assessing the available evidence regarding the validity 
and utility of rapidly emerging genetic tests for clinical practice.  This 
independent, multidisciplinary panel prioritizes and selects tests, reviews CDC-
commissioned evidence reports and other contextual factors, highlights critical 
knowledge gaps, and provides guidance on appropriate use of genetic tests in 
specific clinical scenarios.”23  
• The Cochrane Collaboration – The Cochrane Collaboration is dedicated to 
improving global healthcare decision-making by conducting systematic reviews 
of the effects of specific healthcare interventions.  The results of these reviews are 
published in The Cochrane Library.24 
• National Institute of Health and Clinical Excellence (NICE) – NICE is the 
technology assessment agency in the United Kingdom.  It is included to provide 
insight as to how HTA is conducted in a national health setting outside of the 
United States.  NICE is unique from United States technology assessment groups 
in that NICE reviews technologies prospectively for the United Kingdom before 
the National Health Service employs the particular technology.  In the United 
States a technologies are typically retrospectively reviewed by technology 
assessment agencies after the technology has been marketed and is in use. 
 
                                                
23 Evaluation of Genomic Applications in Practice  and Prevention. http://www.egappreviews.org/.  
Accessed: August 2, 2009. 
 
24 The Cochrane Collaboration. http://www.cochrane.org/. Accessed: August 2, 2009. 
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Literature Selection 
Information researched included the types of criteria HTA organizations apply to 
technologies used to screening for disease.  The reviewed articles encompass specific 
types of technology assessment criteria used to evaluate diagnostic and screening 
products, are not published prior to 2000; and are published in peer-reviewed journals.  
Diagnostic products were included to capture any references that might include 
information about both diagnostic and screening products, as well as guard against 
possible mischaracterization of technology.  Articles were only included if they were 
peer-reviewed.  In addition, the HTA data searched on organization websites had a 
similar restriction of not published or posted prior to 2000 in order to restrict the search to 
newer technologies used for disease screening.  This date restriction was used because 
these technologies are relatively new and it was used to restrict the size of the retrieved 
material.  Published and posted articles and reviews available HTA for relevant 
technologies older than 2000 were only used as historical sources.25 
Exclusion criteria were articles that do not discuss healthcare technologies used to 
screen for diseases or conditions, not peer-reviewed, in foreign languages, and older than 
2000.  A review of citations, and then abstracts, provided the process for the initial 
selection of articles, with the goal of reviewing the full text of 15-20 articles to determine 
inclusion.  On the websites, assessments that were published before 2000 were excluded 
from review.  In addition, the specific research criteria for the website search was limited 
                                                
25 According to AHRQ’s database of technology assessments, technology assessments conducted prior to 
2004 may be outdated due to more recent research findings not included in the assessments and should be 
viewed cautiously in current medical practice. They are maintained by AHRQ for archival purposes only.  I 
have selected an article inclusion date limit of 2000 to evaluate whether or not a history can be established 
regarding how the technology assessment criteria for diagnostic and screening products may have evolved 
for more current assessments.  http://www.ahrq.gov/clinic/techix.htm   Accessed February 22, 2009. 
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to criteria used to conduct HTA for screening products.  Technology assessment agencies 
require published studies for review; however, some agencies also review material that is 
not peer-reviewed (e.g., summaries of evidence prepared by research associates 
employed by the agency, thought-leader presentations at meetings, etc).  These types of 
additional materials are excluded from this literature review. 
The keyword searches yielded a list of citations.  These citations were reviewed 
for relevance to the field of HTA, as well as HTA involving screening tests.  If a citation 
appeared relevant, the abstract was reviewed for relevance.  If the abstract was deemed 
relevant, the full text of the article was retrieved and reviewed. 
If the article provided information regarding the HTA criteria, the results of the 
HTA were reviewed to derive ideas regarding the validity or appropriateness of the 
methods.  This informed the research objective and may serve as a baseline for 
comparing different HTA organizations, if relevant, to establish best practices for 
assessing technologies developed to screen for disease during interviews. 
Literature Review Results 
 This section describes the overall search results for this literature review and 
corresponding themes of research.  The search results were generated using the key word 
searches set forth in Tables 1 and 2, above, and was conducted using PubMed and 
Google Scholar.  In addition, search results were also compiled from the websites of 
agencies and institutions set forth in Table 3, above.   
Description of Search Results 
 Based on the results of the preliminary key word searches set forth in Table 2, the 
key words were grouped and divided into three search cohorts.  Key word searches were 
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repeated employing date inclusion criteria to narrow the search for relevant articles 
published between: January 1, 2000 and January 1, 2009.  In addition, based on the depth 
and breadth of the search results, the cohort was either deemed excluded from further 
evaluation (e.g., Cohort 1), or included for further evaluation (e.g., Cohorts 2 and 3). The 
results of the key word searches from the three search cohorts and whether they were 
included or excluded from evaluation are set forth below in Table 4.   
Table 4. Search Cohort Inclusion & Exclusion for Word Search & Results 
Search Cohort 
Inclusion / Exclusion 
 
Key Words 
Search 
Results 
Cohort 1 
Excluded from Evaluation 
Healthcare Technology Assessment Criteria 767 
Healthcare Technology Evaluation Criteria 1,079 
Healthcare Technology Assessment Diagnostic 1,247 
Healthcare Technology Evaluation Screening 681 
Cohort 2 
Included in Evaluation 
Healthcare Technology Assessment Diagnostic Test 26 
Healthcare Technology Assessment Screening Test 155 
Cohort 3 
Included in Evaluation 
Healthcare Technology Evaluation Diagnostic Test 36 
Healthcare Technology Evaluation Screening Test 246 
 
The key word search terms were the most broad in Cohort 1.  The search focused 
on the type of criteria used in HTA and evaluations and was not limited by a type of 
condition or whether a diagnostic or screening product was used.  Thus, although these 
two searches yielded a tremendous number of articles, 767 and 1,079, respectively, the 
topics of the articles included every type of healthcare technology assessment and 
evaluation conducted.  As such, these searches were deemed too broad and were 
excluded from further evaluation. 
By substituting the words “diagnostic” and “screening” for “criteria” in Cohort 1, 
yielded somewhat narrower results; however, still too broad for specific research.  The 
word “diagnostic”, and variants thereof, are frequently used to indicate that a disease was 
diagnosed, not that a diagnostic test was used.  Similarly, in the case of “screening”, this 
word, and variants thereof, are frequently used to explain that an x-ray or other form of 
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screening technology, and not test used to screen for disease, was used.  Because the 
results from these four key word searches were not limited to technology assessments and 
evaluations involving diagnostic or screening test products, they were excluded from 
further evaluation.   
Key word limitations were then applied to narrow the search results to those HTA 
that involved either a “healthcare technology assessment” with a “diagnostic test” or 
“screening test” (Cohort 2) or a “healthcare technology evaluation with a “diagnostic 
test” or “screening test” (Cohort 3) published between the dates: January 1, 2000 and 
January 1, 2009.  While these key word searches yielded a significant number of articles, 
they were limited to the research topic.  Consequently, article titles and, if relevant, 
abstracts, were reviewed for the key word search terms included in Cohort 2 and 3.   
A total of 463 results were reviewed by citation and title.  If the citation and/or 
title were reflective of the research question, the abstract was examined to determine if it 
was relevant.  Of the 463 articles, a total of 17 articles were deemed relevant for further 
review.  These 17 articles were retrieved and reviewed in their entirety.  Upon reviewing 
these 17 articles, 12 were deemed relevant for the purposes of this literature review. 
Table 5. Search Cohort Inclusion for PubMed Key Word Search & Results 
Search Cohort 
Inclusion / Exclusion 
Key Words Search 
Results 
Relevant 
Articles 
Cohort 2 
Included in Evaluation 
Healthcare Technology Assessment Diagnostic Test 26 7 
Healthcare Technology Evaluation Screening Test 155 1* 
Cohort 3 
Included in Evaluation 
Healthcare Technology Assessment Diagnostic Test 36 8 
Healthcare Technology Evaluation Screening Test 246 2 
Total Articles  463 17 
* Indicates repetitive citations, therefore excluded from Total Articles calculation. 
Description of Search Results – Website 
 Web searches were conducted for the agencies and institutions set forth in Table 
3.  The websites for these agencies and institutions were chosen due to their influence and 
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participation in HTA in the United States.  The Centers for Medicare and Medicaid 
Services (CMS) represents the largest public payer in the United States for people age of 
65 and older.  CMS’ technology assessments are conducted by the Agency for Healthcare 
Research and Quality (AHRQ).  As a result, the websites for both of these institutions are 
included for review due to the breadth of the patient population that may be affected by 
HTA for diagnostic and screening products.   
Using the key word searches from Cohort 2 and Cohort 3, the majority of the 
articles retrieved in this search outlined specific technology assessments for particular 
products.  The specific technology assessment criteria for evaluating diagnostic and 
screening were not specified.  Thus, when specific products are selected to research the 
technology assessment process, the search will be easily narrowed to the specific product 
and review articles that are relevant to the particular disease state and technology 
reviewed.   
Similarly, AHRQ, BCBSTEC, USPSTF, EGAPP, DERP, State of Washington’s 
Health Technology Assessment, CTAF, and the United Kingdom’s NICE websites also 
provided information regarding technology assessments that had been completed, or are 
in process, for a wide variety of technologies.  Thus, once a product is selected, these 
resources will also be helpful in identifying the means by which technologies for specific 
diseases have been evaluated.  
Peer-Reviewed Journal Themes 
 A total of 12 peer-reviewed journal articles were identified that appeared relevant 
to the research question.  None of the articles were directly on point; however, they did 
either address a component of technology assessment, complexity of evaluating 
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diagnostic and screening technologies, cost-effectiveness and how it might relate to 
technology assessment, or an HTA for a specific disease or condition.   
 Among the 12 articles, there were 4 prevalent themes: (1) value and attainability 
of outcomes evidence; (2) evaluation of cost-effectiveness of new technologies; (3) 
evaluation of patient perspectives; and (4) danger of developing fragmented healthcare 
policy.  Each of these themes is discussed in detail, below. 
(1) Value of Outcomes Evidence. 
One of the prevalent themes in the literature involves the type of evidence that 
should be collected and evaluated in order to assess a screening technology.  Many 
authors recognize the traditional strength of outcomes evidence collected during a 
randomized clinical trial; however, the cost involved in collecting this type of evidence 
for screening technologies is prohibitive.26  Another data and cost consideration is how 
long to collect evidence for a screening technology.  For example, should data be 
collected until the disease presents itself, or should data collection continue through 
therapeutic treatment until the eventual death of the patient?  Thus, the key issue is 
distinguishing the ideal: until natural death of all cohort members versus a feasible study 
(i.e., IRB-approved study that is affordable to conduct).  
Expert opinion regarding the level of evidence needed for a screening technology 
was not found.  However, the literature did provide guidance relative to diagnostics.  
Bruns and Hartmann set forth the complexity of determining an appropriate level of 
evidence in evaluating diagnostic products.  While outcomes studies have worked well 
for therapeutic interventions, the study of laboratory-related outcomes is more complex 
                                                
26 Bruns, D. E. (2001). Laboratory-related outcomes in healthcare. Clinical Chemistry, 47(8), page 1548. 
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because multiple steps occur between the time of the test and the eventual healthcare 
outcome.27  Outcomes studies address questions such as: “is use of test X associated with 
outcome Y?”28  As a result, a question might be whether a test occurring early on in the 
treatment cycle decreases eventual length of stay.  Bruns argues that outcomes studies, 
such as randomized controlled trials, may not be appropriate measures for the 
effectiveness of tests because they are cost prohibitive.  As a result, while outcomes 
studies might be used in evaluating these types of technologies, they may not always be 
possible.29  Hartmann concludes the opposite, that “prospective measurement of 
outcomes is essential to make clinical decisions about test methods and to guide policy.30 
For 30 years, Evidence-based Practice Centers (EPCs) have used a 6-level 
framework to evaluate diagnostic technologies.  This framework consists of the following 
levels: (1) technical feasibility and optimization; (2) diagnostic accuracy; (3) diagnostic 
thinking impact; (4) therapeutic choice impact; (5) patient outcome impact; and (6) 
societal impact.31  Sunshine summarizes applies the 6-level test to radiological diagnostic 
imaging technologies in Table 6, below. 
                                                
27 Bruns, D. E. (2001). Laboratory-related outcomes in healthcare. Clinical Chemistry, 47(8), 1547-1552. 
 
28 Ibid, page 1548. 
 
29 Ibid, page 1552. 
 
30 Hartmann, K. E., Nanda, K., Hall, S., & Myers, E. (2001). Technologic advances for evaluation of 
cervical cytology: Is newer better? Obstetrical & Gynecological Survey, 56(12), 765-774. 
31 Ibid, page 1049 and 1054. 
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Table 6. Hierarchy of Efficacy for Diagnostic Technologies 
EPC Level Typical Measures 
1. Technical Efficacy • Resolution of line pairs 
• Pixels per millimeter 
• Section thickness 
• Noise level 
2. Diagnostic Accuracy • Sensitivity 
• Specificity 
• Area under the receiver operating characteristic curve 
3. Diagnosis • Percentage of cases in which image is judged helpful in making the 
diagnosis 
• Percentage of cases in which diagnosis made without the test is 
altered – or altered substantially – when information from the test is 
received 
4. Treatment • Percentage of cases in which image is judged helpful in planning 
patient treatment 
• Percentage of cases in which treatment planned without the test is 
changed after information from the test is received 
5. Patient Health Outcomes • Percentage of patients improved with test conducted compared with 
that improved without test conducted 
• Percentage difference in specific morbidities with test compared 
with those without 
• Mean increase in quality-adjusted life years with test compared with 
that without 
6. Societal Value • Cost-effectiveness from a societal perspective 
• Cost per life saved, calculated from a societal perspective 
 
Sunshine sets forth that the basic questions of the efficacy of a diagnostic 
intervention are, “[h]ow much does this do to improve the health of people?” and “How 
much does it cost for that gain in health?”32  From this perspective, one way to consider 
the gap between diagnostic accuracy and outcomes is to use the 6-level “hierarchy of 
efficacy” test.33  Unfortunately, there is rarely sufficient study evidence to satisfy each of 
                                                
32 Sunshine, J. H., & Applegate, K. E. (2004). Technology assessment for radiologists. Radiology, 230(2), 
309-314. 
 
33 Ibid, page 309.  Citing the 6-level test belonging to: Fryback DG, Thornbury JR.  The efficacy of 
diagnostic imaging. Med Decis Making 1991; 11:88-94. Also citing: Thornbury JR. Clinical efficacy of 
diagnostic imaging: love it or leave it. AJR Am J Roentgenol 1994; 162:1-8. 
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the levels. Sunshine describes decision analysis and cost-effectiveness analysis as two 
other ways to measure the efficacy of diagnostic technology.34 
(2) Evaluation of Cost-Effectiveness of New Technologies. 
A second prevalent theme in the peer-reviewed literature is that screening 
technologies may identify the presence of disease earlier.  As a result, physicians and 
patients may have more treatment options available for the treatment of the disease at an 
earlier phase of disease development.  Consequently, this may lead to savings in the 
overall treatment of the disease.  A counter-argument exists that earlier discovery of 
disease results in higher cost because although the disease is identified earlier on in the 
development of the disease, it ultimately results in requiring the disease to be treated for a 
longer duration of time, thus incurring higher overall cost.35 
Tatsioni argues that the main purpose of a test is to help guide patient 
management decisions in order to improve patient outcomes.  As a result, because tests 
are important to healthcare decision-making, they should be evaluated with the same 
amount of effort as a therapeutic intervention.36  Supporters of new technologies 
frequently indicate that the use of these technologies would improve outcomes, avoid 
unnecessary procedures and possibly reduce costs.37  However, these positions depend on 
early screening for a condition for which there is an effective intervention to either cure 
or slow the progression of symptoms in a substantial subset of patients who can be 
                                                
34 Sunshine, page 310. 
 
35 Tatsioni, A., Zarin, D. A., Aronson, N., Samson, D. J., Flamm, C. R., Schmid, C., et al. (2005). 
Challenges in systematic reviews of diagnostic technologies. Annals of Internal Medicine, 142(12 Pt 2), 
1048-1055. 
 
36 Ibid, page 1048. 
 
37 Ibid, page 1053. 
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identified prior to screening.  Further, the disease or condition should be sufficiently 
serious to warrant a medical intervention.  For an example, the stated terms of payer’s 
plan might specifically indicate the scenarios in which an intervention is warranted or 
not. 
Bodenheimer focuses on describing methods to control costs while ensuring 
quality care.38  The purpose of this research study is not to reflect on process measures 
and patient experience.  As a result, a discussion about quality of care is outside the range 
of the evaluation of this research study.  With this taken under consideration, while this 
article does not specifically address screening technologies, it does outline several 
strategies to contain healthcare costs by employing various disease management 
approaches, as well as outlining the importance of improved technology assessment to 
reduce the overuse of new technologies that may not be appropriate.  Specifically, 
Bodenheimer sets forth six interrelated strategies to manage cost and increase quality: (1) 
programs that target the percent of the overall population that incur significant healthcare 
costs; (2) disease management programs used to prevent expensive complications of 
chronic conditions; (3) ways to prevent medical errors; (4) increasing the strength of 
primary care; (5) decision-support tools to help avoid services that are not needed; and 
(6) better diffusion of technology assessment.39   
Based on an analysis of Medicare data, Bodenheimer indicates 10% of the 
population is responsible for 70% of healthcare expenditures.40 This high-cost 10% of the 
                                                
38 Bodenheimer, T et al.  High and rising health care costs.  Part 4: can costs be controlled while preserving 
quality?  Ann.Intern.Med., 2005, 143, 1, 26-31. 
 
39 Ibid. 
 
40 Ibid. 
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Medicare patient population typically have long term chronic diseases that could have 
been mitigated in terms of better quality care and decreased healthcare expenditure if the 
patient had access to primary care.  However, the purview of the Medicare program is to 
provide treatments to patient, not to deliver preventative care via screening and diagnosis 
of disease.  Bodenheimer argues that the use of these six strategies can play a significant 
role in decreasing overall healthcare cost by reducing hospital use and increasing quality 
of care to patients on an ongoing basis.41   
Thus, while this article does not exclusively focus on technology assessment or 
technology assessment for screening products, it does set forth the premise that 
technology assessment should be used to help direct appropriate technology to 
appropriate patients and postulates that this will result in decreased healthcare 
expenditures.  This theme is congruent with the goal of screening products to identify 
disease earlier to better understand and select appropriate treatment options for relevant 
patient populations.  While this conclusion might be true for therapeutic interventions, 
Rogowski sets forth that favorable cost-effectiveness ratios have not yet been obvious for 
genetic testing technologies.42 
(3) Evaluation of Patient Perspectives. 
A third theme that appeared in the peer-reviewed literature involved including the 
patient’s perspective in evaluating the overall effectiveness of a technology.  For 
example, although a technology such as virtual colonoscopy might be extremely effective 
in screening for colorectal cancer.  But, if patients are not adherent in getting the 
                                                
41 Ibid. 
 
42 Rogowski, W. (2007). Current impact of gene technology on healthcare. A map of economic 
assessments. Health Policy (Amsterdam, Netherlands), 80(2), 340-357. 
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procedure, then the offering screening program is not efficacious because patients are not 
receiving the test.43  As a result, patient perspectives might be a valuable criterion to 
consider in evaluating the effectiveness of new procedures.  Patient perspectives can 
relate to satisfaction and quality of life.  These factors influence adherence and patient 
outcomes. 
For screening tests, Schneider, Birch, Inadomi, and Brawley take into account the 
perspective of the patient in selecting an intervention.  Schneider tries to determine the 
actual usefulness of high-cost imaging technologies in Germany by evaluating the level 
of specificity of a patient’s complaint.  Birch discusses taking into account patient 
preference in evaluating whether or not to pursue a particular intervention as it may affect 
the patient’s ultimate well-being.44, 45  Inadomi examines how patient adherence to going 
to get a screening test might affect the use of a test that is highly effective in identifying 
disease early.46  Lastly, Brawley sets forth that a screening test should only be used when 
the potential for benefit outweighs the potential for harm.47  Specifically, Brawley sets 
forth that “[t]o be of benefit, screening must find disease earlier and lead to an efficacious 
treatment, and earlier use of the efficacious treatment must offer better outcome 
compared to treatment at the onset of symptoms.  The benefits must also outweigh the 
                                                
43 Inadomi, J. M. (2008). Taishotoyama symposium barriers to colorectal cancer screening: Economics, 
capacity and adherence. Journal of Gastroenterology and Hepatology, 23 Suppl 2, S198-204. 
 
44 Schneider, A., Rosemann, T., Wensing, M., & Szecsenyi, J. (2005). Physicians perceived usefulness of 
high-cost diagnostic imaging studies: Results of a referral study in a german medical quality network. BMC 
Family Practice, 6(1), 22. 
 
45 Birch, S., & Ismail, A. I. (2002). Patient preferences and the measurement of utilities in the evaluation of 
dental technologies. Journal of Dental Research, 81(7), 446-450. 
 
46 Inadomi, page 198. 
 
47 Brawley, O. W., & Kramer, B. S. (2005). Cancer screening in theory and in practice. Journal of Clinical 
Oncology : Official Journal of the American Society of Clinical Oncology, 23(2), 293-300. 
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harms.”48  Brawley cites that there are examples in which screening tests and treatment 
found cancer at an earlier stage; however, while survival from the date of diagnosis was 
longer, mortality was not affected and a net harm was incurred.49 
Schneider determined that diagnostic technologies were most effective in 
situations in which the patient had a specific complaint.  The usefulness of the technology 
decreased if the patient had a vague complaint for diagnosis.  As a result, he concludes: 
“quality improvement should focus on patients with unexplained complaints to avoid 
expensive, unnecessary or dangerous diagnostic investigations.”50  The data from this 
study supports an investigation into whether specificity of the patient’s complaint should 
be factored into the level of evidence used when evaluating a diagnostic tool.  Inadomi 
concludes that if a patient is not adherent to a highly effective screening test, we should 
question the overall effectiveness of a test that patients do not want to take.51 
(4) Danger of Developing Fragmented Healthcare Policy. 
The fourth theme identified in the literature was a risk of developing fragmented 
healthcare policy in conducting HTA of screening technologies.  Because there are many 
different agencies conducting HTA, these agencies have different missions, visions, and 
funding.  Further, organizations that use HTA as a means for making decisions about 
which technologies to offer to beneficiaries employ different strategies for applying 
HTA.  These organizations have different objectives and responsibilities in the type of 
healthcare that is owed to their beneficiaries. As a result, if access to healthcare for all 
                                                
48 Ibid, page 293. 
 
49 Ibid. 
 
50 Schneider, page 5. 
 
51 Inadomi, page 203. 
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patients should be equal, currently organizations that provide healthcare to beneficiaries 
do not have a point of congruence in the level of evidence required for new technologies, 
there is a substantial risk of creating policy that is not stable.  Conversely, if it is 
acceptable to have different types of healthcare offerings available to beneficiaries, then 
it is acceptable to have different policies.  The overarching danger results when 
fragmented healthcare policy results in stymied innovation and lack of reasonable access 
to care. 
Vermeulen sets forth the overall policy theme regarding the danger of 
fragmentation in the HTA policy environment.  Specifically, Vermeulen discusses the 
challenges faced when involving different authoritative bodies with different agendas in 
evaluating new technologies.  Although this paper refers to agencies and technology 
assessment policy in Belgium, the results are translatable to the United States.  The 
conclusion that involving multiple authorities with different agendas results in 
fragmented policy is a solid conclusion that is a warning sign for the need to develop 
congruencies between HTA agencies.52   
Agency and Institution Website Themes 
 In the United States, there are several agencies that conduct HTAs.  AHRQ 
conducts HTAs for CMS; in addition, they work in collaboration with private institutions 
to conduct HTAs through their Evidence-based Practice Centers (EPC) Program.  In 
addition, there are several private institutions that conduct HTAs.  The common theme 
throughout the evaluation of these institution websites is that there is congruence between 
                                                
52 Vermeulen, V., Coppens, K., & Kesteloot, K. (2001). Impact of health technology assessment on 
preventive screening in belgium: Case studies of mammography in breast cancer, PSA screening in prostate 
cancer, and ultrasound in normal pregnancy. International Journal of Technology Assessment in Health 
Care, 17(3), 316-328. 
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institutions that HTAs are important in evaluating the contribution that a particular 
technology may make.  In addition, there is congruence for the criteria used to evaluate 
therapeutic interventions.  However, one area that is developing is the review of 
screening technologies.  An overview of each institutional website as it relates to HTA is 
set forth below. 
The website for the Centers for Medicare and Medicaid Services (CMS) does not 
have a direct link to either “technology assessment” or “technology assessment for 
diagnosis or screening”.  The results of both of these searches provide links to the 
Agency for Healthcare Research and Quality (AHRQ) that reviews specific technologies 
for CMS.  These HTAs are used by CMS to formulate national coverage decisions for the 
Medicare patient population, as well as to provide information to Medicare carriers.  The 
CMS website does not contain content that specifies the general guidelines or assessment 
criteria for products used to diagnose or screen for disease. 
 The AHRQ website contains information about the Center for Practice and 
Technology Assessment (CPTA).53  Specifically, CPTA “helps to narrow the gap 
between what is known from research about effective and efficient clinical care and what 
is practiced in health care settings.”54  The organization “was established to serve as a 
single contact for organizations and individuals searching for comprehensive evidence 
reviews on health conditions, treatments and technologies.”55  CPTA has four program 
activities: (1) Evidence-based Practice Centers (EPCs) that conduct technology 
assessments; (2) National Guideline Clearinghouse that is a source of clinical practice 
                                                
53 http://www.ahrq.gov/about/cpta/cptafact.htm  Accessed: April 12, 2009. 
 
54 Ibid, Accessed: April 12, 2009. 
 
55 Ibid, Accessed: April 12, 2009. 
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guidelines; (3) US Preventative Services Task Force (USPSTF) which educates primary 
care physicians, health plans, and payers about what services should be included in 
periodic health examinations; and (4) Research and Evaluation focused on methodologies 
used in conducting systematic, evidence-based reviews and syntheses, as well as 
approaches used for implementing evidence-based clinical information into the health 
care delivery system.56 
The EPCs and USPSTF are the most relevant of AHRQ’s four programs to 
understand the technology assessment criteria that might be used for new screening 
technologies.  The function of the EPCs is to “develop evidence reports and technology 
assessments about clinical topics that are common, expensive, and/or significant for the 
Medicare and Medicaid populations.”  Currently, there are 14 EPCs that are contracted in 
the United States and Canada to participate in the program for 5-year intervals.  Table 7 
sets forth the current EPCs that are under contract with AHRQ. 
Table 7. AHRQs Evidence-Based Practice Centers 
Blue Cross and Blue Shield Association, Technology Evaluation Center 
Duke University* 
ECRI Institute* 
Johns Hopkins University 
McMaster University 
Minnesota Evidence-based Practice Center 
Oregon Evidence-based Practice Center** 
RTI International – University of North Carolina 
Southern California 
Tufts – New England Medical Center* 
University of Alberta* 
University of Connecticut 
University of Ottowa 
Vanderbilt University 
* EPCs that focus on HTAs for CMS. 
** EPCs that focus on evidence reports for USPSTF. 
Evidence reports and technology assessments are based on rigorous review of all 
relevant scientific literature and include specific analyses, such as meta-analyses and cost 
                                                
56 Ibid, Accessed: April 12, 2009. 
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analyses, as warranted. Use of these reports and assessments will help reduce 
inappropriate variations in medical care and improve the overall quality and efficiency of 
the health care system.57  The EPC section of the website provides specific HTAs for 
products.  Thus, once a screening intervention is selected for comparison across 
institutions, a search of this section of the website will be helpful in identifying HTAs 
that have been performed relevant to diagnosing or screening for that disease.  These 
specific assessments might provide insight as to whether HTA criteria are modified in 
reviewing products used to screen for disease.  However, the website does not contain 
content that specifies the assessment criteria for products used for screening.  Rather, 
AHRQ and EPCs engage in systematic reviews of technologies. 
One portion of the website provided guidance in determining whether or not a 
technology should be reviewed.  As applied to screening technologies, one component of 
the decision-making process in identifying technologies to review is the development of a 
causal pathway or analytic framework.58  Developing the causal pathway or analytic 
framework is a means for specifying evidence questions for new technologies.  
Specifically, a graphical display can show direct and indirect links between interventions 
and outcomes and are particularly useful for screening interventions.  Because screening 
interventions involve a series of decisions that could each be a topic of an evidence 
question, the graphic is helpful in illustrating where questions of evidence might occur.  
A sample causal pathway is set forth in Figure 1, below. 
 
                                                
57 Ibid, Accessed: April 12, 2009. 
 
58 http://www.ahrq.gov/clinic/epcpartner/epcpartner2.htm#fig1  Accessed: August 15, 2009. 
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Figure 1. General Causal Pathway – Screening Procedure and Alternative Treatments59 
 
This figure provides some guidance as to the possible evaluation points of a screening 
technology.  
The other section of AHRQs website that is useful is the USPSTF.  The USPSTF 
“is an independent panel of experts in primary care and prevention that systematically 
reviews the evidence of effectiveness and develops recommendations for clinical 
preventive services.”60  The USPSTF portion of AHRQs website sets forth tools and 
resources that clinicians can integrate into their practice in order to develop best practices 
for prevention. Once screening interventions are selected for review, this website will be 
searched for USPSTFs review of the particular intervention. 
The Blue Cross Blue Shield Association’s Technology Evaluation Center 
(BCBSATEC) website provides a record of the technology assessments conducted by the 
                                                
59 http://www.ahrq.gov/clinic/epcpartner/epcpartner2.htm  Accessed: August 15, 2009.  Citing: Harris RP, 
Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force. A review of the 
process. Am J Prev Med 2001;20(3S):21-35. 
 
60 http://www.ahrq.gov/clinic/prevenix.htm Accessed: August 15, 2009. 
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BCBSATEC.  These reports are designed to help readers understand the scientific 
evidence on the effectiveness of different treatments and tests, as well as make informed 
decisions about healthcare.61  The five BSBSATEC criteria are set forth on the website: 
(1) the technology must have final approval from the appropriate governmental 
regulatory bodies; (2) the scientific evidence must permit conclusions concerning the 
effect of the technology on health outcomes; (3) the technology must improve the net 
health outcome; (4) the technology must be as beneficial as any established alternatives; 
and (5) the improvement must be attainable outside the investigational settings.62  Like 
the AHRQ website, there is a library of drugs, medical devices, and biotechnology 
products that have received a technology assessment; however, the website does not 
contain content that specifies the assessment specific criteria for products used to screen 
for disease.   
Like the BCBSATEC website, the National Library of Medicine (NLM) website 
has information regarding HTAs.  While the NLM does not conduct technology 
assessments like AHRQ or BCBSATEC, it does have a resource that describes the history 
of health technology assessment by Cliff Goodman, PhD, a noted expert in the HTA 
field.  In order to learn more about resources about HTA and whether the criteria for the 
assessment might change for technologies used to screen for disease, I contacted Dr. 
Goodman directly.63  Dr. Goodman has offered to help identify appropriate products to 
serve as the focus for additional research and subsequent technology assessments that 
                                                
61 http://www.bcbs.com/blueresources/tec/  Accessed: April 12, 2009. 
 
62 http://www.bcbs.com/blueresources/tec/tec-criteria.html  Accessed: April 12, 2009. 
 
63 Goodman, C.  HTA 101 Introduction to Health Technology Assessment. 2004.  
http://www.nlm.nih.gov/nichsr/hta101/ta10103.html#Heading4  Accessed: April 12, 2009. 
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might be helpful for the research question.64  As a preliminary suggestion, Dr. Goodman 
recommended examining technology regarding computed tomographic colonography, a 
type of “virtual colonoscopy” technology. 
The State of Washington’s Health Technology Assessment (WAHTA) website 
provides detail regarding the state’s program.  “The primary purpose of [WA]HTA is to 
ensure medical treatments and services paid for with state health care dollars are safe and 
proven to work.”65  Because of the cost of conducting technology assessments, only 10 
have been conducted by WAHTA within the past two years.  These assessments are 
posted on the website and some are still open for review and comment.  The topics are set 
forth below in Table 8. 
Table 8.  State of Washington Health Technology Assessments 
Technology Category Date Status 
Cardiac Stent Therapeutic 5/8/09 Review Open 
Computed Tomographic Angiography Diagnostic 11/14/08 Review Open 
Artificial Discs Therapeutic 10/17/08 Review Open 
Implantable Infusion Pumps Therapeutic 8/15/08 Decision Complete 
Arthroscopic Knee Surgery Therapeutic 8/15/08 Decision Complete 
Discography Diagnostic 2/15/08 Decision Complete 
Virtual Colonoscopy or Computed Tomographic 
Colonography 
Diagnostic 2/15/08 Decision Complete 
Lumbar Fusion Therapeutic 11/16/07 Decision Complete 
Pediatric Bariatric Surgery Therapeutic 8/24/07 Decision Complete 
Upright/Positional MRI Diagnostic 5/18/07 Decision Complete 
 
Six of these technologies address therapeutic products, 4 address diagnostic products. 
 California Technology Assessment Forum (CTAF) “is a public service forum that 
assesses new and emerging medical technology.”66  This organization believes that the 
growth of new technologies represents the most important change for the delivery of 
                                                
64 Teleconference with Dr. Cliff Goodman, April 13, 2009. 
 
65 http://www.hta.hca.wa.gov/about.html  Accessed: April 12, 2009. 
 
66 http://www.ctaf.org/section/aboutus  Accessed: February 27, 2010. 
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healthcare in America.  While technologies have a positive effect for patients, there is 
also a risk of misuse and overuse of technology.  CTAF is an active proponent of 
evidence-based medicine.  CTAF is spearheaded by Blue Shield of California Foundation 
which manages the technology assessment reviews and organizes all CTAF meetings and 
events.67  CTAF has assessed a significant number of technologies.  Interestingly, like 
WAHTA, virtual colonoscopy was reviewed; however, CTAF distinguished this 
technology as a screening technology, while WAHTA identified it as a diagnostic.  This 
indicates that there may be confusion of terminology between agencies assessing the 
same technology. 
The primary criteria for these assessments include: potential patient harm/safety 
concerns; concerns about therapeutic efficacy or diagnostic accuracy and appropriateness 
of outcomes for patients; and estimated total direct cost per year (estimated 
increase/decrease).68  The secondary criteria for these assessments include: number of 
persons affected per year, severity of condition treated by technology, policy related 
urgency/diffusion concern, potential or observed variation; and special 
populations/ethical concerns.69  Because these criteria are broader than those of 
BCBSATEC, the technology assessments may provide guidance once a specific 
screening product is selected. However, the website does not contain content that 
specifies the assessment criteria for screening products.  
The website for the Evaluation of Genomic Applications in Practice and 
Prevention (EGAPP) provides guidance on the use of genetic tests in specific clinical 
                                                
67 Ibid. 
 
68 http://www.hta.hca.wa.gov/documents/prioritization_criteria.pdf  Accessed: April 12, 2009. 
 
69 Ibid. 
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settings.70  There is a recent report posted regarding Outcomes of Genetic Testing in 
Adults with a History of Venous Thromboembolism.71  Once a specific screening 
procedure is selected for review, this website will be reviewed for any relevant reports. 
The Cochrane Collaboration seeks to improve global healthcare by conducting 
systematic reviews of technology.72  The website will be searched once relevant 
screening products are selected for review and comparison across organizations that have 
conducted HTAs. 
Like AHRQ, BCBSATEC, WAHTA, and CTAF, the National Institute of Health 
and Clinical Evaluation (NICE) website also sets forth their criteria for health technology 
assessments and a library of completed assessments.  Guidance is provided in five key 
areas: cancer service, clinical guidelines, interventional procedures, public health, and 
technology appraisals.  Of these five areas, “technology appraisals” specifies those 
technologies that have published reports, as well as those that are slated for review.  As 
with the other websites, there is no content that provides detail about the assessment 
criteria for products used to screen for disease. 
In each of the websites, the general technology assessment criteria were set forth; 
however, the bulk of the published material involves specific technology assessments for 
particular technologies.  As a result, a selection of technologies directed toward a 
particular product used to treat a specific disease is recommended in order to compare the 
evaluation across agencies for the same technology used to screen for disease. 
 
                                                
70 http://www.egappreviews.org/  Accessed: August 15, 2009. 
 
71 Ibid. 
 
72 http://www.cochrane.org/  Accessed: August 15, 2009. 
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Role of Comparative Effectiveness Research in HTA 
 Comparative Effectiveness Research (CER) emerged from the concern that when 
multiple treatment options exist, there is limited evidence of the effectiveness of one 
particular product over another when used in a routine care setting.  In this context, 
“effectiveness” is defined as “whether an intervention does more good than harm when 
provided under usual circumstances of health care practice.”73  CER is receiving a 
significant amount of attention due to provisions in the American Recovery and 
Reinvestment Act of 2009 (ARRA).74  ARRA provides approximately $1.1 billion 
toward conducting and supporting CER, including establishing a Federal Coordinating 
Council on Comparative Effectiveness Research (FCCCER).75 
Both physicians and health care payers have an interest in CER.  Physicians 
generally have choices among products to prescribe or use to treat a particular condition.  
Therefore, when multiple treatment options are available, the question becomes: which 
product or treatment should be chosen because it is the most effective?76  Similarly, 
health plans are interested in CER for two reasons.  First, health plans have a vested 
interest in the health of their beneficiaries.  Second, health plans have an interest in their 
financial health.  As such, health plans want to structure utilization mechanisms, such as 
formularies and co-payments, to motivate physicians and patients to use the equally 
                                                
73 Schneewiss, S. (2007). Developments in post-marketing comparative effectiveness research. Clinical 
Pharmacology & Therapeutics, 82(2), 143-156, page 143. 
 
74 American Recovery and Reinvestment Act of 2009 (February 17, 2009). 
http://frwebgate.access.gpo.gov/cgi-bin/getdoc.cgi?dbname=111_cong_bills&docid=f:h1enr.pdf. Accessed: 
January 17, 2010.  Congress passed ARRA on February 13, 2009, and President Obama signed it into law 
on February 17, 2009. 
 
75 Ibid. 
 
76 Ibid. 
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effective, but less costly, treatment alternative.77  CER is a mechanism to compare 
multiple options that are available in the market, while HTA is a mechanism to examine 
the risks and benefits of one particular product. 
Literature Review Discussion 
Description of Current Knowledge 
 The objective of this literature review was to determine how researchers and 
policy makers assess technologies related to screening products as they relate to a 
particular disease.  A search of relevant literature and websites revealed that it is not 
immediately apparent whether the criteria for healthcare technology assessments for 
products that screen for a particular disease are any different from assessments for 
therapeutic products.   
As presented earlier, there are three major thematic findings that have been 
revealed through the literature review process.  These findings are set forth below in 
Table 9: 
Table 9.  Literature Review Thematic Findings 
Finding Thematic Finding 
1 The overall value of outcomes evidence to evaluate screening products in a HTA is unclear. 
2 While screening products may identify elevated risk of disease earlier and expand treatment 
options, it is not clear that the overall cost of care is reduced.  Therefore, it is unclear whether 
cost or cost effectiveness should be a criterion for evaluating these technologies as a part of an 
HTA. 
3 Whether patient experience should be a criterion in the HTA process of evaluating a new 
screening product is not considered. 
4 There is a danger of further fragmented healthcare policy without consistent guidance. 
 
A discussion of each of these thematic findings follows. 
 
 
 
 
 
                                                
77 Ibid, at 144. 
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Finding 1. The overall value and attainability of outcomes evidence 
to evaluate screening products in a HTA is unclear. 
 
 Understanding the appropriate level of evidence to evaluate screening 
technologies is the first essential step of an HTA.  It appears from the existing peer-
reviewed literature that there is a lack of agreement regarding what type of evidence 
might best support the HTA evaluation and eventual use of a screening technology.  
While outcomes evidence that is collected by conducting a randomized controlled clinical 
trial certainly produces the highest level of evidence, it is unclear whether this high 
standard should be applied to technologies that detect the presence of disease, rather than 
treat the disease.  
This particular finding is discussed in the Bruns, Hartmann and Sunshine articles. 
Bruns argues that studies that yield outcomes evidence, such as randomized controlled 
trials, may not be appropriate measures for the effectiveness of diagnostic tests because 
they are cost prohibitive.  As a result, while outcomes studies might be used in evaluating 
these types of technologies, they may not always be possible.78  Hartmann concludes the 
opposite, that “prospective measurement of outcomes is essential to make clinical 
decisions about test methods and to guide policy.”79  Meanwhile, Sunshine evaluates the 
6-level test used by EPCs and suggests rather than using outcomes evidence to evaluate 
these technologies, perhaps decision analysis and cost-effectiveness are two more 
appropriate measures.80 
                                                
78 Ibid, page 1552. 
 
79 Hartmann, K. E., Nanda, K., Hall, S., & Myers, E. (2001). Technologic advances for evaluation of 
cervical cytology: Is newer better? Obstetrical & Gynecological Survey, 56(12), 765-774. 
 
80 Sunshine, page 309.s 
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In a review of the websites, a comparison of reviews of a select number of 
technologies across organizations may yield an understanding of how the assessment 
criteria for technologies used to screen for disease might be different than the criteria for 
therapeutic technologies.  The current knowledge gleaned from the identified websites 
supports this first thematic finding.  Once a particular product is selected for comparisons 
across HTA agencies, differences in levels of evidence might become apparent.  If there 
are differences in evidence levels, an evaluation as to why the levels are different might 
yield new approaches, beyond the collection of outcomes evidence, which might support 
the HTA of a screening product. 
Finding 2. While screening products may identify elevated risk of 
disease earlier and expand treatment options, it is not clear that the 
overall cost of care is reduced.  Therefore, it is unclear whether cost or 
cost–effectiveness should be a criterion for evaluating these technologies 
as a part of an HTA. 
 
 The evaluation of cost has been an area of interest for HTA in the United States.  
Traditionally, cost and cost effectiveness have been excluded as a review factor.  
However, in cases in which it is unclear whether a health benefit is being delivered, an 
analysis of cost would be helpful to distinguish whether establishing the presence of 
disease earlier results in better health outcomes that are cost effective. 
This second finding is discussed in various forms in the Bodenheimer, Tatsioni 
and Rogowski articles.81  The thesis of the Bodenheimer article is that there are strategies 
that involve some form of technology assessment that can be employed to reduce the risk 
of inappropriate patient care at a high cost to the healthcare system.  The arguments in 
support of this finding in the Bodenheimer article are compelling, particularly in the 
                                                
81 Bodenheimer, et al.  Page 30. 
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demonstration that in an analysis of the Medicare population, 10% of the population is 
responsible for 70% of healthcare expenditures.82 
Tatsioni argues that the main purpose of a diagnostic test is to help guide patient 
management decisions in order to improve patient outcomes.  As a result, because 
diagnostic tests are important to healthcare decision-making, they should be evaluated 
with the same amount of effort as a therapeutic intervention and cost should play a role in 
the evaluation.83  By way of a baseline, Rogowski sets forth that favorable cost-
effectiveness ratios have not yet been obvious for genetic testing technologies.84 
The current knowledge from the published literature supports the finding that 
evidence-based medicine and coordinated care can result in better quality care, less 
illness and lower healthcare expenditure.  In each of the articles, technology assessment 
comes to play in the establishment of whether or not a particular technology and its effect 
on a specific patient population furthers the spectrum of evidence-based medicine for 
patients who have a specific disease or condition.  This finding is congruent with the 
notion that screening technologies, when used appropriately, may expand treatment 
options for patients; however, at what cost is not clear. 
This thematic finding is also supported in the websites that were reviewed.  In 
particular, the AHRQ, BCBSATEC, National Library of Medicine, State of Washington 
Health Technology Assessment, CTAF, and NICE websites all contain information 
related to the core mission of the role of technology assessment in improving patient care 
and impacting cost.  AHRQ, BCBCATEC, State of Washington, CTAF, and NICE set 
                                                
82 Ibid, page 26. 
 
83 Tatsioni, page 1048. 
 
84 Rogowski, page 350. 
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forth criteria that their organizations follow to assess healthcare technology.  Similarly, 
the resources found on the AHRQ and the National Library of Medicine websites support 
the finding that the purpose of technology assessment is to guide the development of 
evidence-based medicine in order to increase quality of care while decreasing illness and 
healthcare costs.  Further, AHRQ, BCBSATEC, State of Washington, CTAF, and NICE 
have specific reviews of technologies that address various screening technologies.   
This second thematic finding is also covered in the websites for CMS, AHRQ, 
BCBS, State of Washington, CTAF and NICE.  As discussed above in the Results 
section, the mission of these organizations is to establish with regard to particular 
technologies whether the benefit to patient care through the use of the technology might 
result in inappropriate care and increased cost with marginal return.  The technology 
assessments of specific technologies help the organization, and providers of healthcare 
for the organization, to understand whether the technology is beneficial or not.  Thus, 
because several organizations have been established to address the concerns of this 
particular finding, it can be concluded that the current knowledge supports this second 
finding.  However, to what degree is not clear. 
Finding 3. Whether patient experience should be a criterion in the 
HTA process of evaluating a new screening product is not considered. 
 
In both the literature and the website research, there were no statements about 
particular levels of evidence or criteria that are specific for the evaluation of new 
technologies that are used to screen for a particular disease.  Four articles: Schneider, 
Birch, Inadomi and Brawley, suggested that patient preferences should be taken into 
account in evaluating the overall efficacy of a particular intervention.  Specifically, 
Inadomi discusses in great detail that a screening technology might yield impressive 
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ability to screen for disease; however, if a patient does not adhere to getting the test, then 
the utility of the technology is substantially diminished.85  Patient adherence was not 
examined on the organizational websites that were examined. 
As Dr. Goodman suggested in his telephone interview, the selection of a 
particular technology and a comparison across technology assessment organizations 
might yield evidence of different criteria.  However, Dr. Goodman expressed his concern 
that the criteria might be different across organization due to exogenous factors such as 
the mission of the organization (e.g., source of public policy or return on investment for 
investors), source of funding (e.g., taxpayer funds or private funds), and patient 
population served (e.g., Medicare or private payer).  For example, patient adherence or 
minimization of cost drivers, might be a mission of one of the organizations and not the 
others.  Thus, while the current knowledge supports this third thematic finding, the 
rationale for the finding may be difficult to discern due to the influence of outside 
factors.86  
 Criteria for a screening HTA should be different than therapeutic options because 
screening technologies serve a different purpose.  The purpose of screening tests and 
procedures is to identify the presence of disease.  It is not the purpose of a screening 
product to actually treat disease.  Screening occurs at the beginning of the clinical 
pathway.  To hinge the acceptance of a screening product on the eventual outcome of the 
case at the end of the clinical pathway may not be appropriate for these technologies.  
Similarly, a HTA that only evaluates outcomes evidence could be extremely damaging to 
the development of new screening products because acquiring the level of evidence 
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86 Teleconference with Dr. Clifford Goodman, April 13, 2009. 
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necessary for a therapeutic option may not be applicable to a screening product.  In 
addition, if HTA criteria use the highest standards of evidence such as outcomes evidence 
produced from a randomized controlled clinical trial, innovation in the field of screening 
may be substantially stifled due to the high standard of evidence required.   
Finding 4: Danger of Further Fragmenting Healthcare Policy without 
Consistent Guidance. 
 
The fourth theme identified in the literature was a risk of further fragmenting 
healthcare policy in conducting HTA of screening technologies if standards are not 
consistently applied.  While healthcare policy is already fragmented, the development of 
best practices and standards helps to provide clinical guidance and prevent further 
fragmentation.  Because there are many different agencies conducting HTA, these 
agencies have different missions, visions, and funding.  Vermeulen stated that involving 
multiple authorities with different agendas results in fragmented policy is a solid 
conclusion that is a warning sign for the need to develop congruencies between HTA 
agencies.87  Further, AHRQ is trying to centralize and unify the development of 
healthcare policy regarding HTA via their network of EPCs that conduct assessments.  
However, this point emphasizes that if agencies do not have a point of congruence in the 
level of evidence required for new technologies, there is a substantial risk of exacerbating 
the existing fragmentation in healthcare policy by neglecting to take advantage of 
opportunities to creating consistent standards to guide decision-making. 
 
 
                                                
87 Vermeulen, V., Coppens, K., & Kesteloot, K. (2001). Impact of health technology assessment on 
preventive screening in Belgium: Case studies of mammography in breast cancer, PSA screening in 
prostate cancer, and ultrasound in normal pregnancy. International Journal of Technology Assessment in 
Health Care, 17(3), 316-328. 
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Quality of Studies 
 The quality of the studies reviewed in the literature was strong.  Although there 
were only 12 sources to review, each had strong sample sizes, viable study designs, and 
were specific in the topic each article addressed.  With regard to this last point, while 
none of the articles expressly addressed the research question for this literature review, 
each paper did make clear what particular topic was to be addressed in the article and 
engaged in a rigorous review process.  
 The content in the websites that were reviewed were stronger than the articles. 
Because websites are created by organizations with specific missions and agendas, biases 
about the importance or significance of technology assessment could be skewed.  
However, the strength of the websites can be attributed to their overall purpose: to 
educate the public about the purpose of technology assessment for their particular 
organization.  As such, the quality of the websites in explaining their purpose and criteria 
for technology assessment was strong.  However, there was lower usefulness for 
addressing the particular research question for this literature review.  Specifically, absent 
an intensive review of a particular technology assessment for a single product that 
addresses screening for a particular disease, it is not clear whether these organizations 
have different review criteria for products that are therapeutic.  Further, as described by 
Dr. Goodman, even an intensive comparison of the review of a technology may not 
deliver consistent results about the criteria used due to the outside factors that might have 
influence over the organization.88 
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Gaps in Current Literature 
 The clear gap in the current literature is that there is nothing that directly 
addresses whether the technology assessment criteria for products used to screen for 
disease are any different than those used to treat a disease.  As described above, a review 
of a specific screening product across technology assessment organizations might provide 
insight into this question.  However, this additional research must include a discussion 
regarding external factors that might influence the criteria used by the organization such 
as the mission of the organization, funding source, and patient populations served by the 
organization. 
Implications for Future Research 
The objective of this literature review is to determine how healthcare technology 
agencies assess technologies used to screen for a particular disease.  Based on an initial 
review of the peer-reviewed literature it appears that there is a lack of knowledge and 
congruence concerning healthcare technology assessment criteria for products used to 
screen for disease.  While there were no articles that were directly addressing the research 
question, there were several articles that addressed pieces of the issue.  These findings 
may indicate that:  
(1) determining how healthcare technology agencies assess technologies used to 
screen for a particular disease is an area that requires the piecing together of several 
studies via the information published on the organizational websites identified through 
the literature review process; 
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 (2) a review of aspects of healthcare, such as drivers of healthcare costs, may 
result in a more focused view regarding how assessments might be applied to improve 
screening for disease through cost management and patient quality of care; and  
(3) an understanding of outside factors that might influence a technology 
assessment organization may provide insight into the rationale for the criteria used for a 
particular technology assessment.   
 These are areas for recommended additional research in the process of 
determining whether technology assessment criteria might vary for a screening 
technology, and what factors might influence the differences. 
Limitations of Review Process 
The most significant limitations of the review process were whether the keywords 
used and the databases searched yielded the most relevant and comprehensive sources 
available to address the research question.  Few relevant articles were identified using 
Google Scholar and PubMed.  Similarly, the websites that were researched did not 
provide specific guidance regarding the research question.  Thus, this method of article 
identification poses a significant risk of missing relevant literature and website resources.  
Interviews with thought leaders may help in the identification of additional sources of 
information, policies, and reports. 
The second significant limitation of the review process is that the small number of 
studies and websites may not be indicative of the available information.  The keywords 
used were very specific to “healthcare technology assessment” and “diagnostic” and 
“screening”.  If a specific product used to diagnose or screen for a particular disease is 
used to narrow the search further, it may be that additional resources will become 
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evident.  For example, there are several screening products that have received a 
technology assessment such as virtual colonoscopy.  Interestingly, State of Washington 
identified this technology as a diagnostic, while CTAF identified it as a screening 
technology.  Regardless of terminology, assessments for the same technology should be 
compared across different technology assessment agencies to determine if the technology 
assessment criteria and levels of evidence are congruent or divergent.  In addition, 
international agencies that conduct technology assessment for the same product should be 
reviewed to determine whether the criteria and levels of evidence are the same or 
different.  From this analysis, perhaps a best practice can be construed to provide 
guidance to the screening industry regarding the level of evidence that their product must 
support in order to receive a positive technology assessment recommendation.  Thus, 
perhaps a highest common denominator might be created across countries. 
Literature Review Conclusion 
Given the rising cost of healthcare and the significant policy discussion regarding 
the cost of healthcare being driven by varying degrees of patient access to healthcare 
technologies, it is interesting that there is little data and guidance found regarding the 
review of products that are used to screen for disease.  Arguably, due to the lengthy time 
to treat many chronic conditions that are discovered by screening products and 
procedures, one would expect significant data and information about assessing whether or 
not screening products offer patients better care because the disease is discovered earlier 
in the clinical pathway.  The existing research as discussed here, identifies the 
preliminary findings that points to gaps in the literature, as well as provides direction 
regarding initiating additional research for a more thorough understanding of the topic. 
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It is hoped that the limitations of the current review process can be mitigated 
through additional research, including interviews with thought leaders.  Specifically, the 
three areas for future research, identified above, will likely reveal additional resources 
who may further elucidate more of the answer to the research question posed in this 
study.   
  
 
Chapter 3: Methods and Analysis Plan 
The objective of this study is to determine how health technology assessment 
agencies assess technologies related to screening products.   Specifically, the previous 
chapter identified four prevalent themes: (1) value of outcomes evidence; (2) evaluation 
of cost-effectiveness of new technologies; (3) evaluation of patient perspectives; and (4) 
danger of developing fragmented healthcare policy without guidance. 
Study Design and Data Sources 
Qualitative interviews involving technology assessment experts, decision-makers, 
and other personnel at relevant organizations provide the most current and credible 
information on existing levels of evidence, as well as the future direction of technology 
assessment for screening products.  While quantitative analysis of the levels of evidence 
required by health technology agencies for diagnostic and screening products would 
produce a desirable study design, the findings of the literature review indicate that 
quantitative evidence does not exist for health technology assessment.  As a result, 
qualitative methods are the most appropriate for this study. 
This study employs primarily qualitative research methods.  Specifically, a “best 
practices” document review will examine existing levels of evidence employed by 
technology assessment agencies and other relevant organizations.  This approach 
provides the researcher with an overview of the current methods for health technology 
assessment for screening products and preliminary evidence of any future trends.  
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Sources for the document review consist of publicly available technology 
assessment decisions, working documents from subject matter experts, articles in peer-
reviewed journals, newspaper articles, websites, and other relevant documents.  
In addition, the study includes interviews involving subject matter experts (e.g., 
technology assessment experts and decision-makers, etc.) at health insurance companies 
and other organizations implementing healthcare technology assessments.  The basic 
objectives of these interviews will be to develop a more detailed understanding of the 
objectives, drivers, structure, effectiveness, organizational commitment to and lessons 
learned from the development of standards of evidence for screening products.  
Respondents for the interviews include technology assessment thought leaders, decision 
makers at technology assessment organizations, or related personnel at organizations 
implementing technology assessments. 
The data collection and analysis portions of the study are estimated to require 
approximately five months. The limitations presented by this approach lie in the possible 
absence of standards of evidence for evaluating these types of products, inability for 
thought leaders to comment on levels of evidence currently in use, and the availability of 
experts to respond to the interview questionnaire.   
Other limitations to this approach include the following:  the possible lack of 
availability of documentation or information on best practices, as they may be considered 
confidential or proprietary trade secrets, or they may not be publicly accessible; the 
quality of the information shared (e.g., accuracy or completeness of the documentation); 
potential bias that interviewees may inject into their responses, either due to presence of 
the researcher or to the respondents’ role in the program being evaluated; and the natural 
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variability in respondents’ abilities to fully perceive and to effectively communicate all of 
the information requested by the researcher.  The researcher’s role as a healthcare 
consultant regarding the coverage and payment of new technologies, which may inhibit 
the ability of experts to answer a questionnaire or interview, is also a limitation to be 
considered. 
Addressing these limitations requires careful validation techniques such as 
triangulating multiple sources of information, asking respondents to review and affirm or 
modify transcripts or other summaries of their interviews. 
Data Collection Procedures 
Document Review 
Technology assessments will be reviewed to select specific products that have 
been reviewed by HTA agencies.  The document review will serve two purposes.  First, it 
will provide a secondary data source for the subset of research questions focused on 
specific screening technologies.  Secondly, it will identify organizations to tap for 
interviews.  Information gathered in the document review will be summarized 
thematically, in tabular format. 
Interviews 
 Respondents for the interviews will include technology assessment thought 
leaders, decision makers at technology assessment organizations, or related personnel at 
organizations implementing technology assessments.  Respondents will be identified on 
the basis of the following factors:  
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1. A determination, via the best practices and literature review, that the subject’s 
organization is implementing/has implemented (or is a leader in the community 
that is the intended beneficiary of) a program to evaluate screening technologies.   
2. The subject’s responsibilities related to either the implementation or ongoing 
oversight of such program(s). 
3. A representative from the manufacturer of the selected screening technology that 
is being evaluated. 
4. A representative from a patient advocacy group that is a supporter or detractor of 
the screening technology that is being evaluated. 
All interviews will be conducted by telephone. See Appendix 1 for the 
recruitment document and Appendix 2 for the interview guide.  Results will be evaluated 
for completeness and summarized in a data table.  
Data Management and Analysis 
Since the research question is an emerging field of technology assessment, it is 
anticipated that relatively few interviews, 8 to 10, will be conducted.  Considerations 
regarding the bias of the interviewed subject and agency must be taken into account.  The 
analysis will likely parallel that of a literature review, e.g., groupings of themes, a 
discussion of findings, and a presentation of conclusions.  The notes taken from the 
interviews will be analyzed to identify themes and to compare and contrast responses 
across interviews.  To the extent possible, the data will be quantified.  For example, if 
similar technology review endpoints between agencies are identified, these themes will 
be counted or weighted either by frequency of mention, extent of treatment of a theme, or 
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both.  Further, themes illuminated by the initial document review may yield a set of 
scales with which to quantify one or more aspects of the interviews. 
If an organization has performed a quantitative analysis of their program, and is 
willing to share that information, it will also be included in the study as secondary data.  
For example, there may be evidence tables or criteria that have already been developed 
by an organization to evaluate screening products.  If this information is made available 
to the researcher, it will be included in the study.  However, issues related to bias and 
validity must be considered if these materials are not published or peer-reviewed. 
Proposed Study Deliverables 
This research will result in a detailed summation of current methods employed by 
technology assessment agencies designed to accomplish any of the following related to 
identifying the criteria used to evaluate screening products: (1) value and of outcomes 
evidence; (2) evaluation of cost-effectiveness of new technologies; (3) evaluation of 
patient experience; and (4) danger of further fragmenting healthcare policy when there 
may be an opportunity to create a standard. 
The approach outlined above includes an intentional narrowing of the research 
focus from very broad to the most narrow.  This method both anticipates that the levels of 
evidence identified and examined will drastically decline as the focus narrows, and 
appreciates that there will be valuable information to be derived from each program that 
shares information about how they conduct technology assessments for screening 
products.  
The summation will include a discussion and evaluation of any and all relevant 
data or other evidence provided by the evaluated programs that indicates success against 
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stated objective(s).  Examples of such markers include: (1) stated levels of evidence for 
screening products; (2) the thoroughness of the health technology assessments for a 
particular technology; and (3) any information regarding the future development of 
specific guidelines in this area of health technology assessment. 
A recommendation will be created for health technology assessment agencies, 
health insurers, and other organizations to take to establish levels of evidence for the 
technology assessment of screening products in the United States.  Depending upon the 
volume and quality of information discovered through the research, this may consist of 
simply of a “best practices” checklist in the event that few programs or methods exist to 
be reviewed, or as elaborate as a specific description of relevant levels of evidence to 
integrate into a health technology assessment to guide an organization through the 
prioritization and sequencing of levels of evidence to effectively evaluate new screening 
products.  In addition, where relevant, differing objectives of technology assessment 
panels will be acknowledged.  
IRB and Confidentiality Issues 
This study will require research that involves direct interaction with human 
subjects; therefore all relevant information was submitted to the Public Health-Nursing 
Institutional Review Board (IRB).  The study was approved by the IRB and is identified 
as Study Number 11-0624.  
 Qualifying subjects will be recruited via email and telephone contact.  
Respondents will be provided with a full written description of the study prior to the 
interviews, and provided with an opportunity to ask questions and/or express concerns 
via the method of their choice (e.g., email or telephone) prior to scheduling their initial 
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interview.  Verbal or signed consent from proposed respondents will be obtained prior to 
any data collection, in accordance with the IRB approval conditions. 
Appointments will be made ahead of time for the phone interviews. This will give 
the interviewees opportunities to schedule a time when they can talk in a private space. 
Voice recording will not be used.  At no point will the name, location or any other 
element that may allow the reader to ascertain the specific insurer or organization be 
identified.  Maximum interview time will be 60 minutes. 
 
 
 
 
 
Chapter 4: Health Technology Assessment Comparison 
Computed Tomographic (CT) Colonography for Colon Cancer Screening 
  
Computed Tomographic (CT) colonography, also called virtual colonoscopy, is a 
screening technology for colon cancer.  A review of the HTA websites set forth in Table 
10 identified CT colonography as the only screening technology with publicly available 
HTAs from different HTA agencies. 
Table 10. HTA Websites 
 
Institution/Agency 
 
Website 
HTA of CT 
Colonography 
Centers for Medicare and Medicaid 
Services 
http://www.cms.hhs.gov/default.asp? No 
Agency for Healthcare Research and 
Quality 
http://www.ahrq.gov/ No 
Blue Cross Blue Shield Association 
Technology Evaluation Center 
http://www.bcbs.com/blueresources/tec/ Yes 
California Technology Assessment 
Forum 
http://www.ctaf.org/ Yes 
U.S. Preventative Services Task Force http://www.ahrq.gov/CLINIC/uspstfix.htm Yes 
National Library of Medicine – 
National Institutes of Health 
http://www.nlm.nih.gov/ No 
State of Washington’s Health 
Technology Assessment 
http://www.hta.hca.wa.gov/ Yes 
Evaluation of Genomic Applications in 
Practice and Prevention 
http://www.egappreviews.org/ No 
Cochrane Collaboration http://www.cochrane.org/ No 
National Institute of Health and 
Clinical Excellence 
http://www.nice.org.uk/ Yes 
 
Background: Colorectal Cancer 
 Colon cancer forms in the longest part of the large intestine in the tissues of the 
colon.  Rectal cancer forms in the last several inches of the large intestine in the tissues of 
the rectum.  Colorectal cancer is a disease in which cells in the colon or rectum become 
 60 
abnormal and divide without control, forming a mass that may spread to form new 
masses in other parts of the body.89  According to the National Cancer Institute: 
“Colorectal cancer is the third most common type of non-skin cancer in 
men (after prostate cancer and lung cancer) and in women (after breast 
cancer and lung cancer). It is the second leading cause of cancer death in 
the United States after lung cancer. Although the rate of new colorectal 
cancer cases and deaths is decreasing in this country, more than 145,000 
new cases were diagnosed and more than 49,000 people died from this 
disease each year over the past 5 years.”90 
In 2010, there are an estimated 102,900 new cases of colon cancer and 39,670 of rectal 
cancer in the United States.91  Deaths from colon cancer and rectal cancer, combined, in 
the United States are 51,370 in 2010.92 
 The United States Preventative Services Task Force (USPSTF) reports that more 
than 80% of diagnosed cases of colorectal cancer occur in patients over age 55.  USPSTF 
also reports the age-adjusted incidence is 51.6 per 100,000 persons, with a lifetime risk of 
diagnosis of 5.7% for men and 5.1% for women.93  Increased incidence is associated with 
increased age, male sex and black race.  The incidence rate has decreased over the past 20 
                                                
89 National Cancer Institute, U.S. National Institutes of Health. Colorectal Cancer Screening. 
http://www.cancer.gov/cancertopics/factsheet/Detection/colorectal-screening Accessed: November 13, 
2010. 
 
90 Ibid. 
 
91 National Cancer Institute, U.S. National Institutes of Health. Colon and Rectal Cancer. 
http://www.cancer.gov/cancertopics/types/colon-and-rectal Accessed: November 13, 2010. 
 
92 Ibid. 
 
93 U.S. Preventative Services Task Force. (2008). Screening for colorectal cancer: U.S. Preventative 
Services Task Force Recommendation. Ann Intern Med, 149:627-37, at 631. 
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years among men of all racial and ethnic groups except for Hispanics/Latinos and Alaska 
Natives.  Incidence has stabilized among women of all racial and ethnic groups except 
Alaska Natives.94  In 2002, USPSTF issued a strong recommendation that average-risk 
adults, age 50 or older, receive screening for colorectal cancer.95 
Colorectal Cancer Screening 
Although the exact causes of colorectal cancer are not known, there are studies 
that have identified factors, such as age, presence of colon or rectal polyps, and personal 
history; that are linked to an increased likelihood of developing the disease.96  The early 
identification and removal of polyps may help to prevent colorectal cancer.  As a result, 
screening for colorectal cancer can help to detect cancer, polyps, and nonpolypoid lesions 
that might develop into colorectal cancer over time. Colorectal cancer is more treatable 
when found early.  If the screening reveals an issue, diagnosis and treatment can occur 
quickly.97 
There are data from several sources that demonstrate a reduction in mortality 
when there is regular screening for colorectal cancer.98 However, “[d]espite its 
                                                
94 Ibid. 
 
95 Ibid. 
 
96 National Cancer Institute, U.S. National Institutes of Health. Colorectal Cancer Screening. 
http://www.cancer.gov/cancertopics/factsheet/Detection/colorectal-screening Accessed: November 13, 
2010. 
 
97 Ibid. 
 
98 Johnson CD, Chen MH, Toledano AY, et al. (2008). Accuracy of CT colonography for detection of large 
adenomas and cancers. N Engl J Med, 359(12):1207-17, page 1208.  Cross-referencing the following 
sources: 
 
Liedenbaum MH, Vries AH, Rijn AF, et al. (2010). CT colonography with limited bowel preparation for 
the detection of colorectal neoplasia in an FOBT positive screening population. Abdominal Imaging, 35:6, 
661-668. 
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effectiveness, colorectal-cancer screening remains underused for many reasons, including 
drawbacks in terms of the performance, comfort, availability, and expense of currently 
endorsed test options.”99 Table 11 sets forth the National Cancer Institute’s catalog of 
advantages and disadvantages of the currently available methods for colorectal cancer 
screening.    
Table 11. National Cancer Institute: Advantages and Disadvantages of Colorectal Cancer Screening 
Tests100 
Test Advantages Disadvantages 
Fecal Occult Blood Test 
(FOBT) 
• No cleansing of the colon 
is necessary. 
• Samples can be collected 
at home. 
• The cost is low compared 
with other colorectal 
cancer screening tests. 
• FOBT does not cause 
bleeding or 
tearing/perforation of the 
lining of the colon. 
• This test fails to detect most polyps and some 
cancers.101,102 
• False-positive results (the test suggests an abnormality 
when none is present) are possible.103 
• Dietary restrictions and changes, such as avoiding 
meat, certain vegetables, vitamin C, iron supplements, 
and aspirin, and increasing fiber consumption, are often 
recommended for several days before a guaiac FOBT. 
These restrictions and changes are not required for 
immunochemical FOBT. 
• Additional procedures, such as colonoscopy, may be 
necessary if the test indicates an abnormality. 
                                                                                                                                            
Heresbach D, Chauvin P, Grolier J, et al. (2010). Cost-effectiveness of colorectal cancer screening with 
computed tomography colonography or fecal blood tests. European Journal of Gastroenterology & 
Hepatology, 22:11, 1372-1379. 
 
Sacher-Huvelin S, Coron E, Gaudric M, et al. (2010). Colon capsule endoscopy vs. colonoscopy in patients 
at average or increased risk of colorectal cancer. Alimentary Pharmacology & Therapeutics, 32:9, 1145-
1153. 
 
99 Ibid. 
 
100 National Cancer Institute, U.S. National Institutes of Health. Colorectal Cancer Screening. 
http://www.cancer.gov/cancertopics/factsheet/Detection/colorectal-screening Accessed: November 13, 
2010. 
 
101 Burch JA, Soares-Weiser K, St John DJ, et al. (2007). Diagnostic accuracy of faecal occult blood tests 
used in screening for colorectal cancer: A systematic review. Journal of Medical Screening; 14(3):132–
137. 
 
102 Ouyang DL, Chen JJ, Getzenberg RH, Schoen RE. (2005). Noninvasive testing for colorectal cancer: A 
review. American Journal of Gastroenterology; 100(6):1393–1403. 
 
103 Ibid, footnotes 14 and 15. 
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Test Advantages Disadvantages 
Sigmoidoscopy • The test is usually quick, 
with few complications. 
• For most patients, 
discomfort is minimal. 
• In some cases, the doctor 
may be able to perform a 
biopsy (the removal of 
tissue for examination 
under a microscope by a 
pathologist) and remove 
polyps during the test, if 
necessary. 
• Less extensive cleansing 
of the colon is necessary 
with this test than for a 
colonoscopy. 
• This test allows the doctor to view only the rectum and 
the lower part of the colon. Any polyps in the upper 
part of the colon will be missed. 
• There is a very small risk of bleeding or tearing/ 
perforation of the lining of the colon.104 
• Additional procedures, such as colonoscopy, may be 
necessary if the test indicates an abnormality. 
Colonoscopy • This test allows the doctor 
to view the rectum and 
the entire colon. 
• The doctor can perform a 
biopsy and remove polyps 
or other abnormal tissue 
during the test, if 
necessary. 
• This test may not detect all small polyps, nonpolypoid 
lesions, and cancers, but it is one of the most sensitive 
tests currently available. 
• Thorough cleansing of the colon is necessary before 
this test. 
• Some form of sedation is used in most cases. 
• Although uncommon, complications such as bleeding 
and/or tearing/perforation of the lining of the colon can 
occur.105 
Virtual Colonoscopy • This test allows the doctor 
to view the rectum and 
the entire colon. 
• This is not an invasive 
procedure, so there is no 
risk of bleeding or 
tearing/perforation of the 
lining of the colon. 
• This test may not detect all small polyps, nonpolypoid 
lesions, and cancers.106, 107 
• Thorough cleansing of the colon is necessary before the 
test. 
• If a polyp or nonpolypoid lesion 6 to 9 millimeters in 
size or larger is detected, standard colonoscopy, usually 
immediately after the virtual procedure, will be 
recommended to remove the polyp or lesion or perform 
a biopsy.108, 109 
                                                
104 Gatto NM, Frucht H, Sundararajan V, et al. (2003). Risk of perforation after colonoscopy and 
sigmoidoscopy: A population-based study. Journal of the National Cancer Institute; 95(3):230–236. 
 
105 Ibid. 
 
106 Pickhardt PJ, Choi JR, Hwang I, et al. (2003). Computed tomographic virtual colonoscopy to screen for 
colorectal neoplasia in asymptomatic adults. New England Journal of Medicine; 349(23):2191–2200. 
 
107 Johnson CD, Chen MH, Toledano AY, et al. (2008). Accuracy of CT colonography for detection of 
large adenomas and cancers. New England Journal of Medicine; 359(12):1207–1217. 
108 Rex DK, ACG Board of Trustees. (2004). American College of Gastroenterology action plan for 
colorectal cancer prevention. American Journal of Gastroenterology; 99(4): 574–577. 
 
109 Summerton S, Little E, Cappell MS. (2008) CT colonography: Current status and future promise. 
Gastroenterology Clinics of North America; 37(1):161–189. 
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Test Advantages Disadvantages 
Double Contrast Barium 
Enema (DCBE) 
• This test usually allows 
the doctor to view the 
rectum and the entire 
colon. 
• Complications are rare. 
• No sedation is necessary. 
• This test may not detect some small polyps and 
cancers.110 
• Thorough cleansing of the colon is necessary before the 
test. 
• False-positive results are possible. 
• The doctor cannot perform a biopsy or remove polyps 
during the test. 
• Additional procedures are necessary if the test indicates 
an abnormality. 
Digital Rectal Exam 
(DRE) 
• Often part of a routine 
physical examination. 
• No cleansing of the colon 
is necessary. 
• The test is usually quick 
and painless. 
• The test can detect abnormalities only in the lower part 
of the rectum. 
• Additional procedures are necessary if the test indicates 
an abnormality. 
  
The American Cancer Society recommends that people at average risk should 
begin screening for colorectal cancer at age 50.  Options for testing are as follows:111 
Tests that find polyps and cancer: 
• Flexible sigmoidoscopy every 5 years 
• Colonoscopy every 10 years 
• Double-contrast barium enema every 5 years 
• CT colonography (virtual colonoscopy) every 5 years 
Tests that mainly find cancer: 
• Fecal occult blood test (FOBT) every year 
• Fecal immunochemical test (FIT) every year 
• Stool DNA test (sDNA), interval uncertain 
An interval of 10 years is recommended for rescreening patients with a negative 
finding from a colonoscopy.  This interval “is based on the average time to progression 
                                                
110 PDQ® Cancer Information Summary. National Cancer Institute; Bethesda, Maryland. Colorectal 
Cancer Screening—Health Professional. Date last modified: 08/26/2008. Available at 
http://www.cancer.gov/cancertopics/pdq/screening/colorectal/healthprofessional. Accessed: October 3, 
2008. 
 
111 American Cancer Society. Can colorectal cancer be found early? 
http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-detection Accessed: 
December 27, 2010. 
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from an adenomatous polyp to cancer is at least 10 years.”112 The Centers for Disease 
Control and Prevention states that “[t]he decision to be screened after age 75 should be 
made on an individual basis.”113  
USPSTF notes that there are harms associated with all forms of colorectal cancer 
screening.  For example, a positive test leads to follow up testing to confirm the 
diagnosis, usually a colonoscopy.  Colonoscopy can result in: morbidity, patient anxiety, 
inconvenience, discomfort, as well as additional medical costs.114  Thus, while screening 
is recommended for age-appropriate asymptomatic patients to decrease mortality, there is 
no preferred method and there is risk of harm with each option. 
CT Colonography for Colorectal Cancer Screening 
The impetus for CT colonography is to allow visualization of the colon and 
rectum with lower risk of perforation and other complications.115  CT colonography uses 
helical computed tomography combined with computer software to generate detailed 
images of the inner surface of the colon for review by a radiologist.116  Similar to a 
conventional colonoscopy, CT colonography requires a full bowel cleansing and uses a 
tube to fill the colon with air.  The test typically takes 10 minutes and involves two scans.  
                                                
112 Madison Clinic, Harborview Medical Clinic, University of Washington Medical Center. Screening for 
Colorectal Cancer. http://depts.washington.edu/madclin/providers/guidelines/colorectal.html Accessed: 
December 27, 2010. 
 
113 Centers for Disease Control and Prevention. Colorectal Cancer Screening Guidelines.  
http://www.cdc.gov/cancer/colorectal/basic_info/screening/guidelines.htm Accessed: December 27, 2010. 
 
114 U.S. Preventative Services Task Force. (2008). Screening for colorectal cancer: U.S. Preventative 
Services Task Force Recommendation. Ann Intern Med, 149:627-37, at 632. 
 
115 Ibid, at 633. 
 
116 CT Colonography (“Virtual Colonoscopy”) for Colon Cancer Screening. (2009).  Blue Cross Blue 
Shield Association, Technology Evaluation Center.  Assessment Program, Volume 24, No. 1, page 1. 
August 2009. 
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One while the patient is lying on their back and the other with the patient lying on their 
stomach.  Each scan lasts 10 to 15 seconds.117  Advantages of the technology include: fast 
imaging of the entire colorectum, minimally invasive technique, no need for sedation, 
and there is a low-risk for complications from the procedure.118 
Prior to 2008, several small clinical trials for CT colonography had been 
conducted.  In 2008, the results of the National CT Colonography Trial of the American 
College of Radiology Imaging Network (ACRIN study) were published in the New 
England Journal of Medicine.119  The objective of the ACRIN study was to evaluate the 
technology in a prospective trial setting in order to evaluate the performance of CT 
colonography versus the standard of care colonoscopy.  The ACRIN study involved 15 
training centers and recruited 2600 asymptomatic patients aged 50 years old or older.  
“CT colonographic images were acquired with the use of standard bowel preparation, 
stool and fluid tagging, mechanical insufflation, and multidetector-row CT scanners (with 
16 or more rows).  Radiologists trained [and tested for participation this trial] in CT 
colonography reported all lesions measuring 5mm or more in diameter…[t]he primary 
end point was detection by CT colonography of histologically confirmed large adenomas 
and adenocarcinomas (10 mm in diameter or larger) that had been detected by 
                                                
117 American Cancer Society. Can colorectal cancer be found early? 
http://www.cancer.org/cancer/colonandrectumcancer/detailedguide/colorectal-cancer-detection Accessed: 
December 28, 2010. 
 
118 Johnson CD, Chen MH, Toledano AY, et al. Accuracy of CT colonography for detection of large 
adenomas and cancers. New England Journal of Medicine 2008; 359(12):1207–1217. 
 
119 Ibid. 
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colonoscopy; detection of smaller colorectal lesions (6 to 9 mm in diameter) were also 
evaluated.”120   
The ACRIN study is of particular interest because completed data were collected 
for 2531 patients (97%) and same day CT colonographic and colonoscopic exams were 
performed on 2512 of the 2531 patients.121  In addition, 89% of participants had no 
known risk factors for colorectal cancer, other than age.  This multicenter study of 
asymptomatic patients showed that 90% of patients with adenomas and cancers 
measuring 10 mm or more were identified with CT colonography.  As a result, the 
ACRIN study substantially supported previous studies regarding the accuracy of CT 
colonography.122 
Health Technology Assessment (HTA) and CT Colonography 
Screening technologies are difficult for HTA agencies to review.  In the 
assessment process, HTA agencies are looking for screening technologies that can both: 
(1) identify disease with sufficient sensitivity and specificity to be considered accurate; 
and (2) allow available screening technology interventions to be used in order to avoid 
the shortening of life and reduction of functioning status before other diseases and aging 
do so.  As a result, the proof of the value of a screening technology depends to a much 
greater degree than other medical technologies on: (1) the availability of successful 
interventions to patients; and (2) the ability to counter hypotheses that a large proportion 
of positive findings are either indolent or sufficiently slow in progression to mean that 
other conditions are more likely to cause mortality of morbidity.   
                                                
120 Ibid. 
 
121 Ibid. 
 
122 Ibid. 
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These challenges related to the assessment of screening technologies are apparent 
in the reports issued by five different HTA agencies regarding CT colonography.  
Assessments and reports were issued from 2004 to 2009 and resulted in two agencies 
finding sufficient evidence to support the use of this technology. The agencies, dates of 
review and outcome of the HTA are set forth in Table 12. 
 
Table 12. HTA Agencies with Assessments of CT Colonography 
Date  HTA Outcome 
June 2004 California Technology Assessment Forum Insufficient Evidence 
July 2004 Blue Cross Blue Shield Association TEC Insufficient Evidence 
June 2005 National Institute of Health and Clinical Excellence Sufficient Evidence 
August 2008 State of Washington HTA Insufficient Evidence 
November 2008 U.S. Preventative Services Task Force Insufficient Evidence 
March 2009 California Technology Assessment Forum Insufficient Evidence 
August 2009 Blue Cross Blue Shield Association TEC Sufficient Evidence 
 
Detail follows regarding each technology assessment agency, levels of evidence applied 
to CT colonography, and the outcome for each assessment. 
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California Technology Assessment Forum 
 California Technology Assessment Forum employs a four-step assessment 
process for the evaluation of new and emerging technologies.   
Step 1. 
Literature Search 
 
Step 2.  
Data Analysis & Recommendation 
 
Step 3. 
Public Meetings & Invitations 
 
Step 4.  
Panel Member Vote 
 
 
First, a scientific literature search is conducted and may be augmented by 
soliciting positions and opinions from medical specialty societies and physician experts.  
In addition, reports from government agencies are obtained.  Examples of government 
agencies are the U.S. Food and Drug Administration, National Institutes of Health, and 
Agency for Healthcare Research and Quality.123 
 Second, data from the first step are analyzed and a recommendation is formed.  
Medical consultants who are experts in evaluating scientific evidence prepare a 
recommendation.  The Blue Shield of California Foundation contracts with the University 
of California, San Francisco (UCSF) to conduct the evidence review, analysis, and 
prepare a written recommendation.  In order to be considered safe and effective, the 
technology must meet five technology assessment criteria.124  The five criteria 
                                                
123 Assessment Process.  California Technology Assessment Forum. 
http://www.ctaf.org/section/assessment/process Accessed: November 21, 2010. 
 
124 Ibid. 
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are set forth in Table 13.125 
Table 13. CTAF HTA Criteria 
No. Criteria 
1 The technology must have final approval from the appropriate government regulatory bodies. 
2 The scientific evidence must permit conclusions concerning the effect of the technology regarding 
health outcomes. 
3 The technology must improve net health outcomes. 
4 The technology must be as beneficial as any established alternatives. 
5 The improvement must be attainable outside the investigational setting. 
 
Regarding the second criterion, evidence of effectiveness is graded as follows:126 
• Level 1: Randomized trials that had enough power to demonstrate a statistically 
significant health outcome. 
 
• Level 2: Randomized trials with results that were not statistically significant but 
where a larger trial might not have shown a clinically important difference. 
 
• Level 3: Nonrandomized concurrent cohort comparisons between 
contemporaneous patients. 
 
• Level 4: Nonrandomized historical cohort comparisons between current patients 
and former patients (from the same institution or from the literature). 
 
• Level 5: Case series without control subjects. 
 
While Level 1 is the preferred to determine whether the second criterion is met, in the 
absence of this type of study, “technologies may meet this criterion if, overall, Level 2-4 
studies indicate that: 
a. The technology provides substantial benefits to important health outcomes, and 
b. The new technology has been shown to be safer or more beneficial than existing 
technologies or alternative treatments in comparative studies. 
 
In general, technologies will not be approved based on evidence from Level 5 studies 
(case studies without controls).”127 
                                                
125 Criteria. California Technology Assessment Forum. http://www.ctaf.org/section/assessment/criteria  
Accessed: November 21, 2010. 
 
126 Ibid. Evidence about the effectiveness are according to the criteria proposed by: Cook DJ, et al. (1992). 
Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest. 4(suppl):305S-
311S. 
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 Third, CTAF holds open forum meetings three times a year.  “Invitations are 
extended to leaders of local medical and professional societies, representatives of 
healthcare and regulatory agencies, physician experts from academic centers and the 
community, health plan representatives and manufacturers.  Guests and medical 
professionals are invited to attend and comment at the meeting.”128   
Fourth, once a topic is presented, reviewed, and public opinion has been provided, 
then the Forum panel takes a vote.  The panel may vote to accept, modify, reject, or table 
the discussion until more information is available.129 
The first HTA for CT colonography occurred in June 2004.130  The second 
occurred in March 2009, after the publication of the ACRIN study data.131  Both times, 
CTAF recognized that the technology met the evidence criteria for 1 and 2; however, 
ultimately rejected the technology due to an inability to satisfy criteria 3, 4, and 5: 
Criterion 1: The technology must have final approval from the 
appropriate government regulatory bodies. 
 
CTAF noted that the technology does have regulatory clearance from the U.S. 
Food and Drug Administration.  As a result, in both the 2004 and 2009 HTAs, criterion 1 
is met. 
                                                                                                                                            
127 Criteria. California Technology Assessment Forum. http://www.ctaf.org/section/assessment/criteria  
Accessed: November 21, 2010. 
 
128 Assessment Process.  California Technology Assessment Forum. 
http://www.ctaf.org/section/assessment/process Accessed: November 21, 2010. 
 
129 Ibid. 
 
130 Feldman M. (2004). Computed tomographic colonography (virtual colonoscopy) for screening of 
colorectal cancer. California Technology Assessment Forum. June 9, 2004. 
 
131 Walsh J. Computed tomographic colonography (virtual colonoscopy) for colorectal cancer screening in 
average risk individuals. (2009). California Technology Assessment Forum. March 11, 2009. 
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Criterion 2: The scientific evidence must permit conclusions concerning 
the effectiveness of the technology regarding health outcomes. 
 
CTAF’s 2004 HTA indicates that colorectal screening is effective based on results 
from a randomized controlled study of FOBT and case-control studies of sigmoidoscopy.  
As a result a decision was made that CT colonography did demonstrate that it has equal 
or better performance to the “gold standard” of optical colonoscopy.132  The data 
supported CTAF’s level of evidence 3, nonrandomized concurrent cohort comparisons 
between contemporaneous patients; and CTAF’s level 5, case series without control 
subjects.  As a result, criterion 2 was met.133 
In CTAF’s 2009 HTA, the ACRIN study data is considered as a part of satisfying 
this criterion.  CTAF concluded that “[t]he results of this study suggest that the accuracy 
of CT [colonography] in detecting significant colorectal abnormalities is relatively 
comparable to [colonoscopy].”134  The data represents CTAF level 3, nonrandomized 
concurrent cohort comparisons between contemporaneous patients.  Criterion 2 was 
met.135 
Criterion 3: The technology must improve the net health outcomes. 
In CTAF’s 2004 HTA, this third criterion reads: “[t]he technology must improve 
the net health outcome.  For diagnostic tests, there is evidence that the use of the test 
                                                
132 Feldman M. Computed tomographic colonography (virtual colonoscopy) for screening of colorectal 
cancer. (2004). California Technology Assessment Forum. June 9, 2004. Page 5. 
 
133 Ibid. 
 
134 Walsh J. Computed tomographic colonography (virtual colonoscopy) for colorectal cancer screening in 
average risk individuals. (2009). California Technology Assessment Forum. March 11, 2009.  Page 8. 
 
135 Ibid, page 9. 
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would result in improved medical management in a way that will benefit the patient.”136  
The HTA noted that of the over 20 studies comparing the accuracy of CT colonography 
to colonoscopy, only 5 contain data with patients from an average risk population who 
present for routine screening.137  As a result, the efficacy of the test in an average-risk 
screening population was called into question.  In addition, there was insufficient 
published evidence to establish that CT colonography could be reliably taught and 
implemented in a community-based practice.138  Further, the HTA noted that while CT 
colonography might have better patient acceptance, data has only been examined in a few 
studies and if pre-procedure preparation for colonoscopy was less rigorous, it could be 
that colonoscopy could become better tolerated.  As a result, improved medical 
management is not clear and the criterion was deemed not met.139 
 CTAF’s 2009 HTA specifically examined average risk individuals.140  The data 
from the ACRIN study helped to overcome this barrier from CTAF’s 2004 HTA in which 
only high risk patients were considered.  In addition, this third criterion was truncated to: 
“[t]he technology must improve net health outcomes.”141  The HTA noted three benefits 
of CT colonography: (1) ability to detect small polyps; (2) fewer complications than 
colonoscopy; and (3) procedure may be more acceptable to patients than more invasive 
                                                
136 Feldman M. Computed tomographic colonography (virtual colonoscopy) for screening of colorectal 
cancer. (2004). California Technology Assessment Forum. June 9, 2004. Page 6. 
 
137 Ibid. 
 
138 Ibid, page 10. 
 
139 Ibid, page 11 and 12. 
 
140 Walsh J. Computed tomographic colonography (virtual colonoscopy) for colorectal cancer screening in 
average risk individuals. (2009). California Technology Assessment Forum. March 11, 2009.  Page 6. 
 
141 Ibid, page 9. 
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techniques.142  Potential harms included: (1) concern regarding radiation exposure over a 
patient’s lifetime; (2) although relatively few, procedure related harms such as one out of 
2531 patients hospitalized for bacteremia for a patient who had both a CT colonography 
followed  by a colonoscopy; and (3) identification of extra-colonic findings.  This last 
concern is related to the CT obtaining images of structures outside the colon.  In some 
cases, radiologists requested follow up tests to investigate the finding and this resulted in 
increased patient anxiety and overall cost.  CTAF found that “[a]lthough it is possible 
that early detection of these abnormalities may lead to improved outcomes, it is also 
possible that there will be additional unnecessary medical testing of these abnormalities 
with associated anxiety.”143  Thus, although the accuracy of CT colonography approaches 
that of colonoscopy, CTAF concluded that it is unclear whether the harms outweigh the 
benefits.  As a result, this criterion was not met.144 
Criterion 4: The technology must be as beneficial as any established 
alternatives. 
 
 Both the 2004 and 2009 HTAs noted three established alternatives used for 
screening for colorectal cancer: (1) Fecal Occult Blood Testing (FOBT); (2) flexible 
sigmoidoscopy; and (3) colonoscopy.  The 2004 HTA noted that because “[m]ost of the 
current studies of CT colonography do not demonstrate sensitivity comparable to 
colonoscopy, and none demonstrate a reduction in mortality seen with flexible 
                                                
142 Ibid. 
 
143 Ibid, page 10. 
 
144 Ibid, page 11. 
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sigmoidoscopy or FOBT.”145  Further, because there was limited evidence of efficacy in 
an average risk population, the fourth criterion was not met.146 
 The 2009 HTA applauded the additional evidence published in the ACRIN study.  
However, the HTA also set forth that the benefit of the technology depends not only on 
its diagnostic accuracy, but also on the overall risks and benefits as compared to other 
screening technologies.  Concerns related to radiation exposure and the identification of 
extra-colonic findings led to this criterion not being met.147 
Criterion 5: The improvement must be attainable outside the 
investigational settings. 
 
CTAF’s 2004 HTA indicated that there was not enough evidence to demonstrate 
that CT colonography could be disseminated without a great deal of extra training for 
radiologists.   As a result, the clinical data could not be easily replicated in the 
community based setting and the criterion was not met.148 
CTAF’s 2009 HTA acknowledged the features of the ACRIN study to make the 
procedure more easily shared outside the investigational setting.  However, again, the 
potential risks related to radiation exposure and high rates of extra-colonic findings were 
                                                
145 Feldman M. Computed tomographic colonography (virtual colonoscopy) for screening of colorectal 
cancer. (2004). California Technology Assessment Forum. June 9, 2004. Page 13. 
 
146 Ibid, page 14 
 
147 Walsh J. Computed tomographic colonography (virtual colonoscopy) for colorectal cancer screening in 
average risk individuals. (2009). California Technology Assessment Forum. March 11, 2009.  Pages 11 and 
12. 
 
148 Feldman M. Computed tomographic colonography (virtual colonoscopy) for screening of colorectal 
cancer. (2004). California Technology Assessment Forum. June 9, 2004. Page 14. 
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cited as not establishing an improvement in health outcomes.  As a result, this criterion 
was not met.149 
While the ACRIN study changed the scope of CTAF’s HTA from 2004 to 2009 to 
include average risk patients and helped to establish CT colonography as a technology 
that could be disseminated into community-based practice, concerns regarding the 
possible harm of the procedure outweighed the benefit.  In both HTAs, the technology 
failed to meet all five criteria and did not receive a positive recommendation. 
Blue Cross Blue Shield Association Technology Evaluation Center 
 Like CTAF, the Blue Cross Blue Shield Association Technology Evaluation 
Center (TEC) both conducted HTAs of CT colonography on two occasions.  Both 
agencies have a similar five criteria methodology for conducting HTAs of new 
technologies.  TEC’s criteria are almost identical to those of CTAF, except the third 
criterion for CTAF indicates that the technology must improve the net health outcome.  
TEC’s third criterion indicates that the technology must have a net health outcome.  
While CT colonography did not receive a positive TEC recommendation when it 
was first assessed in 2004, it did receive a positive recommendation in 2009 after the 
issuance of the ACRIN study data.  Notably, the authors commented that the 2004 HTA 
concluded that the TEC criteria were not met for the following reasons: (1) the sensitivity 
in the literature was variable among studies; (2) variability in performance could be 
attributed to interpreter experience and technical factors; and (3) that clear criteria were 
                                                
149 Walsh J. Computed tomographic colonography (virtual colonoscopy) for colorectal cancer screening in 
average risk individuals. (2009). California Technology Assessment Forum. March 11, 2009. Page 12. 
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needed regarding polyp size threshold for removal and for frequency of screening in 
order to appropriately assess the effectiveness of the technology.150   
The ACRIN study helped to fill the gaps of the prior HTA.  The TEC HTA was 
initially reviewed by the Blue Cross and Blue Shield Medical Advisory Panel on June 10, 
2008.  Their review was purposefully delayed until the ACRIN study data was published 
later that year.151  The primary aim of the study was to evaluate the sensitivity of CT 
colonography vs. colonoscopy in detecting lesions greater than 10 mm with a secondary 
aim of detecting polyps from 5-10 mm.  Second, the ACRIN trial trained radiologists and 
tested their proficiency in order to qualify to participate in the study.152  Thus, the ACRIN 
study data helped to establish TEC confidence in both the sensitivity and the ability to 
introduce the technology to the community-based setting. 
Criterion 1. The technology must have final approval from the 
appropriate governmental regulatory bodies. 
  
TEC determined that the appropriate regulatory body, U.S. Food and Drug 
Administration, had approved CT colonography technology.  This criterion was 
satisfied.153 
Criterion 2. The scientific evidence must permit conclusions concerning 
the effect of the technology on health outcomes. 
 
                                                
150 CT colonography (“virtual colonography”) for colon cancer screening. (2009).  Technology Evaluation 
Center. Assessment Program. Vol. 24, No. 1, August 2009.  Blue Cross Blue Shield Association.  
 
151 Ibid, page 10. 
 
152 Ibid, page 2. 
 
153 Ibid, page 21. 
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 TEC’s HTA determined that there is no direct evidence linking CT colonography 
to health outcomes.  However, an “inference of effectiveness” can be made based on the 
sensitivity data presented in the ACRIN study which demonstrated 90% sensitivity for 
detection of polyps 10 mm or larger.  As a result, this criterion was met.154  Thus, like 
CTAF’s HTA, while there was no definitive direct evidence of the technology affecting 
health outcomes, the ACRIN study helped to establish sufficient evidence. 
Criterion 3. The technology must improve the net health outcome; and 
Criterion 4. The technology must be as beneficial as any established 
alternatives. 
 
TEC’s HTA bundled these two criteria together.  Again, citing the chain of 
evidence and the value of the ACRIN study data regarding sensitivity and 86% 
specificity, the HTA noted that some unnecessary colonoscopies might have to be 
conducted due to false-positives.  However, the benefit of identifying and removing 
cancer outweighed the unquantifiable risks, presumed to be small, of detecting unrelated 
health problems and radiation exposure.  As such, these criteria were deemed satisfied in 
the HTA.155 
Criterion 5. The improvement must be attainable outside the 
investigational settings. 
 
 Again, citing the ACRIN study data, the techniques employed to ensure that 
radiologists were appropriately trained and had the necessary skill to perform the CT 
colonography, this criterion was deemed satisfied in the HTA.  Specifically, the HTA 
                                                
154 Ibid, page 22. 
 
155 Ibid. 
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noted that if the outcomes of the ACRIN study could be replicated in the community, 
health outcomes would indeed be improved.156 
 The ACRIN study data helped satisfy the TEC HTA.  Notably, the size of the 
study, the sensitivity and specificity data, and the ability to train practitioners provided 
the reviewers with confidence in CT colonography despite the risks identified by both 
CTAF and TEC. 
National Institute of Health and Clinical Evidence 
 The United Kingdom’s National Institute of Health and Clinical Evidence (NICE) 
issued a guidance regarding CT colonography in June 2005.  The two-page guidance 
indicates that the current safety and efficacy data for CT colonography “appears adequate 
to support the use of this procedure provided that the normal arrangements are in place 
for consent, audit and clinical governance.”157  The guidance provides its support to CT 
colonography both as a diagnostic in symptomatic patients, as well as in high risk 
asymptomatic patients.   
Efficacy was established via sensitivity and specificity data from 14 studies with a 
total of 1324 patients.  Pooled per-patient sensitivity is set forth below in Table 14. 
Table 14. Pooled Per-Patient Sensitivity158 
Polyp Size Sensitivity Confidence Interval 
10 mm or larger 88% 95% CI, 84-93% 
6-9 mm 84% 95% CI, 80-89% 
5 mm or smaller 65% 95% CI, 57-73% 
 
                                                
156 Ibid. 
 
157 Computed tomographic colonography (virtual colonoscopy). National Institute for Health and Clinical 
Excellence. June 2005. http://www.nice.org.uk/guidance/IPG129 Accessed: November 21, 2010. 
 
158 Ibid. 
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In addition, a large study of 1233 asymptomatic patients reported “per-polyp” sensitivity 
set forth in Table 15. 
Table 15. Pooled Per-Polyp Sensitivity159 
Polyp Size Sensitivity Confidence Interval 
10 mm or larger 81% 95% CI, 76-85% 
6-9 mm 62% 95% CI, 58-67% 
5 mm or smaller 43% 95% CI, 39-47% 
 
While advisors to the guidance noted that small, flat, lesions could be missed; 
they also stated that these could be missed by other diagnostic techniques as well.160  
While the technology is dependent on the experience of the technician and the type of 
equipment, the guidance states that the technology could be particularly helpful in 
detecting tumors in patients who are frail and/or elderly.161  As a result, NICE supports 
the use of the technology. 
State of Washington HTA 
 The Washington State Health Technology Clinical Committee (HTCC) consists 
of 11 health care practitioners.  The function of the independent committee is to 
determine how technologies are covered by state agencies and are based on the 
technology’s safety, efficacy, and cost effectiveness.162  “Evidence includes a report 
concerning the technology provided by a company specializing in objective reviews of 
pertinent scientific literature; information submitted by the affected state agencies; and 
                                                
159 Ibid. 
 
160 Ibid. 
 
161 Ibid. 
 
162 Washington State Health Care Authority. (2008). Health Technology Clinical Committee. Findings and 
Coverage Decision: Computed Tomographic Colonography. Meeting date: February 15, 2008. Final 
adoption: August 15, 2008. Page 4. 
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public comment.”163  State agencies are required to comply with the recommendation 
issued by the HTCC.164 
 HTCC’s review of the effectiveness, safety, and cost of CT colonography 
determined that the technology is not a covered benefit for routine colorectal cancer 
screening.165   
Effectiveness 
The HTCC report set forth that effectiveness was an area of substantial 
discussion.  In particular they noted that radiologists require special training to use the 
technology.  There was concern that clinical results may not be replicable in the 
community based setting in terms of the availability of equipment and ability to enforce 
training levels.  Further, sensitivity evidence was mixed based on polyp size.166 
Safety 
 HTCC was concerned about both radiation exposure from the technology and 
overall lifetime radiation accumulation from other tests. However, ultimately the HTCC 
found that CT colonography was either equivalent or safer than optical colonoscopy.167 
Cost 
 HTCC was concerned over the cost of CT colonography.  They felt that if the cost 
was reduced to one-third of optical colonoscopy then the technology might be more 
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feasible from a cost perspective.  Ultimately HTCC determined there was insufficient 
evidence to make a firm determination about cost.168 
U.S. Preventative Services Task Force 
 The USPSTF provides “recommendations about preventive care services for 
patients without recognized signs or symptoms of the target condition.  It bases its 
recommendations on a systematic review of the evidence of the benefits and harms and 
an assessment of the net benefit of the service.”169  USPSTF acknowledges that given 
their recommendation, it is still up to the physician to make a clinically appropriate 
decision regarding whether or not to use a particular technology based upon their 
assessment of an individual patient.170   
USPSTF employs a grading system to evaluate new technologies.  USPSTF’s 
grades and suggestions for practice are set forth in Table 16. 
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169 U.S. Preventative Services Task Force. (2008). Screening for colorectal cancer: U.S. Preventative 
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Table 16. USPSTF Grades and Suggestions for Practice171 
Grade Definition Suggestion for Practice 
A USPSTF recommends the service.  There is high certainty that 
the net benefit is substantial. 
Offer/provide this service. 
B USPSTF recommends the service.  There is high certainty that 
the net benefit is moderate or there is moderate certainty that 
the net benefit is moderate to substantial. 
Offer/provide this service. 
C USPSTF recommends against routinely providing the service. 
There may be considerations that support providing the 
service in an individual patient. There is moderate or high 
certainty that the net benefit is small. 
Offer/provide this service only if 
other considerations support offering 
or providing the service in an 
individual patient. 
D USPSTF recommends against the service. There is moderate 
or high certainty that the service has no net benefit or that the 
harms outweigh the benefit. 
Discourage the use of this service. 
I Statement USPSTF concludes that the current evidence is insufficient to 
assess the balance of benefits and harms of the service. 
Evidence is lacking, of poor quality, or conflicting, and the 
balance of benefits and harms cannot be determined. 
Read clinical considerations section 
of USPSTF Recommendation 
Statement. If the service is offered, 
patients should understand the 
uncertainty about the balance of 
benefits and harms. 
 
USPSTF’s levels of certainty regarding the net benefit of a technology are set forth in 
Table 17. 
Table 17. USPSTF Levels of Certainty Regarding Net Benefit172 
Level of 
Certainty 
 
Description 
High The available evidence usually includes consistent results from well-designed, well-conducted 
studies in representative primary care populations. These studies assess the effects of the preventive 
service on health outcomes. This conclusion is therefore unlikely to be strongly affected by the 
results of future studies. 
Moderate The available evidence is sufficient to determine the effects of the preventive service on health 
outcomes, but confidence in the estimate is constrained by such factors as: 
• The number, size or quality of individual studies 
• Inconsistency of findings across individual studies 
• Limited generalizability of findings to routine primary care practice 
• Lack of coherence in the chain of evidence 
As more information becomes available, the magnitude or direction of the observed effect could 
change, and this change may be large enough to alter the conclusion. 
Low The available evidence is insufficient to assess effects on health outcomes. Evidence is insufficient 
because of: 
• Limited number or size of studies 
• Important flaws in study design or methods 
• Inconsistency of findings across individual studies 
• Gaps in the chain of evidence 
• Findings that are not generalizable to routine primary care practice 
• A lack of information on important health outcomes 
More information may allow an estimation of effects on health outcomes. 
 
                                                
171 Ibid, at 636. 
 
172 Ibid. 
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 USPSTF reviewed CT colonography in 2008.  In their analysis, they concluded 
that there was insufficient evidence to assess the harms related to extracolonic 
findings.173  This finding was based on four considerations: (1) USPSTF found that CT 
colonography could help reduce cancer mortality if patients would submit to this form of 
testing and not other forms; however, (2) the potential harms of CT colonography could 
be significant, particularly regarding lifetime cumulative radiation risk from the test as 
well as other tests that involve radiation exposure; further, (3) radiologists need 
specialized training in order to be proficient with the test; and (4) the overall cost of CT 
colonography is high because bowel preparation is still required.174  As a result, USPSTF 
recommends randomized clinical trials to clearly define the benefits and harms of the 
technology.175 
Discussion of the Different Assessments and Guidances 
 Of the five HTA organizations that issued assessments and guidance regarding 
CT colonography, two approved the technology for use and three did not.  Each HTA 
organization has a different mission and purpose.  As a result, it is not surprising that 
there are different conclusions among HTA organizations regarding the same technology.  
Thus, the issue of consistency is not necessarily among the separate findings of each 
HTA organization.  However, consistency does become an issue when the technology 
assessment is counter to the stated objectives and/or definitions of desirable types of 
evidence for the HTA organization.  Table 18 summarizes the key criteria across all 5 
HTA organizations regarding CT colonography. 
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174 Ibid, at 630. 
 
175 Ibid, at 631. 
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Table 18. Summary of Different HTA Criteria for CT Colonography 
Criteria CTAF TEC NICE HTCC USPSTF 
Regulatory Approval ✓ ✓ ✓ ✓ ✓ 
Evidence allows conclusions about 
health outcomes 
✓ ✓ ✓ X ✓ 
Shows improvement of health 
outcomes 
X ✓ ✓ X ✓ 
As beneficial as any established 
alternatives 
X ✓ ✓ X X 
Improvement attainable outside 
investigational setting 
X ✓ ✓ X X 
Cost N/A N/A ✓ X X 
 
CTAF and TEC are two organizations with almost identical HTA criteria.  Both 
organizations agree that the technology meets the first two criteria: (1) approval from the 
appropriate government body; and (2) scientific evidence permits conclusions concerning 
the effectiveness of the technology.   
The third criterion is the point of divergence between CTAF and TEC: improving 
the net health outcome.  CTAF argues that the potential harms of the technology 
outweigh the benefits.  Specifically, follow up regarding extracolonic findings is a key 
area of difficulty for CTAF.  TEC, on the other hand, found an inference of effectiveness 
that allowed the panel to issue a positive finding for this criterion.   
The fourth criterion is also a point of divergence.  CTAF issued concerns related 
to radiation exposure and the identification of extra-colonic findings.  While TEC found 
that the benefit of identifying and removing cancer outweighed the small, unquantifiable, 
risks of detecting unrelated health problems and radiation exposure.  Lastly, the fifth 
criterion is also different with CTAF finding CT colonography to be too difficult to offer 
in community-based settings while TEC held that the ACRIN data demonstrated that 
radiologists could be trained to use the technology effectively.   
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The disagreement between CTAF and TEC outlines a question of level of 
evidence required.  CTAF expects a higher level of evidence than TEC.  TEC supports 
the data set forth in ACRIN while CTAF acknowledges but does not accept the ACRIN 
findings as sufficient to sway their decision. 
NICE, HTCC and USPSTF examined different criteria than CTAF and TEC.  The 
guidance issued by NICE supports the use of the technology based on sensitivity and 
specificity data.  HTCC based its review on the effectiveness, safety, and cost of the 
technology that was insufficient for a positive finding.  Lastly, USPSTF based its review 
on benefits and harms of the technology, and included comments about costs.  In the case 
of CT colonography, the harms outweighed the benefits. 
Conclusion 
The area of commonality among all of these health technology assessments of CT 
colonography is that the levels of evidence used by the agencies are inconsistent.  These 
inconsistencies become particularly apparent when reviewing a screening technology to 
be used in a patient population that is asymptomatic because evidence of benefits and 
harms become more subjective.  While understanding whether a screening technology 
has achieved the requisite approval from the governmental regulatory authority is 
relatively straightforward, establishing the efficacy, effect on health outcomes, and 
whether or not the technology is as beneficial as established alternatives are not as 
evident.  Differences of HTA agency missions and funding are a likely reason for the 
inconsistencies at one level.  However, whether or not a more robust set of criteria could 
be used in assessing screening technologies is a question that may be further investigated 
via interviews with HTA decision makers. 
  
 
Chapter 5: Interview Results 
Interviews  
Purposeful sampling was used to select respondents to participate in this study.  
First, HTA organizations were selected for inclusion in the sample based on the literature 
review.  Next, leaders within those organizations were researched.  Last, Clifford 
Goodman, PhD, health technology assessment expert at The Lewin Group was consulted 
regarding the list of organizations and corresponding leaders. 176  Dr. Goodman provided 
feedback to focus the list of respondents on exceptional leaders in the field of health 
technology assessment in the United States, Canada, Germany, and the United Kingdom.  
A total of 20 individuals from 16 different technology assessment organizations 
and 4 countries were contacted to participate in the study.  Respondents were selected for 
participation on the basis of their responsibilities related to the implementation of health 
technology assessment programs within their organizations, or their participation in the 
creation of assessments.  Individuals were recruited via email.  As a part of the invitation, 
respondents were informed that the purpose of the interview was to develop a best 
practice for health technology assessment of screening technologies, see Appendix 1.  
Recruitment continued until 12 respondents agreed to participate in the study.   
                                                
176 The Lewin Group is a nationally recognized healthcare consulting firm with consultants drawn from 
industry, government, academia. Many of The Lewin Group’s consultants are national authorities whose 
strategies for health and human services system improvements come from their personal experience with 
imperatives for change.  The Lewin Group is often consulted by government agencies, including the office 
of the President of the United States, to provide guidance regarding healthcare matters.   
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Twelve of the 20 (60%) individuals invited participated in the interviews.  Of the 
8 individuals that were not included in the study, 4 (50%) were unable to participate, 
citing busy work schedules.  The remaining 4 (50%) did not respond to the email or two 
follow up recruitment emails.   
The 12 respondents represent 11 different health technology assessment 
organizations in 3 countries: United States, Canada and United Kingdom.  While 
healthcare in Canada and the United Kingdom are delivered via national mechanisms, 
like the United States, both countries have employed HTA as a method for making 
decisions about accessibility to technologies.  Table 19 and Figure 2, respectively, 
provide an overview of the distribution of participating organizations across the types of 
health technology assessment organization they represent.  Table 20 provides an 
overview of the distribution of non-participating organizations across the same variable 
as Table 19. 
Table 19. Distribution of Participating Organizations 
 
Respondent 
 
Type of HTA Organization 
 
Source of Funding 
Findings Directly 
Determine Coverage 
for Health Plan (Y/N) 
Respondent 1 For Profit Organization Private Contracts N 
Respondent 2 Government Agency Government Y 
Respondent 3 Government Agency Government Y 
Respondent 4 Not for Profit Organization Government and Donation Y 
Respondent 5 Not for Profit Organization Government and Donation Y 
Respondent 6 Academic Medical Center Multiple Funding Sources N 
Respondent 7 Academic Medical Center Multiple Funding Sources N 
Respondent 8 Government Agency Government Y 
Respondent 9 Government Agency Government Y 
Respondent 10 Private Payer Private Contracts Y 
Respondent 11 Not for Profit Organization Multiple Funding Sources N 
Respondent 12 Government Agency Government Y 
 89 
Figure 2. Distribution of Participating Organizations by Type of Organization 
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Table 20. Distribution of Non-Participating Organizations 
 
Respondent 
 
Type of Organization 
 
Source of Funding 
Findings Directly 
Determine Coverage 
for Health Plan (Y/N) 
Respondent 1 Academic Medical Center Multiple Funding Sources N 
Respondent 2 Not for Profit Organization Donation N 
Respondent 3 Government Agency Government Y 
Respondent 4 Not for Profit Organization Multiple Funding Sources N 
Respondent 5 Not for Profit Organization Multiple Funding Sources N 
Respondent 6 Not for Profit Organization Multiple Funding Sources Y 
Respondent 7 Government Agency Government Y 
Respondent 8 Government Agency Government Y 
 
 Interviews were conducted individually with each respondent.  Ten of the 12 
interviews were with leaders within their organization.  In a health technology assessment 
organization the titles of the leaders include: president, executive director, director, and 
program manager.   The remaining 2 respondents were research analysts within their 
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organizations.  These individuals were recommended by their respective leaders to 
participate in the interviews because they were the most knowledgeable people about 
specific health technology assessment criteria. 
Interviews took place from in May and June 2011.  Due to the geographic 
location of respondents and the cost parameters of this study, interviews were conducted 
via telephone.  Respondents were informed that the information collected during the 
interview would be kept confidential.  Specific answers would not be attributed to the 
respondent or their organization.  The interview results would only be used in summary 
form.  The interview guide and confidentiality terms are in Appendix 2. 
The sources of the questions posed were from the literature and discussions with 
researchers who have previously studied the process and use of HTA evaluations.  The 
interview guide was pilot tested via cognitive interviews with 3 individuals who were 
knowledgeable about health technology assessment.    The interviews with respondents 
were semi-structured.  Modifications were made during the interview based on the 
respondent’s responses to the preceding questions.  Interview telephone calls were not 
recorded.  To ensure accuracy, the interviewer and one research assistant took 
handwritten notes to record responses.  Respondents were provided the option to review 
and edit the notes from the interview at their request. 
Data Analysis  
 The information obtained from the interviews was both quantitative and 
qualitative.  The quantitative portion of the interview involved several questions with 
respondents providing a numeric rating.  The rating was based upon a five point Likert 
scale in which 1 was “strongly disagree”, 2 was “disagree”, 3 was “neither agree nor 
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disagree”, 4 was “agree”, and 5 was “strongly agree”.  In this section, the figures display 
the respondent’s answers to questions asked in the interview guide.  Blue circles 
represent respondents based in the United States and red circles represent respondents 
based outside of the United States.  Where the data had sufficient differentiation, the 
center line of “box and whisker” diagrams represents the median.  The green shaded box 
encloses the 25 and 75 percentiles.  The extended lines, or “whiskers”, represent the 
minimum and maximum of the respondents’ answers. 
The majority of the interview information was qualitative.  The analysis of the 
qualitative information involved a review of the interview transcripts to identify themes 
and to compare and contrast responses across interviews.  The volume of interview data 
was minimal.  As a result, themes were manually coded, and where possible and 
appropriate, counted and weighted by frequency of mention.  Themes were grouped for 
discussion and conclusion purposes.   
Descriptive Analysis  
 The interview was divided into three sections.  All 12 respondents answered the 
questions in each section.  Some respondents elected to not answer some specific 
questions and these are specifically noted.  The three sections of the interview included: 
(1) Health Technology Assessment at Your Organization; (2) Value and Obtainability of 
Outcomes Evidence; and (3) Evaluation of Cost-Effectiveness of New Screening 
Technologies. 
1. Health Technology Assessment at Your Organization 
Questions in the first section of the interview were quantitative and addressed 
details about health technology assessment at the respondent’s organization.  In terms of 
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familiarity with the health technology assessment program at their organization, 10 (83%) 
out of 12 respondents represented their knowledge of HTA as a 10 on a scale of 1 to 10 in 
which 1 is not at all familiar and 10 is extremely familiar.  The remaining 2 (17%) 
respondents represented their level of knowledge as an 8 on the 10 point scale.  As a 
result, the 12 respondents were all very familiar with their HTA programs.   
Figure 3. 
 
There are a number of critical components for the development of HTA programs 
at organizations.  Respondents were asked a series of questions to understand the most 
important components for development of HTA programs at their organizations.   
Seven (58%) out of 12 respondents strongly agreed that HTA is a part of the 
mission statement of their organization.  Organizations represented included: 1 for profit 
company (n=1), 2 government agencies (n=5), 1 academic medical center (n=2), 2 not for 
profit organizations (n=3), and 1 private payer (n=1).  One of the 6 respondents indicated: 
We don’t have a mission statement.  If the word “mission” 
wasn’t in there, then the statement would be entirely 
accurate, but I will strongly agree since it is what we do. 
 
Four (33%) of the respondents neither agreed nor disagreed that HTA is a part of 
the mission statement of the organization.  These organizations represented 3 government 
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agencies (n=5) and 1 academic medical center (n=2).  One of the 4 respondents 
commented: “HTA is implicit in our mission statement, not explicit.” 
One (8%) respondent that disagreed that HTA was a part of the mission statement 
is a part of a large not for profit (n=3) that has a diverse mission for a local government. 
Figure 4. 
 
 
Seven (58%) out of 12 respondents indicated that HTA is a part of the vision of 
the organization.  Organizations represented included: 1 not for profit (n=1), 2 
government agencies (n=5), 2 not for profit (n=3), and 1 academic medical center (n=2), 
1 private payer (n=1).   
One (8%) academic medical center (n=2) agreed.   
Two respondents (17%) disagreed representing a not for profit (n=3) and a 
government agency (n=5).  Two respondents (16%) neither agreed nor disagreed.  Both 
of these respondents represented government agencies (n=5). 
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Figure 5. 
 
 
Five (42%) respondents strongly agreed that HTA is a source of research funding 
for the organization.  Types of organizations included: 1 for profit (n=1), 1 government 
agency (n=5), 2 not for profit (n=3), and 1 academic medical center (n=2). 
One (8%) private payer (n=1) agreed. Two respondents (17%), 1 not for profit 
(n=3) and 1 government agency (n=5), neither agreed nor disagreed. One (8%) academic 
medical organization (n=2) disagreed.  Three (25%) government agency organizations 
(n=5) strongly disagreed. 
Figure 6. 
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Nine (75%) respondents strongly agreed that the HTA department has a specific 
financial budget within the organization.  Types of organizations included: 1 for profit 
(n=1), 4 government agencies (n=5), 3 not for profit (n=3), and 1 private payer (n=1). 
Two (17%) respondents, representing 1 government agency (n=5) and 1 academic 
medical center (n=2) agreed.  One (8%) academic medical center (n=2) neither agreed 
nor disagreed. 
Figure 7.  
 
 No respondents strongly agreed that HTA is the sole purpose of their 
organization.  Two (17%) respondents agreed.  Organizations represented included: 1 
academic medical center (n=2) and 1 private payer (n=1). 
 Two (17%) respondents neither agreed nor disagreed.  Organizations represented 
included: 1 government agency (n=5) and 1 not for profit (n=3). 
 Two (17%) respondents disagreed.  Organizations represented included: 1 for 
profit (n=1) and 1 not for profit (n=3).  One of the respondents commented to clarify the 
response: 
Our core purpose is HTAs, not sole or only, so I would 
have to disagree with your statement. 
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 Six (50%) respondents strongly disagreed.  Organizations represented included: 4 
government agencies (n=5), 1 not for profit (n=3), and 1 academic medical center (n=2). 
Figure 8. 
 
 One (8%) respondent, not for profit (n=3), strongly agreed that HTA drives 
coverage decisions at their organization. 
 Two (17%) respondents, 1 academic medical center (n=2) and 1 government 
agency (n=5), agreed.  One (8%) respondent, private payer (n=1), neither agreed nor 
disagreed.  Two (17%) respondents, for profit (n=1) and government agency (n=5), 
disagreed.  One respondent commented: 
We don’t make coverage decisions.  We provide content to 
drive coverage decisions at other organizations, our clients.  
HTA is a core component to drive decision making at other 
organizations, like health plans, government agencies, 
providers. 
 
 Six (50%) respondents strongly disagreed.  Organizations represented included: 4 
government agencies (n=5), 1 academic medical center (n=2), and 1 not for profit (n=3).  
One respondent commented on their function in the process: 
We don’t actually make decisions here.  It drives coverage 
decisions elsewhere, but not here.  We exist to do the 
assessments, and provide conclusions and/or advice, and 
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the decisions are then made...We are at arms length for the 
decisions, but we are involved in the assessment process. 
 
Figure 9. 
 
The quantitative portion of this section concluded and a qualitative section 
followed.  All 12 respondents were asked if their organization has stated goals and 
objectives for their HTA program.  Ten (83%) respondents indicated that their 
organization has stated goals or objectives for their HTA program.  Two of these 
respondents specifically commented on making decisions that are evidence-based when 
describing their organization’s goals and objectives.  One respondent linked evidence-
based HTAs to a separate organizational goal of making coverage decisions: 
Our goals are really to make evidence-based coverage 
decisions.  But a subsidiary goal is to base those goals, 
those evidence-based decisions, on structured reviews of 
evidence, i.e., an HTA.  Our goal isn’t to produce HTAs for 
the sake of HTA, since we are both the producer and the 
end user. 
 
Another respondent indicated that their organizational goal is not to make decisions, 
rather to weigh  “the valance of benefits, harm and costs of adopting or covering new 
technologies.”  Similarly, a separate respondent spoke to the organizational goal to 
“rigorously summarize, evaluate and communicate unbiased information.” 
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Two (17%) respondents indicated that their organization does not have stated 
goals or objectives for their HTA program.  One of the respondents indicated that their 
organization does HTA work on a contract basis, as a result, there is not an organizational 
stated goal or objective related to HTA.  The other respondent indicated that their 
organization is going through a lot of change and they are revising their organizational 
goals and objectives.  Table 21 summarizes the responses by type of organization. 
Table 21. Stated Goals and Objectives for HTA by Organization Type 
 
Organization Type 
Goals & 
Objectives 
No Goals & 
Objectives 
For Profit √  
Government Agency √√√√√  
Not for Profit √√ √ 
Academic Medical Center √ √ 
Private Payer √  
Total 10 2 
 
All 12 respondents were asked when the HTA program was implemented at their 
organization.  Ten (83%) respondents indicated that the HTA program was implemented 
prior to 2000 and 2 (17%) indicated the HTA program was implemented after 2000.  
Table 22 summarizes the responses by type of organization. 
Table 22. Timing of HTA Program Implementation by Organization Type 
Organization Type Before 2000 After 2000 
For Profit √  
Government Agency √√√√√  
Not for Profit √√ √ 
Academic Medical Center √ √ 
Private Payer √  
Total 10 2 
  
All 12 respondents were asked how many HTAs their organization had conducted 
since 2000.  Seven (58%) respondents indicated that their organization has conducted 
between 30 and 40 HTAs since 2000.  Five (42%) respondents indicated that their 
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organization has conducted over 40 HTAs since 2000.  Table 23 summarizes the 
responses by type of organization. 
Table 23. Number of HTAs Conducted Since 2000 by Organization Type 
Organization Type 30-40 >40 
For Profit √  
Government Agency √√ √√√ 
Not for Profit √√√  
Academic Medical Center √ √ 
Private Payer  √ 
Total 7 5 
 
All 12 respondents were asked to share the criteria for HTA at their organization.  
None of the respondents provided specific criteria; however, they did share the general 
type of criteria.  One (8%) respondent, representing a for profit, indicated that their 
organization uses proprietary criteria: 
We have developed our own evidence scoring 
method…our criteria are an evidence score, which 
considers multiple aspects.  It looks at research design, but 
goes beyond.  [It] looks at implementation and execution of 
research design and methodology, research execution, the 
size of effect, the research statistics, research replication 
and generalizability.  Evidence scores are specific to patient 
indications and patient selection criteria.  A technology 
may have multiple grades or scores based on patient 
indication and use. 
 
 Seven (58%) respondents indicated that their criteria for HTA varied.  The 
rationale for the variance included that different assessments would use different criteria, 
and that the assessment would vary based on the scope of information and analysis the 
client or agency funding the HTA was asking for in the HTA.  
Two (17%) respondents referred to their HTAs as systematic reviews of evidence 
and literature.  In addition, 2 (17%) respondents indicated that the HTA criterion were 
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driven by “issues of national importance.”  Table 24 sets forth the criteria for HTA by 
organization type. 
Table 24. Criteria for HTA by Organization Type 
 
 
Organization Type 
 
Proprietary 
Criteria 
Criteria 
Varies by 
Type of 
HTA 
 
Systematic 
Review 
 
National 
Importance 
For Profit √    
Government Agency  √√√  √√ 
Not for Profit  √√ √  
Academic Medical Center  √ √  
Private Payer  √   
Total 1 7 2 2 
 
 All 12 respondents were asked if their criteria and data requirements were 
published and available.  Ten (83%) respondents indicated that the criteria and data 
requirements were published and available.  Two (17%) respondents indicated that the 
criteria and data requirements were not available.  One of the reasons provided for the 
lack of availability was not stated, while the other reason was due to changes in the 
organization.  Table 25 sets forth the availability of HTA criteria by organization type. 
Table 25. Availability of HTA Criteria by Organization Type 
Organization Type Available Not Available 
For Profit √  
Government Agency √√√√√  
Not for Profit √ √√ 
Academic Medical Center √√  
Private Payer √  
Total 10 2 
 
 All 12 respondents were asked how their organizations select technologies to 
assess.  Eight (67%) respondents indicated that technologies are selected based on client 
request.  In this context, client is defined as the entity for which the respondent’s 
organization is conducting the HTA.  For example, a larger government agency, 
healthcare systems, managed care organizations, and Ministries of Health.  While it is 
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possible that a client could be a patient group or defined group of health consumers, no 
respondent provided these groups as examples of clients.  Several respondents 
commented that technologies are selected if there is a “controversy” about the use of the 
technology that may be triggered by “demands or pressures from specialty groups.”  
Specialty groups may be patients, patient advocacy groups, manufacturers of screening 
technologies, physicians, and payers.  Three (25%) respondents indicated that 
technologies are selected if they rise to the level of national importance. One respondent 
commented: 
If there is significant disagreement, then that’s the entry 
criteria.  Not that we have the infrastructure of budget to 
look at all the criteria, but that gets you through the door. 
 
One (8%) respondent indicated that products are selected based upon selection 
criteria.  Examples of these criteria include the burden of disease in terms of population 
affected, morbidity and mortality; resource impact in terms of the cost to the health 
system; policy importance in terms of whether the topic falls with a government priority 
area; whether there is inappropriate variation in practice across the country; and whether 
there are factors affecting the timeliness or urgency for a guidance to be produced.  Table 
26 sets forth the selection of technologies for HTA by organization type.  
Table 26. Selection of Technologies for HTA by Organization Type 
Organization Type Client-Driven National Importance Selection Criteria 
For Profit √   
Government Agency √ √√√ √ 
Not for Profit √√√   
Academic Medical Center √√   
Private Payer √   
Total 8 3 1 
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 All 12 respondents were asked to describe an HTA decision that was made at their 
organization.  All 12 (100%) respondents indicated that their organizations do not make 
HTA decisions, rather, they “synthesize and summarize evidence.”  In addition, all 12 
(100%) respondents indicated that an existing HTA might change in the future as more 
evidence for the technology becomes available.  One respondent provided an example of 
actively looking for new information by “conducting scans and constant literature 
reviews for new information.”   
All 12 (100%) respondents use a committee or team approach to conduct the 
HTA.  Teams are comprised of clinical experts, medical librarians, and researchers.  Two 
respondents also included economists and members of the community.  One respondent 
included product manufacturers.  Assessments are either delivered directly to clients or 
are posted on websites.   
None of the respondents had explicit metrics used by their organization to 
measure the effectiveness of a particular HTA.  One respondent commented that they 
“use productivity and impact measures” but these measures were not directly linked to 
the overall efficacy of the HTA.  Another respondent commented: 
We do try, but it is difficult to measure at a systems level.  
There can be confounding, and can be difficult to attribute 
to [our organization], particularly around outcomes and 
budget impact.  We do know our impact in diseases with 
independent technologies and we can see [impact] to the 
uptake of technologies based on a yes or no 
[HTA]…overall it is very difficult to have generic metrics 
measure this type of impact. 
 
Ten (83%) respondents indicated that health policy did change once the 
assessment was complete.  One respondent provided an example:   
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One of the most interesting ones, because we tracked it for 
so long, would be PET scans.  That technology was 
considered by most to be investigational, not ready for 
clinical application when it was first introduced about 25 
years ago.  It has steadily evolved in context of use, and 
value demonstrated.  Initially, there was a lot of push back 
from a coverage point of view, because the data was so 
limited at the time of its introduction on its value and 
utility.  Over the 20 year period we have tracked PET 
scans, it has experienced multiple avenues for coverage and 
reimbursement positive decisions.  So, that has changed 
from limited coverage to wide spread coverage. When a 
technology is first introduced, there is usually not a lot of 
evidence, the utility isn’t clear, and the patient selection 
criteria are unclear.  As the body of evidence improves, our 
understanding of its use and value improves.  New 
technology usually would starts at a [low] evidence score 
or grade, and then moves up from there as data and 
evidence are generated in the marketplace 
 
One (8%) respondent did not provide a comment and the other respondent (8%) 
indicated that their organization was not tracking if policy changed over time.  The 
organizations represented were both government agencies. 
 All 12 respondents were asked if feedback from providers, patients or 
manufacturers caused the organization to change or re-evaluate the HTA.  Seven (58%) 
respondents indicated that feedback might cause a change or re-evaluation of an HTA.  
One respondent indicated that while feedback has been received and considered, to date, 
no HTA has required change.  Another respondent commented that their organization is 
“required by law to post a decision and accept 30 days of public comment on it.”  In this 
respondent’s case, while feedback may come from any one in the public, they specifically 
look “for feedback that speaks to medical evidence.”  Another respondent indicated that 
they receive feedback through several mechanisms.  They receive information via an 
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appeal process once an HTA is published, through a consultation process with the public, 
judicial review, and through a process of “interrogating physician and patient experts. 
Three (25%) respondents indicated that their organization does not collect or 
consider feedback.  Organizations included: 2 government agencies (n=5) and 1 academic 
medical center (n=2).  Two (17%) respondents, government agency and academic 
medical center, did not provide comment. 
 All 12 (100%) respondents confirmed that they do have an ongoing or multi-year 
budget commitment for HTA at their organization.  The duration of the budget 
commitment ranged from 1 year to 5 years.  Table 27 sets for the duration of budget 
commitment by organization type. 
Table 27. Duration of Budget Commitment by Organization Type 
 
Organization Type 
 
1 year 
 
2-3 years 
 
5 years 
Multi-Year 
Unspecified 
For Profit    √ 
Government Agency √√√√   √ 
Not for Profit   √√ √ 
Academic Medical Center   √√  
Private Payer  √   
Total 4 1 4 3 
 
 All 12 respondents were asked if they knew the average cost of conducting an 
HTA at their organization.  Four (33%) respondents indicated that the cost of the 
assessment depended upon the complexity of the HTA.  As a result, a specific estimate 
could not be provided.  One respondent commented: 
We prepare a lot of report types, from simple to 
sophisticated.  With such a wide range, an average would 
not be very helpful…The custom type responses would be 
several hundred thousand dollars, unlike the simple, quick 
turnaround assessment.  The large assessments can take 
more than a year to complete. They are very resource 
intensive. 
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Seven (58%) respondents provided estimates ranging from $15,000 to $300,000.  
One (8%) respondent did not have sufficient information to comment.  Table 28 sets forth 
the ranges of estimates based on organization type for the 6 respondents that provided 
information. 
Table 28. HTA Budget Estimate by Organization Type 
 
Organization Type 
 
$15,000 
$150,000-
$200,000 
$300,000 
For Profit    
Government Agency √√ √√  
Not for Profit  √ √ 
Academic Medical Center  √  
Private Payer    
Total 2 4 1 
  
 All 12 respondents were asked if they felt there were specific issues that 
organizations seeking to conduct HTA of screening products should know either before 
they begin, during the analysis, or when the analysis is complete.  All 12 respondents 
identified specific issues that should be considered.  Interestingly, no respondent 
mentioned the cost or burden from a false positive from a test as an issue.  These issues 
are summarized in Table 29.   
Table 29. Summary of Issues to Consider in Conducting an HTA for a Screening Product 
Issue Issues Identified by Organizations 
 FP GA NFP AMC PP 
Reliability, Sensitivity, and Specificity √ √ √ √ √ 
Identification of Appropriate Patient Population √ √    
Link Between Test and Actual Expression of Disease √ √    
Availability of Treatment Options √  √   
Patient Anxiety √  √   
Length of Time To Gather Sufficient Data of Efficacy √     
Natural Course of Disease  √   √ 
Ethical Considerations   √ √ √ 
Availability of Treatment Options if Disease is Identified √ √    
Cost-Effectiveness and Cost of Alternatives  √    
Patient Acceptance of Test   √   
Key: FP = For Profit   GA = Government Agency 
 NFP = Not for Profit  AMC = Academic Medical Center 
 PP = Private Payer 
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One of the respondents concluded with the following statement: 
Screening healthy people has a high ethical obligation to do 
no harm.  Every intervention has that and screening 
magnifies that because you’re actively intervening with an 
otherwise healthy population.  It’s a more proactive 
framework than treating those that symptomatically present 
themselves for treatment. 
 
Another respondent encouraged: “keep things open for discussion, allow some degree of 
contestability, manage vested interests from where these come from.” 
2. Value and Attainability of Outcomes Evidence 
 Screening technologies may be able to help identify whether or not a patient has a 
specific disease in order to inform treatment decisions before symptoms occur.  
Controversies about screening technologies exist.  In this quantitative section of the 
interview, respondents were asked to respond using a five point Likert scale to indicate 
whether they agree or disagree with a particular screening product controversy. 
 Eight (67%) respondents strongly agreed that screening products may be able to 
identify disease earlier.  Organizations represented included: 1 for profit (n=1), 4 
government agency (n=5), 2 not for profit (n=3), and 1 academic medical center (n=2). 
 Two (17%) respondents agreed.  Organizations represented included: 1 
government agency (n=5) and 1 not for profit (n=3). 
 Two (17%) respondents neither agreed nor disagreed.  Organizations represented 
included: 1 academic medical center (n=2) and 1 private payer (n=1). 
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Figure 10. 
 
 Seven (58%) respondents strongly agreed that screening products may identify 
risk factors that never progress to disease.  Organizations represented include: 1 for profit 
(n=1), 3 government agencies (n=5), 2 not for profit (n=3), and 1 academic medical 
center (n=1). 
 Four (33%) respondents agreed.  Organizations represented included: 1 not for 
profit (n=3), 2 government agencies (n=5), and 1 private payer (n=1). 
 One (8%) respondent representing an academic medical center (n=2) neither 
agreed nor disagreed. 
Figure 11. 
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 Three (25%) respondents strongly agreed that screening products may be able to 
decrease payer costs with positive patient outcomes.  Organizations represented included: 
1 for profit (n=1), 1 not for profit (n=3), and 1 government agency (n=5). 
 Four (33%) respondents agreed.  Organizations represented included: 1 not for 
profit (n=3), 1 academic medical center (n=2), and 2 government agencies (n=5). 
 Five (42%) respondents neither agreed nor disagreed.  Organizations represented 
included: 2 government agency (n=5), 1 not for profit (n=3), 1 academic medical center 
(n=2), and 1 private payer (n=1). 
Figure 12. 
 
 
 Four (33%) respondents strongly agreed that screening products may increase 
payer costs with limited patient outcomes.  Organizations represented included: 1 for 
profit (n=1), 2 not for profit (n=3), and 1 government agency (n=5). 
 Six (50%) of respondents agreed.  Organizations represented included: 3 
government agencies (n=5), 1 not for profit (n=3), and 2 academic medical centers (n=2). 
 Two (17%) respondents neither agreed nor disagreed.  Organizations represented 
included 1 government agency (n=5), and 1 private payer (n=1). 
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Figure 13. 
 
 Seven (58%) respondents strongly agreed that screening products may identify 
diseases for which there is not treatment available.  Organizations represented included: 1 
for profit (n=1), 4 government agencies (n=5), 1 academic medical center (n=2), and 1 
not for profit (n=3).  One of the respondents commented that a screening product for 
Alzheimer’s disease might be a relevant example. 
 Four (33%) respondents agreed.  Organizations represented included: 1 
government agency (n=5), 1 not for profit (n=3), 1 academic medical center (n=2), and 1 
private payer (n=1). 
 One (<1%) respondent, representing a not for profit (n=3), disagreed. 
Figure 14. 
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 The quantitative portion of this section of the interview concluded and a 
qualitative section followed.  All 12 respondents were asked if HTA criteria are different 
between therapeutic products and screening products.  Eight (67%) respondents indicated 
that the criteria are different.   
Four (33%) respondents indicated that the criteria are not different.  These 
respondents indicated that while the criteria are not different, the way the analysis and 
type of evidence reviewed might be different.  Specifically, one respondent commented: 
“[t]he process and how you might handle the evidence might differ since you might have 
to deal with more indirect evidence.”  Table 30 sets forth whether the HTA criteria for 
therapeutic and screening products are different by organization type. 
Table 30. Are HTA Criteria Different Between Therapeutic and Screening Products by Organization Type 
Organization Type Criteria Are 
Different 
Criteria Are Not 
Different 
For Profit √  
Government Agency √√√√ √ 
Not for Profit √ √√ 
Academic Medical Center √√  
Private Payer  √ 
Total 8 4 
 
 All 12 respondents were asked what kinds of data are acceptable to support a 
HTA.  Eight (67%) respondents indicated that it depends on the level of confidence that 
is needed.  The higher the quality of the data in terms of the quality of the studies that 
have been done is important.  One respondent commented:  
If data comes in from case studies and retrospective 
designs, then that weakens evidence.  However, there are 
longitudinal cohort studies, like the Nurses Study and 
Framingham Health Study, which do provide insights in 
getting a handle on chronic conditions and treatments. 
 
 111 
Three (25%) respondents indicated that they would take any kind of evidence.  It 
did not have to be randomized clinical trial data.  One respondent added that budget 
impact data and policy papers might also be relevant for an HTA.  One (8%) respondent 
indicated that the data required between therapeutic and screening technologies were the 
same and that they would prefer randomized controlled trial data if it was available.  
Table 31 sets forth the responses by type of organization. 
Table 31. Acceptable HTA data by Organization Type 
 
Organization Type 
 
Depends 
 
Any Data 
Randomized 
Control Trial 
For Profit √   
Government Agency √√√√ √  
Not for Profit √ √√  
Academic Medical Center √  √ 
Private Payer √   
Total 8 3 1 
 
 All 12 respondents were asked if there is a hierarchy of acceptable data, and if so, 
to share their hierarchy of data.  Eight (66%) respondents indicated that there is a 
hierarchy of acceptable data.  Of these 8 respondents, 5 (63%) indicated that randomized 
controlled trial was at the top of the data hierarchy.  Organizations represented included: 
4 government agencies (n=5), 3 not for profit (n=3), and 1 academic medical center 
(n=2).   Two (25%) of the 8 respondents, not for profit (n=3) and academic medical 
center (n=2), did not provide a specific comment.  One of the 8 respondents (8%), 
government agency (n=5), indicated: “the lowest point of entry would be single case 
studies or case series, observational or editorial.” 
Of the 12 respondents, 3 (25%) did not provide a comment regarding the presence 
of a hierarchy of data.  Organizations represented included 1 for profit (n=1), 1 academic 
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medical center (n=2), and 1 private payer (n=1).  One (8%) respondent, government 
agency (n=1) indicated that there is not a hierarchy of data. 
3. Evaluation of Cost-Effectiveness of new Screening Technologies 
 Cost is not a specific criteria that is evaluated as a part of health technology 
assessments conducted in the United States.  While some HTA organizations might 
consider cost, typically, cost is part of a separate study, if it is considered at all.  
However, some health technology assessments that are conducted outside of the United 
States take cost under consideration as a part of the HTA. In this quantitative section of 
the interview, respondents were asked to respond using a five point Likert scale to 
indicate whether they agree or disagree with statements related to HTA and cost. 
 Six (50%) respondents, 3 in the United States and 3 outside the United States, 
strongly agreed that cost should be added as an evidence measure in HTA.  Organizations 
represented included: 1 for profit (n=1), 2 government agencies (n=5), 2 not for profit 
(n=3), and 1 academic medical center (n=2).  One respondent located in the United States 
commented: 
It is foolish and not supportable for our society to avoid 
hard discussions around cost.  Not sure if I would call it an 
evidence measure. 
 
Another respondent located in the United States also commented on the accuracy of the 
statement “evidence measure” when referring to cost: 
Cost is not an evidence measure – it’s an assessment 
measure. You use the evidence to build cost modeling and 
in the assessment. Be careful with the framework and 
language. 
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Two (17%) respondents agreed.  Organizations represented included: 1 
government agency (n=5) and 1 academic medical center (n=2).  One respondent 
commented: 
Sometimes consideration of cost gets in the way of an 
assessment, but more often than not, it should be 
considered. 
 
Three (25%) respondents neither agreed nor disagreed.  Organizations represented 
included 2 government agencies (n=5) and 1 private payer (n=1).  One respondent 
commented: 
Cost is defined as a rationing measure, rather than an 
evidence measure.  If you have a finite budget, then it 
needs to be taken into account. 
 
 One (8%) respondent, representing a not for profit (n=3), strongly disagreed.  This 
respondent commented that the role of the assessment at the organization was to set forth 
a statement of evidence based on facts.  Cost does not have sufficient evidence to put 
forth an evidence-based conclusion: 
We have sections in our reports that speak to cost.  In terms 
of cost-effectiveness, there is insufficient evidence of cost 
and cost-effectiveness to formulate generalizable evidence-
based conclusions.  We look at the pieces differently, and 
then we interpret.  We put forth statements of evidence, but 
not recommendations. 
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Figure 15. 
 
 
 No respondents strongly agreed with the statement that cost is an unstated 
evidence measure for all HTAs.  Two (17%) agreed that in general, cost is an unstated 
evidence measure for all HTAs.  Organizations represented included 1 government 
agency (n=5) and 1 not for profit (n=3). 
 Three (25%) respondents neither agreed nor disagreed.  Organizations represented 
included 2 government agencies (n=5) and 1 academic medical center (n=2).  
One respondent commented: 
Cost may have percolated at the top of the pile, but [it is] 
not taken into consideration as an evidence measure. 
 
Two (17%) respondents, representing 1 academic medical center (n=2) and 1 not 
for profit (n=3) disagreed.  One respondent commented: 
Every AMCP [Academy of Managed Care Pharmacy] 
dossier has a cost analysis in it that provides rationale for 
including it.  [Cost is] only unusual if [there is a] political 
context.  It is routine to have cost information. 
 
 Five (42%) respondents strongly disagreed.  Organizations represented included: 
1 for profit (n=1), 2 government agencies (n=5), 1 not for profit (n=3), and 1 private 
payer (n=1). 
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Figure 16. 
 
 No respondents strongly agreed or agreed with the statement that cost is an 
unstated evidence measure for HTA at my organization.  Three (25%) neither agreed nor 
disagreed.  Organizations represented included: 2 government agencies (n=5) and 1 
academic medical center (n=1).  One respondent commented: 
Around colorectal cancer screening, Congress says we can 
consider cost, but generally, we don’t. 
 
Seven (58%) strongly disagreed.  Organizations represented included: 1 for profit 
(n=1), 2 government agencies (n=5), 3 not for profit (n=3), and 1 private payer (n=1).  
One of the respondents located in the United States commented: 
Cost is an overt consideration at my organization.  If we 
can get our hands on it, we know we will want to report it. 
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Figure 17. 
 
 One (8%) respondent, representing an academic medical center (n=2), strongly 
agreed with the statement that cost is not a relevant evidence measure for HTA.  No 
respondents agreed. 
 Two (17%) respondents, representing a private payer (n=1) and not for profit 
(n=3), neither agreed nor disagreed. 
 One (8%) respondent, representing a government agency (n=5), disagreed. 
 Seven (58%) respondents strongly disagreed.  Organizations represented 
included: 1 for profit (n=1), 4 government agencies (n=5), and 2 not for profit (n=3).  
One respondent located in the United States provided additional clarification: 
It [cost] is relevant.  [It] inform[s] policy development.  
There is a distinction between clinical evidence score and 
overall purpose of HTA.  The HTA includes the clinical 
scoring, but also includes other elements important to 
decision makers.  Systematic review evaluates body of 
evidence.  HTA incorporates systematic review and 
evidence scoring, but goes beyond that so includes 
information [such as cost] for use in policy context. 
 
 One respondent, representing an academic medical center (n=2), 
declined to answer. 
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Figure 18. 
 
 
Key findings for each of the three sections of the interview are set forth in the 
next chapter.  These findings from the literature review and interviews form the basis for 
the creation of more robust criteria for screening products in the plan for change. 
 
  
  
 
Chapter 6: Discussion of Interview Results 
The objective of this research study is to evaluate existing technology assessment 
standards for screening technologies in order to establish a best practice that may be 
implemented by HTA organizations in the United States in the future.  A literature 
review, scan of HTAs for screening products, and interviews with leaders in the field of 
HTA revealed that there is not a consistent approach to HTAs for screening technologies.  
This confirms that screening products offer a useful case study in where and how HTA as 
currently practiced yields differing findings by HTAs reviewing the same screening 
technology.   
While screening products may have an impact on the care of patients in terms of 
identifying disease and appropriate treatment options at an early stage, confounders exist.  
For example, screening products may identify diseases for which no treatments exist, no 
effective treatments exist, or for which costs far exceed documented benefits of 
interventions.  They may not be reliable, sensitive, or specific.  They may cause patient 
anxiety, or present an option that is not acceptable to patients.  In addition, they may 
result in added costs to the healthcare system with limited improved patient outcomes.   
The difficulty of measuring the efficacy of screening technologies regarding a 
reduction in mortality is changing.  A June 29, 2011, article in the New England Journal 
of Medicine presents the first findings of reduction of lung cancer mortality using a 
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screening technology.177  In addition to presenting a reduction in mortality of 20% using 
low-dose CT, the article also addresses the topic of the appropriate comparator for 
evaluating a screening technology: an alternative screen or community practice.  In the 
field of HTA, the comparator is a significant issue in order to be certain that the 
technology meets the HTA criteria that the technology can be used effectively outside of 
the research setting.  “Chest radiography was chosen as the screening method for the 
control group because radiographic screening was being compared with community care 
(care that a participant usually receives) in the Prostate, Lung, Colorectal and Ovarian 
(PLCO) Cancer Screening Trial.”178 
Today, screening products are a focus of private sector innovation.  As a result, in 
order to encourage the development of screening products with a meaningful health 
impact to patients, physicians, and health systems, the use of relevant criteria to evaluate 
these technologies using HTA is important.  While HTA findings will likely continue to 
be diverse given the different focuses of the organizations providing the analysis, use of 
relevant criteria for HTA of screening technologies will be helpful to manufacturers of 
these products. 
 
 
                                                
177 Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening. The National 
Lung Screening Trial Research Team. June 29, 2011. 
http://www.nejm.org/doi/full/10.1056/NEJMoa1102873?query=TOC&#t=article. Accessed July 1, 2011.  
“In the NLST [National Lung Screening Trial], a 20.0% decrease in mortality from lung cancer was 
observed in the low-dose CT group as compared with the radiography group. The rate of positive results 
was higher with low-dose CT screening than with radiographic screening by a factor of more than 3, and 
low-dose CT screening was associated with a high rate of false positive results; however, the vast majority 
of false positive results were probably due to the presence of benign intrapulmonary lymph nodes or 
noncalcified granulomas, as confirmed noninvasively by the stability of the findings on follow-up CT 
scans.” 
 
178 Ibid. 
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Key Findings 
Key findings based upon input from the selected HTA leaders interviewed in this 
research study in three specific areas provide assistance in shaping more robust criteria 
for HTA of screening products. 
1. Health Technology Assessment at Your Organization 
Finding 1: In the experience of the 12 respondents, HTA is incorporated 
in their organization’s mission and vision statements and provides a 
source of funding for HTA programs. 
 
 All 12 respondents were experts in the field of HTA.  The data demonstrated a 
high expertise rating of 8 or 10 on a scale of 1, not at all familiar with HTA, to 10, 
extremely familiar.  In 6 (50%) respondent answers the organization had HTA as a part of 
both the mission and vision of the organization.  
No respondents indicated that HTA was the sole purpose of their organization.  
Typically, HTA was a part of the overarching organization.  Ten respondents indicated 
that their organizations had HTA programs since before 2000.  All 12 respondents have 
completed at least 30 HTAs since 2000.  Similarly, 5 respondents strongly agreed and 1 
agreed that HTA is a source of research funding for the organization.  Further, 9 
respondents indicated that the HTA department has a specific budget within the umbrella 
organization.   
Thus, the interview data indicates that experienced HTA organizations have 
integrated HTA into the overarching purpose of the organization.  While organizations 
that offer HTA often have diverse portfolios of services beyond HTA, they have specific 
budgets to conduct HTAs.  In addition, these organizations have funding support for their 
HTAs that are renewed on an annual basis or are in place for several years at a time.   
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These professional organizations have both a sustainable internal organizational 
model and financial incentive to receive future funding in exchange for providing high 
quality HTAs.  As a result, this is an environment that would respond well to 
implementing a best practice to evaulate different criteria that are specific to screening 
technologies.  This would help to ensure high quality HTAs that will in turn influence 
recurring funding. Therefore, the development of best practices for HTA of screening 
technologies would fit within the organizational strategic and funding frameworks of 
existing HTA organizations. 
Finding 2: In the experience of the 12 respondents, HTA is not always 
linked to coverage decisions and changes to healthcare policy. 
 
 All 12 respondents indicated that the HTAs that they conduct serve to “synthesize 
and summarize information.”  While some HTA may be used to help a larger health 
system make a coverage decision, the core focus of the HTA is to present a judgment 
about a particular product based on existing data and evidence.  However, given that 9 
out of 12 respondents (75%) indicated that the HTA criteria are different between 
therapeutic and screening products, to some degree the HTA for screening technologies 
are more qualitative in nature than perhaps the respondents would like to admit.  The end-
user of the HTA: payer, government, or other decision-making authority, can use the 
HTA as the basis for making an informed decision about whether or not to cover a 
specific technology for a specific patient group. 
Several respondents indicated that their HTAs often shape healthcare policy in 
terms of patient access to a particular technology.  In many cases, these assessments 
affect significant patient populations such as the Medicare population, covered lives of a 
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significant national private payer, and government health systems for provinces and 
countries. 
Thus, while the strict function of the HTA is to present an unbiased set of facts 
about a product, a secondary outcome of an HTA may be a coverage decision that has a 
direct link to patient access to a technology that is reviewed.  According to a majority of 
the respondents, the HTA may, and often does, influence health policy.  The literature 
review indicated that as policies differ, the overarching health policy can become 
fragmented.  However, as these organizations serve different purposes and patient 
populations, the fragmentation of policy helps patients to be able to choose options that 
organizations offer that are most relevant to them.  As such, the danger of fragmented 
health policy becomes a positive, rather than a negative, attribute. 
Best practices that enable the evaluation of relevant criteria to guide HTAs of 
screening technologies could help to create better coverage policies for specific patient 
populations.  Consistency in coverage among stakeholders that serve specific patient 
populations could help to stabilize a payer’s patient population.  Different payer policies 
provide patients with choices to participate in plans that provide them with access to 
specific technologies.  This ability to choose may positively influence the amount of time 
a patient decides to be a member in a payer’s plan.  As such, a best practice that provides 
the ability for a HTA organization to use specific criteria geared toward the assessment of 
screening technologies could enhance coverage for specific patient populations.   
Finding 3: In the experience of the 12 respondents, HTA criteria vary 
depending on the assessment and are available in published reports; 
however, metrics to measure the actual effectiveness of the HTA do not 
exist. 
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All 12 respondents were asked to share the criteria for HTA at their organization.  
None provided specific criteria.  Seven respondents indicated that their criteria varied 
because different types of assessments have different requirements.  As such, it would be 
impossible to set forth a specific set of criteria.  One respondent commented:  
The political environment wants more flexibility than you 
would want through, or expect through, a strict HTA.  The 
evidence is but one of the factors that is considered. 
 
Despite the lack of specific criteria, 10 respondents indicated that the criteria and 
data requirements were published and available in their reports.  Seven respondents 
indicated that feedback from outsiders is accepted.  However, 3 did not accept feedback, 
and two did not provide comment regarding whether or not feedback is accepted.  None 
of the respondents had explicit metrics used by their organization to measure the 
effectiveness of an HTA. 
Thus, while HTA criteria may differ depending on the nature of the assessment, 
ultimately the criteria are public.  However, after the assessment is complete, and 
possibly affecting coverage decisions and influencing health policy, there are no metrics 
in place to measure the overall efficacy of the HTA.  There was no correlation between 
influencing coverage decisions and continued funding of HTA organizations. 
Criteria specific to HTA of screening technologies would serve to make 
evidentiary and data requirements transparent to innovators and patients.  One outcome 
of this change might be to influence the variability in the final assessment between 
different HTA organizations.  However, given the different focuses and funding sources 
of the organizations, variability may continue.  Regardless, as demonstrated by the 
different HTA outcomes for CT colonography, more robust criteria for HTA of screening 
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technologies could provide a means to consistently evaluate the overall effectiveness of 
the screening technology in a specific patient population.  This would provide access to 
this technology to a limited subset of patients.  Under the current model, because the 
criteria do not address the needs of screening technologies, the HTA has become a means 
to deny access to all patients.  
Finding 4: In the experience of the 12 respondents, technologies 
selected for HTA are based on client requests and not necessarily the 
utility of the product. 
 
Eight respondents indicated that technologies are selected for assessment based on 
requests made by clients.  These clients fund the organization to conduct the HTA.  
Examples of HTA clients include: larger government agencies, healthcare systems, 
managed care organizations, hospital systems, and government agencies.  Controversy 
surrounding a product and whether a product presents a national issue are two of the 
drivers that can influence requests for HTA.   
Best practices that promote the evaluation of criteria specific to HTA of screening 
products would help to direct client-driven investment in HTA to products that are most 
helpful to a specific patient population.  Development of detailed selection criteria to help 
determine which screening products might have a broad impact on patient populations, 
no matter how select or small, would serve to select out screening technologies that do 
not have a sufficient sensitivity, specificity, or other benefit to merit review.  In so doing, 
this would focus HTA and client resources on screening products that would deliver a 
more meaningful result to patients and could be used to educate health consumers. 
2. Value and Attainability of Outcomes Evidence 
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Finding 1: In the experience of the 12 respondents, screening products 
may identify disease and risk factors earlier, but also may increase payer 
costs with limited patient outcomes. 
 
The data for this particular finding built upon several outcomes from the 
interviews.  First, 8 respondents strongly agreed and 2 respondents agreed that screening 
products might identify disease and risk factors earlier.  Similarly, 7 respondents strongly 
agreed and 4 agreed that screening products might identify risk factors that never 
progress to disease.  Lastly, 4 respondents strongly agreed and 6 agreed that a screening 
product might increase payer costs with limited patient outcomes. 
While a screening product may have utility in identifying a disease or risk factors, 
it may also identify risk factors that never progress to disease.  Thus, the value of the 
screening product may be outweighed by the increased costs to a payer or patient for a 
limited patient outcome.  Criteria specific for HTA of screening products would help to 
focus criteria and data requirements to identify those screening products that have a 
significant patient outcome.  Products with poor outcomes would universally, and 
consistently, not be recommended by the assessment.   
Finding 2: Among the 12 respondents, HTA criteria are sometimes 
different for therapeutic products and screening products and a 
hierarchy of evidence exists. 
 
Eight respondents indicated that HTA criteria are different for therapeutic and 
screening products.  Four respondents indicated that the criteria are not different; 
however, the manner in which the evidence is handled might be different.  In addition, 8 
respondents indicated that there is a hierarchy of acceptable data.  Five of the 8 
respondents indicated that randomized controlled trial was at the top of the data 
hierarchy.  One indicated that a hierarchy did not exist. 
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Thus, depending upon the organization, the HTA for a screening product might 
require randomized controlled trial data.  While at another organization, less rigorous 
evidence might be permissible.  In the case of the more rigorous standard, a screening 
product may never become available to patients because of the cost involved in 
conducting a randomized controlled trial, or the time involved to collect the data over 
time to determine if the disease ever presented in the patient.  Effectively, this would 
eliminate a screening product with positive patient outcomes from being available at all.  
This finding is consistent with the literature review in that the value and obtainability of 
outcomes evidence to evaluate screening products in HTA is not clear. 
The creation of best practices to evaulate criteria specific to screening products 
would help clarify evidence criteria and may mitigate evidentiary standards that may not 
be relevant for these technologies.  For example, a randomized controlled trial may not be 
a reasonable evidence standard for certain screening products.  Further, in addition to 
using evidentiary standards that may not be applicable, answers from the respondents 
indicate that there is inconsistency in the hierarchy of evidence used by HTA 
organizations.  This inconsistency could prevent helpful screening products from 
becoming available because the evidence standard is too rigorous, or not possible.   
A best practice for selecting criteria relevant to specific screening products would 
effectively set a transparent standard of evidence based upon specific patient population 
factors that affect disease such as age, gender, and national origin.  This would help to 
focus the HTA on relevant evidence that is directly related to the affected patient 
population resulting in a more responsible use of screening products, improved patient 
access, and consistent health policy regarding screening technologies.  Further, this 
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would address the gap identified in the literature review regarding the importance of 
considering the patient’s experience. 
3. Evaluation of Cost Effectiveness of New Screening Technologies 
Finding 1: Among the 12 respondents, cost is an assessment measure 
that should be considered in HTA. 
 
Six respondents strongly agreed and 2 agreed that cost should be added as a 
measure in HTA.  However, several respondents drew a distinction that cost is not an 
evidence measure it is an assessment measure.  Respondents felt that cost should not be a 
sole consideration when assessing a technology.  However, it can be a useful tool in 
determining the cost versus benefit of a particular product.  This finding is consistent 
with the literature review finding that the value of cost and cost-effectiveness is not clear. 
This section of the interview prompted a great deal of additional comment from 
all respondents.  One respondent located in the United States commented regarding the 
inclusion of cost as an input and the responsibility of the final user of an HTA to 
contemplate cost-effectiveness: 
Cost is sometimes incorporated in our technology 
assessments, but not cost-effectiveness.  It is up to the final 
user to do the final step of incorporating cost analysis 
themselves into the overall evaluation/assessment…we 
have limits on the types of information we can provide.  
From a pure speculation standpoint, yes, cost inclusion is 
inevitable.  I think we will need to wait for another 
Presidential election cycle or other Congressional changes 
before we will see it happen.  And once it does, it will need 
to be included carefully. 
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Another respondent commented on the importance of identifying the cost to a 
specific population and whether cost could be used as a way to disinvest in technology 
when it is shown not to be effective via HTA: 
I think that one of the areas where cost effectiveness (CE) 
diverges between the US and other countries, as in Europe, 
where resources for healthcare are centralized.  In this 
country [the US] you have to think of CE for whom, for 
which specific population?  In other countries, the impact is 
more on the overall system.  Here, the specific populations 
to consider include Medicare, children and schools, 
Medicaid…The other question is disinvestment.  Should 
HTAs be used to disinvest previously approved technology 
because it has been shown not to be effective? 
 
 One of the respondents from outside the US commented on the insufficiency of 
Quality Adjusted Life Years (QALYs) as a measure of cost: 
I am an economist myself, and I strongly believe the 
economics have to be involved.  With economics, comes, 
by definition a link to outcomes.  The usual link is quality 
of life, specifically cost per QALYs gained.  We feel there 
is a strong need to find something stronger than QALYs but 
that is not easy.  The first thing we need to develop is that 
something needs to be calibrated, looking very much on 
age. 
 
With QALYs, let me use an example.  So, at the San 
Francisco General Hospital, there is a patient, who is a 
murderer and he is in the emergency room.  He had just 
killed school children at a local school, and is 35 years old.  
At the same time, the ambulance is coming in with a young 
man who has served with Médecins sans Frontières, one 
year older than murderer, but suffering from life 
threatening infectious disease.  Who do you treat? 
 
What decision tools do we have?  If we use QALYs, then 
we choose murderer because he is younger.  But this goes 
against society’s values, where we would prefer the doctor 
to the murderer.  QALYs are too ice cold.  It doesn’t 
discriminate in these types of societal circumstances.  
QALYs shouldn’t be the primary tool for making decisions.  
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But it is a straight-forward measure. We should discuss 
every case, and make age group decisions, which would 
inform intentions of use. 
 
 Regarding the consideration of cost for screening technologies, one respondent 
commented: 
When you talk about evidentiary standards, it is around risk 
communication, how you portray risk, and how people 
interpret those different levels.  How distorted willingness 
to pay gets when you are at low risk.   Has to do with 
perceived value and reaction (favorable or not) to baseline 
risk and changes in risk.   
 
 A component of cost should be considered for HTA of screening technologies.  
Cost could help to help end-users of HTA for screening technologies understand whether 
or not they can afford to adopt a particular screening technology for a particular patient 
population.  For example, if a part of the best practice is to further refine the patient 
population intended for the technology by examining age groups and the burden of the 
cost of the technology to those age groups, more educated decisions about who would 
benefit the most from a particular screening product would become more transparent.   
 In the example of CT colonography, one of the concerns raised in several of the 
published HTAs was whether or not the discovery of extra-colonic findings would 
require follow up to determine if the finding was something that needed to be addressed 
or not.  In this case, using the technology in an older population who are more prone to 
colorectal cancer would help to limit the possibility for overuse of a screening product 
with limited positive patient outcomes.  Understanding what age patient population 
would benefit the most from the use of screening technology might reduce the cost 
burden of the technology by using it on those patients that would benefit the most.  As a 
result, a cost measure would be helpful to include for HTA of screening products. 
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Conclusion 
The findings of this research study indicate that the purpose of an HTA is to 
evaluate existing data and evidence to make a statement about a particular product. HTAs 
are used as tools by agencies and companies such as: health care plans, managed care 
organizations and hospitals to decide whether their patient populations should have 
access to a particular product.  As a result an HTA may directly influence payer coverage 
decisions and, as such, indirectly influence the creation of broader health policy across 
stakeholders who manage patient populations, as well as affect patient access to care. 
Access to healthcare is a changing environment in the United States.  In the 
1950s, healthcare benefits were focused on the delivery of hospital inpatient care.  With 
the creation of the Medicare program in 1965, new settings of care emerged that required 
new methods to compensate for care provided in the hospital outpatient and community 
based settings.  Payment mechanisms for these new sites of service have evolved over 
time as well – transitioning from traditional fee for service models to those based on 
length of stay or bundled payments.  Payments for products used during the course of 
care have similarly evolved.  Itemized payment is almost non-existent as new 
mechanisms bundle product payment within the total payment for the care of the patient.   
These changes to health insurance systems are relevant to the evolution of HTA.  
In the 1960s, HTA began as a way to distinguish technologies that were beneficial to 
patients from those that might present and unintended harm if a technology is adopted 
before understanding whether or not it was safe.  Today, HTA is used to drive patient 
access and payer coverage policy.  These mechanisms have a direct effect on the 
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innovation of new products.  If it is unclear or difficult to provide access to specific 
technologies to patients, innovation in these areas will slow. 
Criteria specific to the evaluation of screening products would positively impact 
HTA stakeholders such as HTA organizations, their clients, and patients, as well as 
technology innovators.  Best practices designed to help HTA organizations choose 
criteria that are focused on screening technologies will help to identify whether relevant 
patient populations for the technology exist.  In so doing, levels of evidence and data 
requirements would be more transparent to screening technology innovators and patients.  
Cost should be a part of the assessment to understand the cost and benefit of using the 
product in specific patient populations for appropriate clinical decision-making.   
As a result, best practices for screening technologies would help provide a 
relevant channel to evaulate the safety and appropriateness of screening products for 
specific patient populations via HTA.  This is consistent with the evolution of patient care 
to a more transparent environment in which the patient is more involved in making access 
decisions. 
Limitations of This Research 
 The components of this research study included the search and assessment of 
literature, web site content, and primary interviews with HTA experts.  The data collected 
provided a basis to provide answers to the research aims, make conclusions, and develop 
a plan for change.  However, there were limitations to this study that are common to 
studies that include a review of literature, publicly available web site content, and 
interviews with technical experts. 
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 A limitation of this study is that mistakes can be made during literature and web 
site reviews.  Key studies and relevant sites can be missed despite best efforts.  Links to 
pertinent parts of web sites can become inactive.  These limitations were mitigated by 
conducting multiple key word searches and by conducting research queries several 
different ways.  These limitations were further mitigated in that the literature that was 
reviewed was comprehensive and began to cite similar references, indicating that the 
review was complete.   
The search for HTAs of screening technologies was limited by the number of 
HTAs that were publicly available.  This limitation was mitigated by one of the 
respondents offering to share information they had collected with the interviewer.  In 
addition, respondents shared with the interviewer where information could be found on 
their websites. 
The small sample size for the interviews and the sampling methodology and 
participation introduced selection bias.  This limitation was addressed by involving, when 
available, more than one person from a particular HTA organization. There are few HTA 
experts that are extremely familiar with their organization’s HTA programs.  As a result, 
the small sample size was anticipated before the study began.  The limitation was further 
addressed by selecting diverse organization types that conduct HTAs.  These 
organizations have a variety of missions, visions, diversity of clients, and funding 
options.  In addition, these organizations were located in very different areas of the 
United States and address differing patient populations.  To manage this limitation, three 
respondents were included in the study from two different countries to provide additional 
international perspectives from Canada and the United Kingdom.  That said, the limited 
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sample size is not be representative of the universe of HTAs in all countries.  As a result, 
the findings set forth in this research study may have some applicability to a larger 
audience; however, some findings may not be generalized to represent all organizations 
in all locations conducting HTAs. 
 Another limitation of the research is that the interviews relied heavily on the 
knowledge and expertise of the respondent.  Limitations were introduced by the inability 
for some of the respondents to be forthcoming with information.  Several of the 
respondents were not able to answer specific questions.  For example, a few respondents 
declined to comment about specific HTA criteria and could not describe specific 
examples of the differing ways in which data are applied to therapeutic versus screening 
technologies.  Similarly, a few respondents were unable to provide data about the cost of 
an HTA at their organization due to the varying size and complexity of HTAs conducted.  
These types of organizationally-specific details are often considered confidential in many 
cases and therefore cannot be made publicly available.  As a result, the absence of 
information creates gaps of information in the study. 
 The non-participation of 8 of the 20 respondents invited to participate in the study 
is another limitation.  While this factor did narrow the total number of observations in 
this study, the 12 respondents did have remarkably similar comments.  Due to the 
geographic distribution of the respondents and the diversity of the types of organizations, 
it is unlikely that any significant bias was introduced to the study.  In addition, a review 
of publicly available HTAs of CTC colonography for colorectal cancer indicate that the 
methods employed by non-participating respondents did not reveal any divergence in 
approach to HTA between participating and non-participating respondents.  Thus, the 
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non-participation of respondents was based more on an individual’s time available to 
participate in the study. 
 A final limitation is that respondents may unintentionally inject bias into their 
responses.  This bias could come from the manner in which the researcher asked the 
question.  The researcher conducting cognitive tests of the interview guide with three 
people familiar with HTA prior to the interview process with the respondents mitigated 
this limitation.  This testing helped to refine questions to minimize the possibility of 
divergence in possible ways to answer the question due to the content of the question 
being misinterpreted by the respondent.   In addition, in one case two people from the 
same organization were interviewed at the same time.  It could be that the differing 
positions of the respondents in the organization could influence the independence of 
responses.  However, based on the long time, collaborative nature, of these respondents 
working relationship, it is unlikely that any discussion was stifled. 
 Any additional study limitations were addressed by comparing the respondents’ 
answers to the documents and websites that they referenced during the interview.  When 
answers provided during the interview were unclear, additional clarifying questions were 
asked to help narrow the response.  Lastly, respondents had the opportunity to review the 
notes of the interview and make any clarifying edits prior to the analysis of the data.  This 
helped to ensure that the intent of the respondent’s comments was clear and well defined. 
 
 
 
 
 
Chapter 7: Plan for Change: Recommendation for A Standard for HTA of 
Screening Technologies 
 
This research will form the basis of best practices that can be used by HTA 
organizations to assess screening technologies.  These best practices will help 
organizations: (1) identify relevant patient populations for specific screening 
technologies; (2) understand which screening technologies meet their stated 
organizational goals and objectives; (3) make intentional choices about which screening 
technologies bring the most value to both patients and payers; (4) direct private sector 
investment in technologies to improve health outcomes; and (5) provide greater 
transparency to patients as they select plans that may offer differing levels of access to 
screening technologies.   
Developing best practices is clearly needed, given the findings regarding the 
diversity in criteria used by key informants respondents regarding CT colonography.  
Notably, we found differences between standards by which therapeutic and screening 
products are interpreted, thereby justifying the importance of refined criteria for 
screening technologies.  Presenting these refined criteria in the form of a “best practice” 
would provide HTA organizations with the flexibility to decide which criteria best serve 
their mission and responsibility to patients.  Specifically, based upon literature review, 
review of HTA, and interviews with 12 leaders in HTA, five best practices were 
identified (Table 32).   
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Table 32.  Best Practices for HTA of Screening Technologies  
Finding Thematic Finding 
1 Determine the types of data and evidence that are sufficient to support screening reliability, 
sensitivity and specificity 
2 Evaluate data to help identify the appropriate patient population.  Take into consideration 
demographic, clinical and genetic characteristics. 
3 Reference the natural course of disease. 
4 Ethical considerations such as: the link between the test and actual expression of disease, 
availability of treatment options if disease is identified, and taking into consideration patient 
acceptability. 
5 Consider the cost. 
 
A discussion of each of these thematic findings follows. 
1. Determine the types of data and evidence that are sufficient to support 
screening reliability, sensitivity and specificity. 
 
One controversy surrounding screening technologies is their ability to be 
sufficiently reliable, sensitive, and specific.  Without these endpoints, the technology 
could result in elevated costs to the healthcare system and unnecessary risks to patients 
when seeking to diagnose a disease that is not present (false positive).  Several 
respondents commented about the potential consequence of screening healthy patients, 
including exposing patients to unnecessary anxiety or treatment.  However, reliability, 
sensitivity and specificity must be balanced against an individual’s right to choose 
whether to be screened for a particular disease.  One respondent commented: 
This can be highly contextual.  For screenings, you can be 
offering them, but since people know there isn’t any 
treatment, then it would be their option to use it.   If a 
screening product is highly accurate, highly effective, then 
patient and clinician preference plays a big role.  That 
outweighs whether the organization says they should have 
that test or not.  It really becomes an individual decision. 
 
 Thus, an HTA assessment best practice for screening products should balance 
detection of disease, treatment of disease, and better patient outcomes.  While 
randomized controlled trial data may be too high of a bar for screening technologies, a 
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best practice should be able to validate the possibilities of applying differential 
evidentiary standards to the severity of particular diseases.  For example if a disease is 
particularly severe, the ability to evaluate whether or not a patient might have the early 
stages of the disease may present more effective treatment options than if the patient 
waited for the disease to formally manifest itself.  Based on this best practice, a patient 
should have the right to choose whether or not they would like to have the test.  As such, 
the individual and their physician may make informed choices about treatment relative to 
the reliability, sensitivity and specificity of the test. 
2. Evaluate data to help identify the appropriate patient population.  Take into 
consideration demographic, clinical and genetic characteristics. 
 
A best practice for the HTA of a screening technology should consider the 
characteristics of individual patients (e.g., demographic, clinical and genetic 
characteristics) so that the product is used in the most appropriate patient population.  
Doing so will enhance the test characteristics (sensitivity and specificity).  Without the 
ability to segment patient populations, we are at risk for screening patients for disease 
that does not take into consideration the overall relevance of the test to the particular 
patient.  One respondent suggested that: 
An example of a harmful screening program – test for 
prostate cancer using PSA [for men] over [age] 64.  Many 
false positives.  As a result, men go unnecessarily to surgery 
and there are many side effects and complications. 
 
Narrowing screening tests to relevant patient populations could make a substantial 
difference in the manner in which we permit testing.  One respondent discussed 
mammography testing in different age groups:  
Whether you are looking at potential benefit over lifetime, 
or adverse events of surgery, it becomes a different question 
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if evaluating in patients who are pre-menopausal or post-
menopausal.  If the patient is 70 years old, and there is a 
concern about cancer, the BRCA mutation, in this case, isn’t 
the underlying cause.  To subject a 70 year old with lower 
tolerance for surgery and multiple comorbidities to invasive 
surgery, it becomes very different if you’re thinking about a 
25 year old, who would be a prime candidate for surgery.  
The bigger risk in that age group would be fertility for 
example, because of the bilateral oophorectomy. 
 
As a result, a best practice for a screening HTA should be to identify the most 
relevant patient population for the test.  This would help to avoid unnecessary testing, 
inappropriate testing, and focus the effort on testing in the most relevant patient 
populations. 
3. Reference the natural course of disease. 
While a screening product might establish that disease is present, it is important to 
understand the overall course of the disease.  For example, some therapies are not 
relevant to specific patient within the context of their particular situation.  One 
respondent commented: 
A lot what we screen for, risk factors, biomarkers, we need 
sufficient evidence to connect to them to the disease 
condition that you’re testing for.  Then we need the 
information to link that it can be influential on decisions and 
that there is something that the physician can do. 
 
Patient treatment and survival are not always appropriate endpoints for specific 
patient populations.  For example, screening tests could be provided to patient 
populations that are not relevant and unnecessary patient anxiety can ensue at the expense 
of a sole focus on treatment and survival.  One respondent commented that a negative 
benefit may come from screening technologies: 
[In a study for mammography w]e followed up with 
women who [were] positive one way or another – that 
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through the screening, they find something that needs to be 
examined further…we took a cohort of 300 women, and 
followed over the years, to see when they were free of 
initial suspicion of “seeing something”.  We knew the 
results, and we took the cohort of false positives, to look 
backwards and see.  During this period of time, many of 
these women fell into depression and had anxiety.  We 
argued that this should be considered a negative benefit of 
mammography screening, but has not been considered a 
concern.  The only concern is the aggressive treatment and 
survival. 
 
As innovators develop screening tests for future disease, we will need to consider 
the natural course of the disease.  In so doing, a best practice for HTA of screening 
products would help identify where the patient is in the natural history of the disease, and 
conversely, when treatment is not helpful given the overall natural course of the disease.  
By understanding the broader context of the natural development of a particular disease, 
HTA for screening tests could be refined to create statements of fact regarding when 
treatment is most effective or not warranted.  
4. Ethical considerations, such as: the link between the test and actual expression 
of disease, availability of treatment options if disease is identified, and taking 
into consideration patient acceptability. 
 
A best practice for the HTA of a screening product should consider data that helps 
to establish a link between the screening product and the actual expression of disease.  
One of the key considerations expressed by respondents was that if no treatment for a 
screened disease exists, then the product should not be used. 
Some proponents feel that information for information’s 
sake can be good.  But it can do harm if you don’t 
understand meaning of information and implications on 
disease.  If there isn’t any action that flows from it, then can 
do more harm than benefit.  It creates anxiety.  The 
downstream of positive sequela, is retesting.   Negative test 
results may give false reassurance.  This is a hard concept to 
explain to public.  We haven’t done a good enough job of 
 140 
explaining of what makes a good screening test valuable and 
why. 
 
The level of analytic precision of the screening product presents a higher 
standard.  Specifically, the link between the test and the formal expression of disease is 
particularly important.  One respondent commented: 
Unlike treatment, where questions are more simplistic, [for 
example], does it work, how well does it work, is it safe, 
how may it compare with an alternative approach…If you 
are talking about molecular diagnostic testing, you are 
adding another dimension, including things that might 
influence expression of gene of allele that you’re testing 
for…What is the link between what you are testing for and 
actual expression of disease? 
 
 
Patient acceptability of the elements necessary to conduct the screening test are 
also important.  One respondent commented: 
Everyone agrees that [colorectal cancer testing] is a very 
important technology.  Part of the process includes 
submitting a fecal sample, which the patient need[ed] to 
mail for analysis.  There are no ethical issues presented, but 
in this case, not everyone wants to process and mail their 
feces. 
 
If the steps of a test, regardless how simplistic, are not easily accepted by the patient, then 
the overall value of the test is inconsequential because there is a barrier to use.  In this 
case, the test was less invasive and the patient could ensure privacy; however, the cultural 
context was not acceptable and the patient compliance with the test was not strong. 
As a result, a best practice for HTA is for the assessment to take into 
consideration that testing for the sake of testing is not a beneficial concept.  The best 
practice should not be solely focused on treatment and survival.  Rather, a part of the 
assessment should be centered on the identification of the most appropriate patient 
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population.  This would help to avoid a potential for being the source of patient anxiety.  
Lastly, the best practice should take into account the patient’s ability to accept the actual 
process of the test.  Without patient willingness, the test is not valuable. 
5. Consider the Cost. 
Distinguish valuable screening technologies from those that offer added costs 
with limited improved patient outcomes.  Cost should be considered in conjunction with 
potential benefits.  One respondent commented: 
There is the whole issue of false positives and false 
negatives to consider.  You also need to look carefully at the 
cost, of course, related to the potential benefits. 
 
A majority of respondents indicated that cost should be an assessment measure in HTA.  
An evaluation of cost helps health systems plan their investments.  In addition, 
transparency of costs helps patients choose whether or not they want a particular 
screening test.  
 A best practice for HTA of screening technologies should include component of 
cost in order to inform both of these stakeholders.  This component could be in the form 
of a cost-effectiveness study to understand the cost of the screening product within the 
broader context of the treatment of the disease.  This view into cost could help to identify 
valuable screening products with positive patient outcomes from those products with high 
cost and little benefit. 
Implementation of HTA Best Practices for Screening Products 
 Issues of coverage, access, and affordability are important components of the 
healthcare policy environment in 2011.  Coverage decisions affect whether or not a 
patient will have access to a particular product, which in turn impacts overall 
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affordability to both the patient and payer.  The respondents in this study indicated that 
the organization conducting the HTA might not be directly responsible for making a 
coverage decision in all cases.  However, HTAs are often used by health plans and 
hospital groups as a means to make coverage decisions for their members.  As a result, 
once a screening product receives a positive HTA and is deemed eligible for coverage by 
the payer, follow up questions exist relative to appropriate patient access and 
affordability.  By implementing the best practices identified in this research study, HTAs 
play a direct role in helping to establish a rational way for screening products to be 
covered by payers so that appropriate patient populations can have access to them.  If 
implemented correctly, screening products will help payers to manage healthcare 
expenses by identifying patients for whom a screening test might have the most value.  
 How should the HTA best practices for screening products be effectively 
implemented by payers in today’s healthcare environment?  The respondents in this study 
indicated that there is a concern regarding appropriate access to screening products when 
a payer’s patient population has unrestricted access to all covered products.   Two 
examples from this study included the overall value of both PSA tests and mammograms 
to patients and payers when used in elderly patient populations.  The respondents stated 
that while these tests have a high value in younger populations by identifying disease 
early, their utility typically wanes significantly when used in elderly populations for 
whom treatment options are limited due to patient age and ability to tolerate treatments.  
Several respondents cited concerns related to increased patient anxiety and cost to the 
payer as follow up tests and procedures are ordered in response to the results of the PSA 
or mammogram.  These respondents felt that there is a definitive link between the value 
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of the test to both the patient and the payer.  As these two examples demonstrate, the 
value of a screening product is not fully realized when a coverage policy assumes that all 
patients are the same and therefore should have universal access.  
 Value-based insurance designs are an ideal mechanism for payers to realize the 
benefit of HTA best practices for screening products.  The principle of value-based 
insurance design is the value of a technology (medication, program, screening test) varies 
within and across patient populations.179  As a result, access to screening products should 
be based upon when the clinical benefit exceeds the cost in specific patient populations.  
Access should not be driven by the uniformity of patient out of pocket expenses.180  
Value-based insurance design provides the mechanism for payers to incentivize services 
that are most valuable to the patient.  This helps to direct access to those products that 
demonstrate value while considering cost.  Similarly, it motivates providers to either 
decrease cost or increase quality to justify a higher price.181  Thus, “[e]fficiency would 
promote the use of ‘valuable’ interventions whose expected net clinical benefits justify 
the associated expenditure and limit access to those services whose costs exceed the 
expected clinical gain.  This is the fundamental paradigm of cost-effectiveness 
analysis.”182   
 Payers with value-based insurance designs could use several strategies to manage 
the use of screening products supported by HTA to make decisions about coverage, 
                                                
179 Chernew, M.E., Rosen, A.B., Fendrick, M. (2007). Value-based insurance design. Health Affairs; 26:2, 
w195-w203. 
 
180 Ibid at w195. 
 
181 Ginsburg, P.B. (2007). Shopping for price in medical care. Health Affairs; 26:2, w208-w216. 
 
182 Chernew, M.E., Rosen, A.B., Fendrick, M. (2007). Value-based insurance design. Health Affairs; 26:2, 
w195-w203. 
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access and affordability.  As a starting point, payers should get involved in the 
development of screening products by sharing with screening product manufacturers 
what types of products would be most valuable to specific patient populations in their 
membership.  Payers are in the best position to know what types of screening products 
would be of the most use to their members.  As a result, by proactively interacting with 
the inventors and manufacturers of screening products, the innovation will match the 
need.   
 Once the need is established, the HTA for a screening product would employ the 
best practices to identify appropriate patients while considering cost.  If coverage for the 
screening product is established, value-based insurance designs would be the mechanism 
for directing screening products to the patient populations for whom the products will 
have the most value.  Patient demographics in the coverage policy would help physicians 
to identify which patients should be proactively screened.  Alternatively, a patient that is 
not in the covered population could choose to pay the out of pocket costs associated with 
access to the particular screening product.  In this way, appropriate patients are covered 
and have access, while those patients who choose to have the test but are not a part of the 
covered patient population could have access via a higher out of pocket, thereby limiting 
financial exposure to the payer.  
 For screening products with less certain value propositions absent a lengthy 
observation period, payers could employ different variants of pay for performance and 
risk-share models.  For example, in a strict pay for performance model, screening 
products would only be covered each time the test reliably establishes that a patient has a 
disease.  Alternatively, in a risk-share model a screening product would be partially 
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covered by both the manufacturer and the payer while clinical evidence and cost 
effectiveness data are gathered to support whether or not the product has a value to 
specific patient populations within the payer’s membership.  Currently, Medicare uses 
coverage with evidence development183 for newer technologies that show a promise of 
value.  This shared risk model would help to stimulate innovation by mitigating the cost 
to the manufacturer associated with a lengthy study and data collection, while providing 
payers with access to new screening products for their members.  Lastly, for those 
screening products with limited data and/or unclear value, patients could opt to pay 
entirely out of pocket for access.184 
 The practical implementation of the best practices for HTA of screening products 
can benefit payers that employ value-based insurance designs.  These types of designs 
help payers to identify screening products in which the clinical benefit exceeds the cost.   
As screening products are adopted, they may establish varying degrees of efficacy in 
different patient populations.  HTA for screening products could become a more active 
tool to establish coverage which would be managed through value-based insurance 
design and cost-effectiveness analysis to provide patients access while managing 
affordability concerns.  Additional studies will need to be conducted relative to the 
feasibility and cost associated with identifying relevant patient populations within payer 
memberships and establishing whether the clinical benefit of a particular screening 
product exceeds the cost. 
 
                                                
183 Centers for Medicare and Medicaid Services. Coverage with evidence development. 
https://www.cms.gov/CoverageGenInfo/03_CED.asp  Accessed September 2, 2011. 
 
184 Brennan, T., Reisman, L. (2007). Value-based insurance design and the next generation of consumer-
driven health care. Health Affairs; 26:2, w204-207. 
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Appendix 1: Recruitment Document 
Study #: 11-0624 
As you may know, screening technologies may be able to help identify whether or 
not a patient has a specific disease in order to inform treatment decisions before 
symptoms occur or verify the cause of symptoms.  It is believed that finding a disease 
early might improve a patient’s prognosis.  However, there is not consensus as to whether 
the discovery of a disease in an early phase may ultimately result in better patient 
outcomes.  Regardless, a significant amount of private sector innovation is occurring to 
develop new technologies that can identify a disease early.  As such, it is unclear how far 
down the clinical pathway one must go in order to validate that a screening product 
actually helped the patient.  The purpose of this research study is to identify whether or 
not agencies that conduct health technology assessments in the United States are 
employing similar standards of evidence to evaluate products that screen for disease.  The 
results of this research study will be used to develop a best practice for conducting these 
types of health technology assessments. 
            Your organization has been identified as a leader in the area of health technology 
assessments. In addition, you have been identified as someone with expertise in this area. 
While there is a great deal of speculation about the levels of evidence required to support 
a HTA of a screening product, there does not appear to be a common standard.  
Information from this research study will be used to try to create such a standard. 
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            During the interview, you may choose not to participate, decline answering any 
question, or stop at any time.  However, your response, if you do participate, will be 
valuable to the results of this research study.  The information collected in this research 
study will be kept confidential.  Your specific answers will not be attributed to you or 
your organization. The interview results will only be used in summary form to discuss the 
suggested levels of evidence for these technologies and to form specific 
recommendations for organizations wishing to create a best practice for evaluating these 
new technologies.   
            I am the Principal Investigator for this research study.  My faculty advisor is John 
Paul, PhD.  Dr. Paul is a Clinical Associate Professor at University of North Carolina, 
Chapel Hill, Gillings School of Global Public Health.  His telephone number is: 919- 
966-7373 and his email is: paulj@email.unc.edu 
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Appendix 2: Interview Guide 
Interview Guide 
 
Health Technology Assessment Evidence Criteria:  
What Types of Evidence Should be Presented for Products Used to Screen 
for Disease in the United States? 
 
 
 
Interviewee Name:       
 
Interviewee Title:       
 
Organization Name:       
 
Date of Interview:       
 
Interview Start:  __:__ 
 
Interview End: __:__ 
 
Duration of Interview:          minutes 
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Introduction 
 
 Good morning/afternoon.  My name is Nancy McGee, and I am a student in the 
Executive Doctoral Program in Health Leadership at the University of North Carolina at 
Chapel Hill Gillings School of Global Public Health.   
 Thank you for your interest in participating in this research study entitled: Health 
Technology Assessment Evidence Criteria: What Types of Evidence Should be Presented 
for Products Used to Screen for Disease in the United States.  I am the Principal 
Investigator for this research study.  My telephone number is: 415-279-4448 and my 
email address is: nancymmcgee@gmail.com.  My Faculty Advisor is John Paul, PhD he 
is a Clinical Associate Professor at the University of North Carolina, Chapel Hill, 
Gillings School of Global Public Health.  Dr. Paul’s telephone number is: 919-966-7373, 
and his email address is: paulj@email.unc.edu   All research on human volunteers is 
reviewed by a committee that works to protect your rights and welfare.  If you have 
questions or concerns about your rights as a research subject you may contact, 
anonymously if you wish, the Institutional Review Board at 919-966-3113 or by email to 
IRB_subjects@unc.edu. 
 As you may know, screening technologies may be able to help identify whether or 
not a patient has a specific disease in order to inform treatment decisions before 
symptoms occur or verify the cause of symptoms.  It is believed that finding a disease 
early might improve a patient’s prognosis.  However, there is not consensus as to whether 
the discovery of a disease in an early phase may ultimately result in better patient 
outcomes.  Regardless, a significant amount of private sector innovation is occurring to 
develop new technologies that can identify a disease early.  As such, it is unclear how far 
down the clinical pathway one must go in order to validate that a screening product 
actually helped the patient.  The purpose of this research study is to identify whether or 
not agencies that conduct health technology assessments in the United States are 
employing similar standards of evidence to evaluate products that screen for disease.  The 
results of this research study will be used to develop a best practice for conducting these 
types of health technology assessments. 
 Your organization has been identified as a leader in the area, of health technology 
assessments. Your participation in this interview is key and very much appreciated.  
While there is a great deal of speculation about the levels of evidence required to support 
a HTA of a screening product, there does not appear to be a common standard.  This 
research will be used to try to create such a standard. 
 You may choose not to participate, decline answering any question, or stop at any 
time.  However, your response, if you do participate, will be valuable to the results of this 
research study.  The information collected in this research study will be kept confidential.  
Your specific answers will not be attributed to you or your organization. The interview 
results will only be used in summary form to discuss the suggested levels of evidence for 
these technologies and to form specific recommendations for organizations wishing to 
create a best practice for evaluating these new technologies.    
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[If interviewing an administrator or manager:] 
As an administrator or manager of a health technology organization, I will 
ask you questions about: 
 
A. Health technology assessment at your organization 
 
[If interviewing a panelist or researcher:] 
As a health technology assessment panelist or researcher, I will ask you 
questions about: 
 
B. Value and attainability of outcomes evidence 
C. Evaluation of cost-effectiveness of new screening technologies 
 
I anticipate that this interview will take one hour.  The interview is not being taped.  I will 
be taking handwritten notes as we talk.  At your request, you may review the summary of 
this interview, as well as the relevant portion of the dissertation that contains the 
interview content, in order to assure sufficient accuracy, attribution, and confidentiality. 
 
Do you have any questions?  May we begin?  
Begin interview of administrator or manager of a health technology assessment 
organization with Section A.  If interviewing a panelist or researcher, skip ahead to 
Sections B and C. 
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A. Health technology assessment at your organization 
 
As an administrator or manager of a health technology assessment organization, I would 
like to ask you several general questions about health technology assessment at your 
organization. 
 
1. On a scale of one to ten, how familiar are you with the HTA program at your 
organization? 
 
Not At All Familiar       Extremely Familiar 
 1    2 3 4 5 6 7 8 9 10 
 
[If response is 4 or lower, thank the interviewee for their participation and ask if they can 
recommend another individual in their organization that might be more familiar.] 
 
 
2. There are a number of critical components for the development of health 
technology assessment programs at organizations such as yours.  The purpose of 
this question is to understand the most important components for development of 
HTA programs at your organization.  We would like to know how would you 
rank these critical components. In this section of the interview, I will read a 
statement to you, please respond whether you agree or disagree with the 
statement.  We will use a 5 point Likert Scale in which 1 is “strongly disagree”, 2 
is “disagree”, 3 is “neither agree nor disagree”, 4 is “agree”, and 5 is “strongly 
agree”.  Are you ready?  Let’s begin. 
 
Critical components 
for the development of 
HTA programs 
 
5 Point Likert Scale 
1. HTA is a part of the 
mission statement of 
the organization 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither Agree 
nor Disagree 
4 
Agree 
5 
Strongly 
Agree 
2. HTA is a part of the 
vision for the 
organization 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither Agree 
nor Disagree 
4 
Agree 
5 
Strongly 
Agree 
3. HTA is a source of 
research funding for 
the organization 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither Agree 
nor Disagree 
4 
Agree 
5 
Strongly 
Agree 
4. The HTA department 
has a specific 
financial budget 
within the 
organization 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither Agree 
nor Disagree 
4 
Agree 
5 
Strongly 
Agree 
5. HTA is the sole 
purpose of the 
organization 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither Agree 
nor Disagree 
4 
Agree 
5 
Strongly 
Agree 
6. HTA drives coverage 
decisions at the 
organization 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither Agree 
nor Disagree 
4 
Agree 
5 
Strongly 
Agree 
7. Other:  
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3. Are there stated goals or objectives for the HTA program(s)?  If so, what are 
they? 
 
 
 
 
4. When (month and year) did you implement your HTA program? 
 
 
 
 
 
5. How many HTAs has your company/agency conducted since 2000?   
 
 <10  11-20  21-30  30-40  >40 
 
6. What are the criteria for HTA at your organization? 
 
 
 
 
 
7. Are the criteria and data requirements published or contained/included in any 
internal reports that are available?    
 
 
 
 
a. Is it possible to obtain copies of the criteria? 
 
 
 
 
8. How does your organization select technologies to assess? 
 
 
 
 
 
 
9. Can you describe an HTA decision your agency made?   
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a. Once the assessment was complete, did policies change over time?   
 
 
 
 
b. Did feedback from your providers or patients or manufacturers cause you 
to change or re-evaulate the decision? 
 
 
 
 
c. Do you use a committee structure to evaluate information? If yes, how is 
the committee formed? 
 
 
 
 
d. Once a decision is made using HTA, what is the process of disseminating 
decisions? Are decisions linked to reimbursement or are decisions 
guidelines? 
 
 
 
 
10. Can you describe an HTA decision you changed because new information came 
to light?  
 
 
 
a. If so, what was the new information that caused a change and how did you 
find it? 
 
 
 
 
11. What metrics have you established to measure the effectiveness of HTAs?  
 
 
 
 
 
12. Do you have ongoing or multi-year budget commitment for HTA assessments?  
For how many years? 
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13. Do you know what the average cost of conducting an HTA is for your 
organization?  
 
 
 
 
 
14. Is there anything else that you think other organizations tackling this issue should 
know in evaluating screening products, either before they begin, during the 
analysis, or when the analysis is complete?  
 
 
 
 
 
Thank you for your time.  Your input and insights will be invaluable to this research 
study.  You will be provided with a summary of the final document, expected in October 
2011. 
 
End of interview for administrators and managers of health technology assessment 
organizations. 
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B. Value and attainability of outcomes evidence 
 
As a health technology assessment panelist or researcher for a health technology 
assessment organization, I would like to ask you questions about the value and the ability 
to attain outcomes evidence when evaluating screening technologies. 
 
1. Screening technologies may be able to help identify whether or not a patient has a 
specific disease in order to inform treatment decisions before symptoms occur.  
Controversies about screening technologies exist.  In this section of the 
interview, I will read a statement to you, please respond whether you agree or 
disagree with the statement.  We will use a 5 point Likert Scale in which 1 is 
“strongly disagree”, 2 is “disagree”, 3 is “neither agree nor disagree”, 4 is 
“agree”, and 5 is “strongly agree”.  Are you ready?  Let’s begin. 
 
Screening product 
controversy 
 
5 Point Likert Scale 
1. May be able to 
identify disease 
earlier 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither Agree 
nor Disagree 
4 
Agree 
5 
Strongly 
Agree 
2. May identify risk 
factors that never 
progress to disease 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither Agree 
nor Disagree 
4 
Agree 
5 
Strongly 
Agree 
3. May be able to 
decrease payer 
costs with positive 
patient outcomes 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither Agree 
nor Disagree 
4 
Agree 
5 
Strongly 
Agree 
4. May increase payer 
costs with limited 
patient outcomes 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither Agree 
nor Disagree 
4 
Agree 
5 
Strongly 
Agree 
5. May identify 
diseases for which 
there is no 
treatment available 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither Agree 
nor Disagree 
4 
Agree 
5 
Strongly 
Agree 
6. Other      
 
2. Are the HTA criteria different between therapeutic products and screening 
products? 
 
 
 
 
a. If so, how? 
 
 
Begin interview of panelists and researchers of health technology assessment 
organizations.  Health technology assessment administrators and managers will not 
answer this section. 
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3. What kinds of data are acceptable in order to support a particular HTA criterion? 
 
 
 
 
 
4. Is there a hierarchy of acceptable data (e.g.: randomized clinical trial data v. 
adaptive trial data)? 
 
 
 
 
a. If so, what is the hierarchy of data? 
 
 
 
 
5. Are the data requirements different between therapeutic products and screening 
products? 
 
 
 
a. If so, how? 
 
 
 
6. Please rank your level of agreement or disagreement with the following 
statements:   
 
a. My organization tends to avoid assessing technologies that screen for 
disease because it is difficult to agree regarding the appropriate length of 
the observation period. 
 
1 
Strongly Disagree 
2 
Disagree 
3 
Neither Agree nor 
Disagree 
4 
Agree 
5 
Strongly Agree 
 
b. My organization tends to avoid assessing technologies that screen for 
disease because the cost of these technologies is not sufficiently 
understood. 
 
1 
Strongly Disagree 
2 
Disagree 
3 
Neither Agree nor 
Disagree 
4 
Agree 
5 
Strongly Agree 
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c. My organization tends to avoid assessing technologies that screen for 
disease because it is difficult to select the appropriate patient population. 
 
1 
Strongly Disagree 
2 
Disagree 
3 
Neither Agree nor 
Disagree 
4 
Agree 
5 
Strongly Agree 
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C. Evaluation of cost-effectiveness of new screening technologies 
 
As a health technology assessment panelist or researcher for a health technology 
assessment organization, I would like to ask you questions about the evaluation of cost-
effectiveness of new screening technologies. 
 
 
1. In Europe, HTA conducted by government payers employ cost as an evidence 
measure;185 while in the US, cost has typically not been included in assessments 
conducted by public payers.  In this section of the interview, I will read a 
statement to you, please respond whether you agree or disagree with the 
statement.  We will use a 5 point Likert Scale in which 1 is “strongly disagree”, 2 
is “disagree”, 3 is “neither agree nor disagree”, 4 is “agree”, and 5 is “strongly 
agree”.  Are you ready?  Let’s begin. 
 
Cost as an evidence 
measure 
 
5 Point Likert Scale 
1. Cost should be 
added as an 
evidence measure 
for HTA 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither Agree 
nor Disagree 
4 
Agree 
5 
Strongly 
Agree 
2. In general, cost is 
an unstated 
evidence measure 
for all HTAs  
1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither Agree 
nor Disagree 
4 
Agree 
5 
Strongly 
Agree 
3. Cost is an unstated 
evidence measure 
for HTA at my 
organization 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither Agree 
nor Disagree 
4 
Agree 
5 
Strongly 
Agree 
4. Cost is not a 
relevant evidence 
measure for HTA 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither Agree 
nor Disagree 
4 
Agree 
5 
Strongly 
Agree 
5. Other 1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither Agree 
nor Disagree 
4 
Agree 
5 
Strongly 
Agree 
  
Closing  
Thank you again for your time.  Your input and insights will be invaluable to this 
research study.  You will be provided with a summary of the final document, expected in 
October 2011. 
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